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ABSTRACT 
Breast cancer remains the leading cause of cancer-related death in women worldwide. 
Furthermore, it has been demonstrated that the treatment-resistant ER
-
PR
-
HER2/neu
-
 sub-type 
is more common among women of African descent, necessitating the search for novel 
chemotherapies for this form of the disease. The secondary metabolites produced by marine 
algae represent a rich source of structurally unique compounds with chemotherapeutic 
potential, particularly in South Africa, whose oceans allegedly host 15 % of the total number of 
species in the world. Indeed, a recent study reported the isolation of a range of novel 
compounds from South African red and brown algae of the Plocamium, Portiera and Sargassum 
genera which displayed cytotoxicity against oesophageal cancer cells in vitro. The molecular 
mechanisms mediating this toxicity were unknown, as was the effect of these and similar 
compounds on metastatic ER
-
PR
-
HER2/neu
- 
breast cancer cell lines or breast cancer stem cells. 
The current study aimed to address these questions by screening a library of twenty-two novel 
marine algal compounds for the ability to inhibit MDA-MB-231 and Hs578T breast cancer cells, 
while having no adverse effects on non-cancerous MCF12A breast epithelial cells. While twelve 
of these were toxic in the micromolar range against breast cancer cells, only the 
polyhalogenated monoterpenes RU004 and RU007, and the tetraprenylated quinone 
sargaquinoic acid (SQA) were identified as hit compounds based on the criteria that their 
cytotoxicity was specific to breast cancer and not healthy breast cells in vitro. On the other 
hand, the halogenated monoterpene RU015 was found to be highly toxic to both breast cancer 
and non-cancerous breast cell lines, while the halogenated monoterpene stereoisomers RU017 
and RU018 were non-toxic to either of these cell lines. 
 
The mode of action of RU004, RU007, RU015 and SQA, together with the previously 
characterized carotenoid fucoxanthin (FXN), was assessed in terms of the type of cell death 
induced and the effect on cell cycle distribution of these compounds. Flow cytometric analysis 
of the extent of Hoescht 33342 and propidium iodide staining along with PARP cleavage studies 
suggested that SQA induced apoptosis in MDA-MB-231 cells. On the other hand, the highly 
toxic compound RU015 appeared to induce necrosis as evidenced by 50 kDa PARP cleavage 
product in MDA-MB-231 cells. The flow cytometry profiles of MDA-MB-231 and Hst578T cells 
treated with the hit compounds RU004 and RU007 were suggestive of the induction of 
apoptosis by these compounds. Cell cycle analysis by flow cytometry with propidium iodide 
staining revealed that both SQA and FXN induced G0-G1 arrest together with an increase in the 
apoptotic sub-G0 population, which agreed with previous reports in the literature. 
 
The molecular mechanism of action of SQA and FXN were further investigated by the 
identification of specific signal transducer molecules involved in mediating their anti-cancer 
activities. SQA was found to require the activity of numerous caspases, including caspase-3, -6, 
-8, -9, -10 and -13, for its cytotoxicity and was demonstrated to decrease the level of the anti-
apoptotic protein Bcl-2. On the other hand, FXN was shown to require caspase-1, -2, -3, -9 and -
10 for its toxicity. This, together with the ability to decrease the levels of Bcl-2, pointed to the 
involvement of the intrinsic pathway in particular in mediating the activity of FXN. 
  
The screening of algal compounds against non-cancerous breast epithelial cells carried out in 
this study, together with the investigation into their mechanisms of action, represent one of 
the few reports in which characterization of algal metabolites goes beyond the initial 
cytotoxicity assays. 
 
Finally, in order to assess the potential anti-cancer stem cell activity of the marine algal 
compounds, a subset of these was screened using a mammosphere assay technique developed 
in this study. The cancer stem cell (CSC) theory proposes that cancers arise from and are 
maintained by a specific subpopulation of cells able to undergo asymmetric cell division and 
termed CSCs. These CSCs are capable of anchorage-independent growth in serum-free culture 
conditions, such as those in the mammosphere assay. Using this assay, the novel halogenated 
monoterpene stereoisomers RU017 and RU018 were demonstrated to possess putative anti-
CSC activity as evidenced by their ability to completely eliminate mammosphere formation in 
vitro. Furthermore, since RU017 and RU018 were non-toxic to both breast cancer and healthy 
breast cells, it appeared that the activity of the compounds was potentially specific to the CSCs. 
The results require further validation, but represent the first report of selective anti-CSC 
activity. 
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1. INTRODUCTION 
 
1.1 Cancer: definition and significance 
Cancer, defined as a disease state in which uncontrolled growth and proliferation occurs in one 
or more cell types (Rhaffagello et al., 2008), is currently responsible for more deaths worldwide 
than HIV/AIDS, malaria and tuberculosis combined (Parkin and Bray, 2006). At the turn of the 
millennium, Hanahan and Weinberg proposed six “hallmarks” to describe the features of 
cancer cells, including: 1) independence of exogenous proliferation signals, 2) insensitivity to 
growth-inhibitory signals, 3) evasion of apoptosis, 4) metastasis and invasion of other tissues, 5) 
the support of angiogenesis and 6) the development of drug resistance (Hanahan and 
Weinberg, 2000). Significant progress in the understanding of the etiology of cancer has led to 
the recent addition of two more hallmarks, namely the deregulation of metabolic processes 
and the evasion of the immune response (Colotta et al., 2009; Hanahan and Weinberg, 2011). 
 
A number of the hallmarks of cancer arise from the deregulation of signal transduction 
pathways (Hanahan and Weinberg, 2000; Dhillon et al., 2007). Cells control and coordinate 
biochemical activities in response to a range of environmental stimuli via complex signalling 
systems (Rosen, 1987). These signalling pathways control survival, proliferation, differentiation 
and apoptosis and allow the cell to cope with changes and stresses in its environment (Weston 
and Davis, 2007). In human cancers, the tight control of the above cellular processes is lost at 
least in part through multiple alterations in the signal transduction machinery (Dhillon et al., 
2007).  
 
What follows is a description of some of the major signal transduction pathways deregulated in 
cancer cells, their significance in terms of the origin and maintenance of the malignant state, as 
well as attempts to target cancer cells by the development of pathway specific inhibitors. 
 
1.2 The relationship between apoptosis and cancer 
As described above, the evasion of apoptosis is one of the key hallmarks of cancer (Hanahan 
and Weinberg, 2000). This occurs either by the over-expression of anti-apoptotic molecules or 
the decreased expression of pro-apoptotic molecules (Speir et al., 2011). While conventional 
cancer treatments such as chemotherapy and radiation aim to induce apoptosis by causing 
damage to the DNA of the transformed cell, it is these alterations in apoptotic molecules that 
allows cells to become resistant to these treatments (Debatin and Krammer, 2004; Klener Jr. et 
al., 2006).  
 
 
 
3 
 
1.2.1 The cellular apoptotic machinery 
The term apoptosis is derived from the Greek description of falling leaves or petals and is an 
essential part of life for multicellular organisms (Jin and El-Deiry, 2005; Klener Jr. et al., 2006) 
Apoptosis or programmed cell death is an active process which was first described in 1972 and 
was found to be vital for development, immune function, tumour suppression and the 
maintenance of cellular homeostasis (Kerr et al., 1972; Jin and El-Deiry, 2005; Iannolo et al., 
2008). During development, an organism produces more cells than are required and apoptosis 
allows for the elimination of these excess cells without eliciting an inflammatory response 
(Meier et al., 2000; Iannolo et al., 2008). Characteristic apoptotic morphological features 
include membrane blebbing, cell shrinkage, DNA fragmentation and chromatin condensation 
(Savill and Fadok, 2000; Jin and El-Deiry, 2005). Other forms of programmed cell death which 
do not elicit an immune response include autophagy and anoikis. Autophagy describes the 
process within a dying cell whereby the cellular components are degraded in autophagosomes 
and is often associated with infection of cells by viruses and other parasites (Lockshin and 
Williams, 1965; Lockshin and Zakeri, 2004). On the other hand, anoikis is a form of programmed 
cell death associated with the detachment of anchorage-dependent cells from the extracellular 
matrix (Frisch and Francis, 1994; Gilmore, 2005). 
 
In contrast to programmed cell death mechanisms, necrosis is described as a passive, 
uncontrolled and irreversible process occurring in response to a major environmental insult 
(Fink and Cookson, 2005; Klener Jr. et al., 2006).  Here, the cell ruptures and releases its 
contents into the surrounding tissues, which produces a strong inflammatory response (Leist 
and Jaattela, 2001; Jin and El-Deiry, 2005). Another form of uncontrolled cell death is mitotic 
catastrophe where aberrant mitosis produces giant, multinucleate cells containing 
uncondensed chromosomes (Takai et al., 2000).  
 
Caspases or cysteine aspartic acid-specific proteases are central initiators and executioners of 
apoptosis (Green and Kroemer, 1998; Jin and El-Deiry, 2005). These enzymes are synthesized as 
inactive precursors called zymogens, which are activated by proteolytic cleavage, resulting in 
cascades where upstream caspases activate their downstream counterparts at specific aspartic 
acid residues (Stennicke and Salvesen, 2000; Klener Jr. et al., 2006). Caspases are divided into 
two groups: those that participate in inflammation (caspase-1, -4, -5, -11, -12, -13 and -14) and 
those involved in mediating apoptosis (caspase-2, -3, -6, -7, -8, -9, 10) (Thornberry et al., 1998; 
Martinon et al., 2002; Jin and El-Deiry, 2005; Klener Jr. et al., 2006). The apoptotic caspases are 
further divided into initiator and effector caspases. The initiator caspases (2, 8, 9 and 10) are 
auto-activated in the presence of certain adaptor proteins by a proximity-induced mechanism 
and activate downstream effector caspases (Thornberry et al., 1997; Boatright et al., 2003). The 
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effector caspases (3, 6 and 7) are more abundant than the initiator variety and cleave various 
cellular substrates to induce cell death (Jin and El-Deiry, 2005). 
 
Apoptosis is induced by both external and internal signals and occurs via two major pathways: 
the extrinsic or receptor-mediated pathway and the intrinsic or mitochondrial pathway 
(Nagata, 1997; Kroemer and Reed, 2000). These pathways converge on a final step, which 
results in the cleavage of regulatory and structural molecules (Klener Jr. et al., 2006).  
 
1.2.1.1 The extrinsic/receptor-mediated apoptotic pathway 
The extrinsic apoptotic pathway, shown in Figure 1.1, is activated by external signals and 
involves the binding of a death-inducing ligand to a cell surface receptor (Nagata, 1997; Klener 
Jr. et al., 2006). Death ligands are type II membrane glycoproteins belonging to the tumour 
necrosis factor (TNF) superfamily and are arranged in stable homotrimers (Gruss et al., 1996; 
Jin and El-Deiry, 2005). These ligands are either membrane bound or cleaved by 
metalloproteinase into soluble form (Gruss et al., 1996). The TNF ligand family includes TNF-α 
(TNFSF2/cachectin), Fas ligand (FasL/TNFSF6/CD95L/Apo-1L) and TNF-related apoptosis 
inducing ligand (TRAIL, TNFSF10) (Ashkenazi and Dixit, 1998; Jin and El-Deiry, 2005). These 
death ligands exert their effects by binding to their respective receptors on the cell surface 
(Klener Jr. et al., 2006). 
 
The death receptors are type I membrane proteins, which belong to the TNF receptor (TNF-R) 
superfamily (Ashkenazi and Dixit, 1998). The TNF-R family is divided into death receptors and 
decoy receptors (DcR) and comprises TNF-R1, which binds TNF-α; Fas (TNFRSF6, Apo-1, CD95), 
which binds FasL (TNFSF6/CD95L/Apo-1L); TRAIL-R1 (DR4/TNFRSF10A/APO-2/MGC9365) and 
TRAIL-R2 (DR5/TNFRSF10B /KILLER/TRICK2), which both bind TRAIL; DR3 and DR6 (Pan et al., 
1997b; Walczak et al., 1997; Wu et al., 2000; Klener Jr. et al., 2006). Decoy receptors include 
the Fas decoy, DcR3, and the TRAIL decoys, DcR1 (TNFRSF10C/TRAIL-R3/TRID), DcR2 
(TNFRSF10D/TRAIL-R4/TRUNDD) and osteoprotegerin (OPG) (Jin and El-Deiry, 2005). Receptors 
belonging to the TNF-R family possess a cysteine-rich extracellular domain (CRD), which is 
responsible for interaction with the death ligand (Baud and Karin, 2001; Jin and El-Deiry, 2005). 
Whereas death receptors possess a highly conserved intra-cytoplasmic death domain, decoy 
receptors lack this domain and are unable to transduce the apoptotic signal but compete for 
binding of the death ligand, thereby abrogating apoptosis via the extrinsic pathway (Pan et al., 
1997a; Ashkenazi and Dixit, 1998).    
 
 
 
 
 Figure 1.1: Overview of the extrinsic, receptor
ligand to its relevant receptor results in the cleavage of procaspase
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are cell shrinkage, membrane blebbing, DNA fragmentation and chromatin condensation leading to 
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receptor (Kischkel et al., 2001; Seol et al., 2001). Procaspase-8 is then autocatalytically cleaved 
to form active caspase-8, which activates numerous downstream targets including caspase-3 
and Bid, the cleavage of which represents the convergence point of the extrinsic and intrinsic 
apoptotic pathways (Chou et al., 1999; Klener Jr. et al., 2006). The pro-apoptotic regulator Bid 
is cleaved to a truncated form, t-Bid, which then translocates to the mitochondrial membrane 
and stimulates the release of pro-apoptotic effectors (Figure 1.2) (Chou et al., 1999). 
 
1.2.1.2. The intrinsic/mitochondrial apoptotic pathway 
The intrinsic pathway depicted in Figure 1.2 is initiated within cells in response to various 
cellular stresses including growth factor deprivation, osmotic shock, hypoxia, DNA damage, 
heat shock, UV radiation, cytotoxic agents, the accumulation of misfolded proteins and the 
disruption of cytoskeletal structures (Jin and El-Deiry, 2005; Klener Jr. et al., 2006; Iannolo et 
al., 2008). All of these stress stimuli converge on pivotal cellular events including mitochondrial 
outer membrane permeabilisation (MOMP), increased production of reactive oxygen species 
(ROS) and mitochondrial fission (Green and Kroemer, 2004; Jin and El-Deiry, 2005). Release of 
Ca2+ from the endoplasmic reticulum as a result cellular stress causes a rapid uptake of Ca2+ by 
the mitochondria. This, in turn results in the release of ROS and the opening of mitochondrial 
permeability transition (MPT) pores. The latter produces a massive mitochondrial inner 
transmembrane potential loss (ΔΨm) and swelling which causes MOMP (Petrosillo et al., 2004; 
Klener Jr. et al., 2006). Thereafter, the outer membrane ruptures releasing cytochrome C and 
other pro-apoptotic molecules from the mitochondrial intermembrane space into the 
cytoplasm (Green and Kroemer, 2004; Jin and El-Deiry, 2005).  
 
The changes in mitochondrial membrane permeability are both mediated and tightly controlled 
by Bcl-2 family members (Green and Kroemer, 2004). In mammals there are around 20 
members of the Bcl-2 family, which are divided into three groups all of which contain between 
one and four Bcl-2 homology (BH) domains (Fesik, 2000; Klener Jr. et al., 2006). The first group 
consists of the anti-apoptotic molecules Bcl-2, Bcl-xL, Mcl-1 and A1, which have all four BH 
domains (BH1234) (Cheng et al., 2001; Jin and El-Deiry, 2005). Next are the pro-apoptotic 
effector Bcl-2 proteins, Bax, Bak and Bok, which contain three BH domains (BH123). The final 
group is made up of the pro-apoptotic damage sensing proteins, Bid, Bad, Bmf and Bim, which 
contain only the BH3 domain (Zong et al., 2001; Jin and El-Deiry, 2005). 
 
 
 Figure 1.2: Overview of the intrinsic or mitochondrial apoptotic pathway. Stresses such as ultraviolet (UV) 
radiation or chemotherapeutic agents trigger the activation and accumulation of pro
proteins such as Bad, Bim, Bax and Bak. The latter two insert into the
causing mitochondrial permeability transition (MPT) pores from which deat
c (cyto C), procaspase-9, second mitochondrial activator of caspases (SMAC), HtrA2/Omi, endonuclease 
G (Endo G) and apoptosis initiating factor (AIF) are released to effect programmed cell death. 
Procaspase-9, cytochrome c and apoptotic protease
which results in cleavage and activation of procaspase
apoptosis. This process is inhibited by inhibitory apoptotic proteins (IAPs), which are themselves inhibited 
by SMAC and HtrA2/Omi. The effect of the survival pathway kinase, Akt, as well as intersection with the 
extrinsic pathway (death receptor) via the Bcl family protein, Bid, are
El-Deiry, 2005). 
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and 2) through disruption of mitochondrial function (Green and Kroemer, 2004). Once released 
into the cytoplasm, cytochrome c, in the presence of ATP, binds to apoptotic protease-
activating factor-1 (Apaf-1) and undergoes a conformational change (Finucane et al., 1999; 
Klener Jr. et al., 2006). The caspase adaptor, Apaf-1, then recruits procaspase-9 to form a 
holoenzyme complex called the “apoptosome,” which activates downstream executioner 
caspases including caspase-3, 6 and 7 (Figure 1.2) (Iannolo et al., 2008).  
 
In addition to cytochrome c, the pro-apoptosis proteins, apoptosis inducing factor (AIF) and 
second mitochondrial activator of caspases/direct IAP binding protein with low pI 
(SMAC/DIABLO) and endonuclease G (endoG), are released from the mitochondrial 
intermembrane space upon MOMP (Klener Jr. et al., 2006). Upon release of AIF into the 
cytoplasm it migrates to the nucleus and induces chromatin condensation and large scale DNA 
fragmentation. Similarly, EndoG moves to the nucleus and facilitates oligonucleosomal DNA 
fragmentation (Susin et al., 2000). The role of SMAC/DIABLO and the related protein, 
HtrA2/Omi, is to competitively bind inhibitory apoptotic proteins (IAPs), thus preventing 
binding and inhibition of caspases (Figure 1.2) (Du et al., 2000; Jin and El-Deiry, 2005).          
 
In the final stages of apoptosis, the cell is “dismantled” step by step, displaying DNA 
fragmentation; proteolysis of structural proteins such as lamin, actin and cytokeratin; and the 
formation of apoptotic vesicles from the shrinking cell (Savill and Fadok, 2000; Klener Jr. et al., 
1997). During these final events, phosphotidylserine moves from the inner to the outer cell 
membrane. This serves as a signal to phagocytes, resulting in engulfment of the apoptotic cell. 
The efficient recognition and clearance of apoptotic cells is essential to prevent leakage of 
potentially cytotoxic cell contents and to maintain tissue homeostasis (Fadok et al., 1998; Jin 
and El-Deiry, 2005).   
 
1.2.2 Targeting of the apoptotic pathway in cancer treatment 
In recent years, the focus in the development of anti-cancer drugs which induce apoptosis has 
moved away from the non-specific DNA-damaging agents towards the targeting of individual 
molecules of the cell death machinery (Debatin and Krammer, 2004; Speir et al., 2011). In 
particular, studies have focused on the use of death ligands, SMAC agonists and both IAP and 
Bcl-2 anti-sense therapy (Ashkenazi et al., 1999; Debatin and Krammer, 2004; Jin and El-Deiry, 
2005; Speir et al., 2011).  
 
In terms of death ligands, research has been carried out on the suitability of TNF, CD95L and 
TRAIL as potential anti-cancer drugs (Nagata, 1997; Ashkenazi et al., 1999; Debatin and 
Krammer, 2004). This is an attractive option in cancer treatment since it triggers an apoptotic 
pathway that is independent of p53, a tumour suppressor which is the most commonly 
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mutated gene in human cancer (El-Deiry, 2001). Disappointingly, the prototypic death ligands, 
TNF and CD95L, showed high toxicity in clinical trials, with administration of TNF resulting in 
septic shock and CD95L treatment leading to hypertension, liver failure and, ultimately, death 
(Nagata, 1997; Jin and El-Deiry, 2005). On the other hand, TRAIL was able to induce apoptosis in 
a wide range of human cell lines, while displaying little toxicity, making it a more promising 
candidate for clinical application (Ashkenazi et al., 1999; Debatin and Krammer, 2004). 
Furthermore, what potential toxicity exists for this ligand, particularly in hepatocytes and brain 
tissue, can be overcome by removing the His-tag and optimizing its zinc content to prevent the 
formation of aggregates within the cells (Jo et al., 2000; LeBlanc and Ashkenazi, 2003). In this 
form, recombinant TRAIL is able to induce apoptosis in vitro in colon, prostate, breast, lung and 
pancreatic carcinoma; as well as in vivo in mouse xenograft models of colon and breast 
carcinoma, multiple myeloma and malignant glioma (Ashkenazi et al., 1999; Walczak et al., 
1999; Chuntharapai et al., 2001; Ichikawa et al., 2001; LeBlanc and Ashkenazi, 2003). Although 
a large number of tumours are refractory to TRAIL, combination with chemotherapy and 
radiation is able to sensitize these cells to treatment with TRAIL (Chinnaiyan et al., 2000). TRAIL 
remains the central extrinsic apoptotic pathway-specific cancer treatment to date (Speir et al., 
2011).  
 
Anti-sense therapies targeted towards the anti-apoptotic molecules up-regulated in various 
tumours have received considerable interest as a means of pharmacological intervention in 
cancer treatment (Debatin and Krammer, 2004). In particular, Bcl-2 has been targeted due to its 
role in resistance to apoptosis induction by cytotoxic drugs (Reed, 1999). The anti-sense 
oligonucleotide G3139 (Genasense), which suppresses bcl-2 expression, has been tested with 
some success both in vitro and in vivo, with clinical trials being carried out in Hodgkin’s 
lymphoma, leukemia, multiple myeloma, prostate and lung cancers (Waters et al., 2000; Chi et 
al., 2001; Rudin et al., 2002). The IAP family of caspase inhibitors, in particular XIAP and 
survivin, have also been targeted by anti-sense therapy due to their overexpression in a 
number of tumours, including breast cancer, melanoma, leukemia and neuroblastoma (Debatin 
and Krammer, 2004). These agents have been shown to resensitize cells to both 
chemotherapeutic drugs and death receptor stimulation (Tamm et al., 2003). 
 
1.2.3 Regulation of apoptosis 
In line with its classification as a programmed form of cell death, apoptosis is stringently 
regulated (Jin and El-Deiry, 2005). This occurs not only via the balance of pro-apoptotic and 
anti-apoptotic Bcl-2 family mitochondrial-associated proteins, but also due to the interaction of 
numerous apoptotic signal transducers with elements of survival pathways such as the 
mitogen-activated protein kinase (MAPK) systems and the Akt/protein kinase B (PKB) pathway 
(Green and Kroemer, 2004; McCubrey et al., 2007; LoPiccolo et al., 2008). 
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1.3 Alterations in cellular survival pathways associated with cancer 
In normal healthy tissues, survival pathways allow for cells to grow and proliferate in a way that 
ensures homeostasis, provided that these pathways are tightly controlled (Finnberg and El-
Deiry, 2004; Grant, 2008). However, when survival cascades are aberrantly activated, cells 
replicate out of control and expand beyond their organ boundaries, which may result in 
diseases such as cancer (Finnberg and El-Deiry, 2004; Song et al., 2005). It has been reported 
that pathway activation is one of the most frequent molecular mutations in human cancers and 
represents an early event in carcinogenesis (Granville et al., 2006; LoPiccolo et al., 2008). Two 
of the most frequently dysregulated signal transduction cascades in cancer are the Raf/MEK 
(mitogen-activated ERK kinase)/ERK (extracellular signal-related kinase) and the Akt/PI3K 
(phosphatidy-linositide-3-kinase)/PTEN (phosphatase and tensin homologue deleted on 
chromosome 10) pathways (Grant, 2008).   
 
 
1.3.1 The MAP kinase signalling pathways   
The mitogen-activated protein kinase (MAPK) pathways are highly conserved kinase modules 
which are involved in mediating cellular responses to almost all environmental stimuli to 
facilitate membrane, cytoplasmic and nuclear signalling (Dhanasekeran and Johnson, 2007; 
Dhillon et al., 2007).  Cellular processes regulated by MAPKs include growth, proliferation, 
differentiation, migration, apoptosis, chromatin remodeling and angiogenesis (Dunn et al., 
2005; Yoon and Seger, 2006; Dhillon et al., 2007). All MAPK pathways are composed of a three-
tier kinase module where a MAPK is phosphorylated and activated by a MAPK kinase (MAPKK) 
which in turn is activated by a MAPKK kinase (MAPKKK) (Figure 1.3) (Dhanasekeran and 
Johnson, 2007; Dhillon et al., 2007). At least eleven MAPKs, seven MAPKKs and 20 MAPKKKs 
have been reported (Dhanasekeran and Johnson, 2007). In mammals, the existing MAP kinases 
are classified into six groups, namely extracellular signal-regulated kinases (ERK) ERK1/2, 
ERK3/4, ERK5, ERK7/8, c-Jun N-terminal kinase (JNK)1/2/3 and the p38 isoforms α/β/γ(ERK6)/δ 
(Figure 1.3) (Schaeffer and Weber, 1999; Chen et al., 2001). 
 
 
 Figure 1.3: Overview and classification of the mitogen
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 Activation of Raf is complex and involves a series of five events, namely (1) recruitment to 
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Figure 1.4: Schematic representation of the Raf/MEK/ERK pathway, the best studied of the MAPK 
signalling systems. Upon binding of a growth factor to its specific receptor, phosphorylation by the 
receptor (receptor tyrosine kinase, RTK) 
factor receptor bound 2-son of Sevenless (
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Activated Raf phosphorylates MEK1 and MEK2 on conserved Ser218 and Ser222 residues within 
the catalytic domain in order to stimulate their dual specificity tyrosine and serine/threonine 
kinase activity (Alessi et al., 1994; McCubrey et al., 2007; Dhillon et al., 2007). While all three 
Raf isoforms are capable of activating MEK, they vary in the strength of their MEK kinase 
activity with B-Raf being the strongest activator, followed by Raf-1 and then A-Raf (Marais et 
al., 1997). Another MEK phosphorylation site, Ser212, has been reported to negatively regulate 
MEK activity (Gopalbhaj et al., 2003).  
 
The downstream targets of MEK1 and MEK2 are ERK1 and ERK2, which phosphorylate more 
than 160 cytoplasmic and nuclear targets, including kinases, phosphatases, transcription factors 
and cytoskeletal elements (Yoon and Seger, 2006; McCubrey et al., 2007; Gough, 2011). ERK 
can enter the nucleus and directly phosphorylate transcription factors such as c-Myc, c-Jun and 
Ets-1; or it may activate the ribosomal kinase, p90Rsk, which in turn activates the transcription 
factor, CREB (cAMP-response element binding protein) (Steelman et al., 2004; McCubrey et al., 
2007). 
 
In line with its role as a survival pathway, Raf/MEK/ERK interacts with a number of apoptotic 
regulatory molecules in order to prevent apoptosis (described in Section 1.2 above) (McCubrey 
et al., 2007). The first apoptotic molecule found to be influenced by this pathway was Bad, a 
mitochondrial-associated pro-apoptotic regulator (Zha et al., 1996). Phosphorylation of Bad on 
Ser112 by the Raf/MEK/ERK pathway results in its inactivation and sequestration by the 
chaperone protein, 14-3-3. As a result, the anti-apoptotic protein, Bcl-2, is able to dimerize and 
inhibit apoptosis. In addition, the pro-apoptotic regulator, Bim, is phosphorylated by ERK on 
Ser69 and targeted for degradation, allowing for the activation of the anti-apoptotic proteins, 
Bcl-2, Bcl-XL and Mcl-1. This, in turn, prevents the dimerization and activation of the pro-
apoptotic protein, Bax (Harada et al., 2004; McCubrey et al., 2007). Apart from mitochondrial 
apoptotic proteins, it has been shown that the Raf/MEK/ERK pathway can modulate the activity 
of the cytoplasmic executioner, caspase-9. Phosphorylation of caspase-9 on Tyr125 results in its 
inactivation, such that apoptosis is prevented (Allan et al., 2003). Caspase-9 may also be 
inactivated by Akt, highlighting the cross-talk between the Raf/MEK/ERK and PI3K/Akt survival 
pathways (McCubrey et al., 2007).      
 
1.3.1.1 The role of Raf/MEK/ERK pathway mutations in cancer 
At least 25 small molecule inhibitors targeting the MAPK pathways have reached clinical trials 
to date (Santarpia et al., 2012). The best studied of these pathways, the Raf/MEK/ERK system, 
is deregulated in one-third of all human cancers and has been the focus of anti-cancer drug 
discovery for at least 15 years (Dhillon et al., 2007). The rationale for targeting this pathway is 
that it is the convergence point for most, if not all, mitogenic signalling pathways (Kohno and 
 Pouyssegur, 2003). In addition, inhibition of the ERK pathway produces anti
due to the effect of the pathway on motility in response to hepatocyte growth factor (HGF), 
and anti-angiogenic effects, as a result of stimulation of vascular endothelial growth factor 
(VEGF), a powerful angiogenic factor (Kohno and Pouyssegur, 2003). The main causes of 
constitutive activation of the pathway are mutations in components which lie upstream of ER
and thus the major targets for pathway inhib
2007).  
 
Figure 1.5: Targeting the Raf/MEK/ERK survival pathway in cancer treatment
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(concentration at which cell survival is 50 % of that of an untreated control) of 9 nm and 12 nm 
for GW5074 and BAY43-9006, respectively (Lackey et al., 2000; Lyons et al., 2001). In addition, 
in vivo inhibitory effects have been noted for BAY 43-9006 in colon, pancreatic and lung 
carcinomas and clinical trials in various locally advanced and metastatic cancers are underway, 
an example of which is the Phase II trial combining BAY 43-9006 with transarterial 
chemoembolization (TACE) and doxorubicin-eluting beads (DEB) in patients with advanced 
hepatocellular carcinoma (Lyons et al., 2001; Kohno and Pouyysegur, 2003; Pawlik et al., 2011). 
An alternate approach to targeting Raf is the use of specific anti-sense oligonucleotides which 
hybridize to the 3' UTR of the mRNA, thus inhibiting translation of a functional Raf enzyme 
(Monia et al., 1996; Kohno and Pouyysegur, 2003). The 20-base pair phosphorothioate 
oligodeoxynucleotide, ISIS 5132, is such a compound and displays IC50 values of between 50 and 
100 nm in vitro in breast, lung and bladder cell lines, with tumour reduction being noted in vivo 
as well as early clinical trials (O’Dwyer et al., 1999; Stevenson et al., 1999; Fidias et al., 2009). 
An example of such a clinical trial is the Phase I study using ISIS 5132 in combination with 
carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (Fidias et al., 
2009).  
 
Whereas the above agents target specific Raf isoforms, it is possible to inhibit all three isoforms 
using geldanamycin. This drug is a highly specific inhibitor of the molecular chaperone, heat-
shock protein 90 (Hsp90), which is, in turn, an obligatory chaperone of the Raf enzymes 
(Chiosis, 2006; Dhillon et al., 2007). Raf is activated upon dimerization, a process which requires 
Hsp90; therefore inhibition of Hsp90 blocks activation of Raf by preventing these essential 
protein-protein interactions (Blagosklonny, 2002; McCubrey et al., 2007). Geldanamycin and its 
derivatives (Figure 1.6C) have shown promising results as anti-cancer drugs in clinical trials for a 
variety of tumour types (Kim et al., 2009). 
 
Since MEK1 and MEK2 interact with numerous upstream kinases but only ERK1 and ERK2 as 
downstream substrates, this convergence point is an attractive therapeutic target in the 
development of pathway-specific inhibitors (Kohno and Pouyssegur, 2003). The first MEK 
inhibitor to be identified was PD98059, followed by U0126 and the second generation inhibitor, 
PD184352 (Figure 1.6 D-F), the latter of which displays an IC50 value of 2 nm (Dudley et al., 
1995; Favata et al., 1998; Sebolt-Leopold et al., 1999; Davies et al., 2000). These agents inhibit 
MEK indirectly by preventing phosphorylation by Raf (Kohno and Pouyysegur, 2003). In 
addition, a number of resorcylic acid lactones have been isolated from microbes, which display 
powerful anti-MEK activity. Examples include Ro 09-2210, which was isolated from fungal broth 
and L-783,277, extracted from a Phoma species (Figure 1.6 G and H, respectively). Here, 
inhibition is by competitive binding of ATP, with IC50 values of 60 nm and 4 nm for Ro 09-2210 
and L-783,277, respectively (Williams et al., 1998). Finally, Compound 14, a 3-cyano-4-
 (phenoxyanilino) quinolone (Figure
vitro with an IC50 value of 2.4 nm in human colon carcinoma cell lines (Zhang 
 
 
 
Figure 1.6: Chemical structures of several inhibitors of the Raf/MEK/ERK pathway. Raf
inhibitors include GW5074 (A) and BAY43
achieved using the Hsp90 inhibitor geldanamycin and 
inhibitors of MEK1 and MEK2 include PD98059 (D), U0126 (E
PD184352 (F), the resorcylic acid lactones, Ro 09
(phenoxyanilino)quinolone, Compound 14 (I
Pouyysegur, 2003). 
 
                                         
It was only recently that specifi
kinase, were reported, although 
al., 2011). Other promising strategi
RNA (siRNA), which are roughly 19 nucleotides long and extremely powerful agents for the 
destruction of specific mRNA transcripts
 1.6I) was developed by Wyeth-Ayers and inhibits MEK 
et al
-9006 (B). Inhibition of all three Raf isoforms
its analogues 17AAG and 17DMAG
), the second generation inhibitor, 
-2210 (G) and L-783,277 (H) and the 3
), developed by Wyeth-Ayers (modified
c inhibitors of ERK1/2, targeting the docking domain of the 
their development has not yet reached clinical trials (Boston 
es to target this pathway include the use of small interfering 
 (Elbashir et al., 2001).   
16 
in 
, 2000). 
 
-1-specific 
 has been 
. Specific 
-cyano-4-
 from Kohno and 
et 
17 
 
1.3.2. The Akt/PKB signal transduction pathway 
The Akt pathway depicted in Figure 1.7 is a key survival pathway which regulates a number of 
processes including nutrient metabolism, cell growth, proliferation and survival (Granville et al., 
2006; LoPiccolo et al., 2008). Activation of this pathway occurs at the cytoplasmic membrane 
(Andjelkovic et al., 1997; Song et al., 2005). Various growth factors, such as insulin-like growth 
factor (IGF) and epidermal growth factor (EGF), bind to their receptors, resulting in the 
activation of the lipid kinase PI3K (Burgering and Coffer, 1995; Robertson, 2005; LoPiccolo et 
al., 2008). Following activation, PI3K catalyzes the phosphorylation of phosphoinositides to 
produce the lipid second messengers, phosphoinositide-4,5-bisphosphate (PIP2) and 
phosphoinositide-3,4,5-tri- phosphate (PIP3) (Vanhausebroek and Alessi, 2000; Robertson, 
2005). PIP3 is able to recruit various proteins, such as Akt and PDK-1 (phosphoinositide-
dependent kinase-1) to the cell membrane via their pleckstrin homology (PH) domains 
(Lemmon and Ferguson, 2000). This process is tightly regulated by the dual protein and lipid 
phosphatase, PTEN, which antagonizes PI3K by dephosphorylating 3'-phosphoinositides 
(Maehama et al., 1998; Blanco-Aparicio, 2007).  
 
Activation of Akt occurs by two site-specific phosphorylation events at both its conserved 
threonine and serine residues (Alessi et al., 1996). Upon production of PIP3 by PI3K, both Akt 
and PDK-1 are translocated to the cell membrane. Here, Akt is phosphorylated by PDK-1 at the 
conserved threonine residue within the central kinase domain of Akt (Alessi et al., 1996; 
Robertson, 2005). Full activation of Akt requires the additional phosphorylation of the 
conserved serine residue within the hydrophobic motif of its C-terminal domain (Alessi et al., 
1996; LoPiccolo et al., 2008). This phosphorylation may be carried out by PDK-1, its homologue 
PDK-2, an integrin linked kinase (ILK), a DNA-dependent protein kinase or by Akt itself via its 
kinase domain (Stephens et al., 1998; Robertson, 2005; Song et al., 2005; LoPiccolo et al., 
2008). Dephosphorylation of Akt by phosphatases such as protein phosphatase 2A (PP2A) 
results in the deactivation of Akt, thereby modulating downstream signalling by this key protein 
(Millward et al., 1999). 
 
Activated Akt has numerous downstream targets, including those involved in the regulation of 
transcription, translation, cell cycle progression, glucose metabolism, apoptosis and many other 
cellular processes (Figure 1.7) (Robertson, 2005; Granville et al., 2006). Akt exerts its effect by 
phosphorylation of target proteins at a consensus sequence, RXRXX(S/T), that is surrounded by 
hydrophobic amino acids (Obenhauer et al., 2003). The best-characterised of the Akt targets is 
the mammalian target of rapamycin (mTOR) (Chiu et al., 1994). mTOR controls a variety of 
important cellular processes such as protein synthesis and degradation, transcription, protein 
kinase C signalling, cell cycle progression and angiogenesis (Sabers et al., 1995; Panwalkar et al., 
2004; Granville et al., 2006).  
 Figure 1.7: Cellular mechanism of activation of Akt
phosphorylates and activates PI3 kinase
bisphosphate) to produce PIP3 (phosphoinositide
and activation of Akt at the conserved threonine 308 (T308) residue in 
phosphoinositide-dependent kinase (PDK1). This is followed by phosphoryl
473 (S473) within the regulatory domain 
itself. Akt is recruited to the plasma membrane via its pleckstrin homology (PH domain)
downstream targets such as the mammalian target of rapamycin (mTOR), so as to stimulate protein 
synthesis, proliferation, cell cycle progression and glucose metabolism
(Modified from Song et al., 2005). 
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activated Akt acts as a “survival signal” and allows cells to evade apoptosis. Examples of 
apoptotic molecules whose activity is modulated by Akt are the pro-apoptotic proteins, Bad 
and Caspase-9, whose ability to induce apoptosis is attenuated as a result of phosphorylation 
by activated Akt (Datta et al., 1997; del Peso et al., 1997; Donepudi et al., 2002; LoPiccolo et al., 
2008). 
 
1.3.2.1 Deregulation of the Akt pathway in cancer 
The Akt/PKB (protein kinase B) survival cascade is subject to strict control via the C-terminal 
regulatory domain of Akt, which contains two regulatory phosphorylation sites (Alessi et al., 
1996). The phosphorylation of these sites depends on the amount of PIP3 generated by PI3 
kinase, a process which is regulated by PTEN (Maehama et al., 1998). Loss of PTEN function is 
thus the most common cause of constitutive activation of the pathway and has been observed 
in human cancers of the brain, bladder, prostate, breast and endometrium (Li et al., 1997; 
Rasheed et al., 1997; Ali et al., 1999; Aveyard et al., 1999; Dahia, 2000; Dreyer et al., 2004; 
LoPiccolo et al., 2008). This may occur by mutation, deletion or epigenetic silencing of PTEN and 
is associated with poor prognosis (Smith et al., 2001; Bertram et al., 2006; LoPiccolo et al., 
2008). Other events which trigger pathway dysregulation include overexpression and activation 
of growth factor receptors, PI3K and Akt (LoPiccolo et al., 2008). Alterations in PI3K activity 
occur by amplification, overexpression or mutations have been observed in 40 % of ovarian and 
50% of cervical cancers (Shayesteh et al., 1999; Ma et al, 2000). Furthermore, it has been found 
that phosphorylation of the Ser473 residue of Akt is associated with poor prognosis in a wide 
range of human cancers (LoPiccolo et al., 2008).   
 
1.3.2.2 Targeting the Akt survival pathway in cancer treatment 
The Akt pathway is an attractive target in cancer treatment as it serves as a convergence point 
for numerous growth stimuli as well as controlling cellular processes which contribute to 
tumour development and maintenance via its large array of downstream substrates. As a 
result, a number of small molecule inhibitors of this pathway are in clinical trials. The main 
targets for pathway-specific therapies are PI3K, Akt and mTOR (Figure 1.8). These inhibitors are 
often combined with one another, with chemotherapy or radiation and with inhibitors of other 
pathways (LoPiccolo et al., 2008). 
 
Research has shown that targeting of the pathway elements which lie furthest upstream is 
advantageous for inhibiting more distal components, as this has a broader effect on 
downstream signalling (LoPiccolo et al., 2008). With this in mind, the phosphoinositide kinase, 
PI3K, appears as an attractive target for therapy. The best-characterized PI3K inhibitors to date 
are wortmannin and 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), (Figure 1.9 A and B, 
respectively) both of which affect the catalytic subunit of the enzyme (Granville et al., 2006; 
 LoPiccolo et al., 2008). Although both commercially available a
in vitro and in vivo, poor solubility and high toxicity have limited their clinical application 
(Schultz et al., 1995; Semba et al
 
 
Figure 1.8: Summary of the targeted inhibition of the PI3K/Akt/mTOR pathway, including the best
characterized pathway-specific small molecule
receptor tyrosine kinase (RTK), phosphoinoside
(mTOR) proteins in this pathway (Adapted
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2011). Phase I and II clinical trials of perifosine have been carried out for a number of different 
cancer types, including that of the pancreas, prostate and breast, as well as Phase III clinical 
trials in AML and colon cancer (Posadas et al., 2005; Leighl et al., 2007; Marsh Rde et al., 2007; 
LoPiccolo et al., 2008; Alexander, 2011). Unfortunately, low efficacy and toxicity concerns 
meant that it was not a good candidate for monotherapy. On the other hand, when combined 
with classic chemotherapeutic drugs or radiation, it showed promising inhibitory activity in 
vitro, with synergistic effects being noted with etoposide (in leukemia), doxorubicin (multiple 
myeloma) and temozolomide (glioma) (Momota et al., 2005; Hideshima et al., 2006; Nyakern et 
al., 2006;). The tricyclic nucleoside, triciribine or API-2 (Figure1.9F), acts by preventing 
phosphorylation at both the kinase and regulatory domains of Akt, thus abrogating its function 
(Mittelman et al., 1983). A number of phase I and II clinical trials using triciribine in various 
advanced cancer types were carried out in the 1980’s and 1990’s (LoPiccolo et al., 2008). In 
these studies, minimal efficacies and serious toxicities such as hepatotoxicity and 
hyperglycemia were observed (Feun et al., 1984; Feun et al., 1993; Hoffman et al., 1996). More 
recent phase I trials are in progress using lower doses of the drug, as well as combinations with 
tyrosine kinase inhibitors, including erlotinib and lapatinib or drugs targeting other molecules of 
the PI3K-AKT-pathway (Yang et al., 2004; Granville et al., 2006; LoPiccolo et al., 2008;  
Gloesenkamp et al., 2012). 
 
By far the most developed class of Akt pathway inhibitors are the agonists of mTOR (Wander et 
al. 2011). Of these, rapamycin, the prototypic mTOR inhibitor was discovered in 1975. 
Rapamycin (Figure 1.9G) is produced by Streptomyces hygroscopicus and was found to be a 
potent fungicide (Sehgal et al., 1975). This compound is a Food and Drug Administration (FDA)-
approved immunosuppressant (Granville et al., 2006). In addition, the compound displayed the 
ability to inhibit cancer cell proliferation, nearly 30 years ago (Douros and Suffness, 1981). The 
analogues RAD-001 (everolimus) and CCI-779 (temsirolimus) (Figure 1.9H and I, respectively) 
have been designed specifically as anti-cancer drugs and have shown great efficacy as both 
single agents and in combination with chemotherapy and radiation in phase I and II clinical 
trials (Raymond et al., 2000; O’Donnel et al., 2003; Granville et al., 2006). In addition, a phase III 
clinical trial has been carried out using CCI-779 to treat metastatic renal cell carcinoma and the 
success resulted in the FDA approval of CCI-779 as a front-line therapy for this disease (Hudes 
et al., 2007). Rapamycin and its analogues have displayed synergy with paclitaxel, vinblastine, 
doxorubicin, cisplatin and other standard chemotherapeutic drugs (Goerger et al., 2001; 
Marimpietri et al., 2005; Haritunians et al., 2007). Similar results have been obtained using 
rapamycin in combination with herceptin in breast cancer and Hsp90 inhibitors in multiple 
myeloma (MM) (Francis et al., 2006; Wang et al., 2007). As a result of the insight gained by 
clinical trials into the effects of treatment with mTOR inhibitors on various downstream signal 
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transduction pathways, second-generation drugs that target mTOR kinase activity, the mTOR 
kinase inhibitors (TOR-KIs) have recently been developed (Wander et al. 2011). 
 
 
1.4 Breast cancer  
Breast cancer is the most common malignancy among women, with 16 % of cancer-related 
deaths attributed to this form of the disease (WHO report, 2008). In Western countries, it 
remains the most fatal disease amongst women (Chodosh, 2011). In the United States, the 
prevalence of breast cancer has been reported as 111 cases per 100 000 women per year, with 
a mortality rate of 24 deaths per 100 000 women per year (Howe et al., 2001; Zhou et al., 
2008). In South Africa, breast cancer makes up 16.6% of all malignancies diagnosed in women 
(Vorobiof et al., 2001). In fact, the 2000-2001 National Cancer Registry (NCR) report shows that 
South African women have a lifetime risk (LR) of 1 in 8 of getting cancer, with breast cancer 
predominating at a LR of 1 in 29 (NCR 200-2001 statistics available online, Internet 3). What is 
rarely published and thus largely unappreciated is that men can also develop breast cancer 
(Ravandi-Kashani and Hayes, 1998). In fact, male breast cancer accounts for approximately 1 % 
of all reported breast cancer cases worldwide. Interestingly, the male-to-female breast cancer 
ratio is higher in black populations than among white populations with male breast cancer 
being highly prevalent in some parts of Africa such as Zambia, where up to 15 % of all breast 
cancer cases occur in men, and Egypt, which reports up to 12 times more of such cases than the 
USA (Ravandi-Kashani and Hayes, 1998).  
 
1.4.1 Breast cancer subtypes 
Breast cancer is a histologically and genetically heterogeneous disease, a factor which has 
important clinical implications (Visvader, 2009). The vast majority of breast tumours arise 
within the lining of the ducts in breast tissue and are thus termed mammary ductal carcinomas 
(Keller et al., 2010). The mammary ducts are composed of a basal layer of contractile, 
myoepithelial cells and a luminal layer of specialized epithelial cells. Three important hormone 
receptors associated with mammary ductal tissue are estrogen receptor (ER), progesterone 
receptor (PR) and human epidermal growth factor receptor 2 (HER-2/neu) (Visvader, 2011). 
Breast cancers may be classified in a number of ways, according to the histopathology, receptor 
status, grade, genetic profile, prognosis or stage of the disease. The most common classification 
divides breast tumours into four subtypes based on their histopathological origin, receptor 
status and grade. These include the basal or triple-negative (ER-, PR- and HER-2-), the ER- HER2+, 
the luminal A (ER+, low grade) and the luminal B (ER+, high grade) subtypes (Perou et al., 2000; 
Sorlie et al., 2001). These subtypes are linked to prognosis, with the greatest chance of relapse-
free survival being associated with the luminal A subtype and the poorest prognosis being 
associated with the basal/triple-negative subtype (Perou et al., 2000; Dent et al., 2000).   
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Of particular importance in Africa, the more aggressive triple negative subtype of the disease 
has been shown to be more prevalent in black women (Morris et al., 2007; Lund et al., 2009). 
This form of the disease results in earlier age of onset, higher mortality and greater risk of 
metastasis (Dent et al., 2000). There is currently no effective therapy available for the triple 
negative subtype of breast cancer (Albeck and Brugge, 2011).  
 
1.4.2 Treatment strategies for breast cancer 
Current clinical practice in the treatment of the majority of cancers conventionally consists of 
surgical removal of the tumour(s), radiation, chemotherapy or combinations of the three (Recht 
and Solin, 2011).  The chemotherapeutic drugs traditionally used in the treatment of breast 
cancer are paclitaxel (Taxol) and doxorubicin (Garcia et al., 2007). The shortcomings of such 
treatments are well known, namely the high toxicity of the drugs as well as their ineffectiveness 
at preventing recurrence of the disease (Widakowich et al., 2007). Hormone therapy is another 
avenue of treatment for breast cancer sufferers. The earliest developed hormone therapy for 
breast cancer is the drug Tamoxifen, which blocks the stimulation of breast cancer cells by 
estrogen via their estrogen receptors (ERs). This drug is used as a chemopreventative measure 
in patients which are considered to have a high risk of developing breast cancer and has been 
associated with decreased recurrence when administered after surgery (reviewed in Jordan, 
2006).  
 
Since the HER-2 receptor has been shown to be over-expressed in 20 % to 25 % of breast 
cancers and has been associated with poor clinical outcome due to increased aggressiveness 
and frequent metastases, specific HER-2 inhibitors such as trastuzumab (Herceptin) and 
lapatinib have been developed (Slamon and Pegram, 2001; Kakarala and Wicha, 2008). 
Although some success has been obtained with this form of therapy in clinical trials, especially 
when used in conjunction with traditional chemotherapeutic agents such as doxorubicin, 50 % 
of patients experienced relapse of the disease (Slamon and Pegram, 2001; Kakarala and Wicha, 
2008). In addition, the above therapies such as Tamoxifen and Herceptin are completely reliant 
on the presence of the relevant receptors and are thus ineffective against the receptor-
negative subtypes of the disease. There is a need for novel therapies which are able to treat 
these more aggressive receptor-negative subtypes of breast cancer (Lund et al., 2009).  
 
Worldwide, there has been a 25 % reduction in breast cancer-related deaths between 1990 and 
2004 (Heron et al., 2007). This may be attributed to earlier detection by mammography 
screening as well as improved adjuvant therapies administered in the early stages of the 
disease (Calvocoressi et al., 2008; Kakarala and Wicha, 2008). Despite these advances, there 
has been no significant change in the survival rates for women diagnosed with metastatic 
breast cancer during this time frame (Takebe et al., 2011). The reasons for this are intimately 
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linked to the cancer stem cell theory described below (Kakarala and Wicha, 2008). The 
identification of cancer stem cells within breast tumours has resulted in a major shift in focus in 
terms of the development of novel therapies to treat this disease. It is now thought that 
specific anti-CSC therapies are needed to remove the source of the tumour and prevent 
metastasis and relapse (Takebe et al., 2011).  
 
Despite numerous advances in the understanding of the etiology of breast cancer, there is still 
no recognized “cure” for the disease (Chodosh, 2011). Many of the new generation pathway 
inhibitors have been hampered in their clinical application due to a number of undesirable 
traits such as poor solubility, unexpected side effects and toxicities as well as limited 
effectiveness (LoPiccolo et al., 2008). Furthermore, a major challenge associated with therapies 
targeting cancer stem cells is the fact that they share a number of pathways with normal, 
healthy stem cells, in particular the self-renewal pathways (Kakarala and Wicha, 2008). This, 
together with molecular complexity of signal transduction pathways and the reality of 
compensatory mutations in these pathways, suggest that the road to a cure for breast cancer 
will be a long and bumpy one (Grant et al., 2008)!   
 
 
1.5 The cancer stem cell theory 
Stem cells are undifferentiated cells that are defined by their ability to self-renew, in addition 
to being able to differentiate into the cell types which make up a particular organ in the body 
(Sell, 2004; Massard et al., 2006). There are three types of stem cells: embryonic stem cells, 
which arise from the earliest divisions of a fertilized egg and are able to give rise to all the cell 
types in the body; germinal stem cells, able to produce eggs and sperm in reproduction; and 
somatic or adult stem cells, which display a more limited differentiation ability and are 
associated with a particular organ (Blagosklonny, 2005).  
 
The concept of a “cancer stem cell” (CSC) was first proposed about 150 years ago by Virchow 
and Conheim and was based on the similarities between the self renewal properties seen in 
fetal development and those in certain tumours. Advances in stem cell biology have resulted in 
scientists revisiting this theory in order to describe the origin and spread of cancers (Korkaya 
and Wicha, 2007). The revised CSC theory calls into question the traditional monoclonal model 
of cancer development and consists of two important and related hypotheses: 1) that tumours 
arise from and are maintained by a unique subset of cells which possess features of both cancer 
cells and stem cells; and 2) that these cells are capable of asymmetric division in that they can 
both self-renew to produce more CSCs as well as differentiate to generate the other cells types 
found within a tumour (Pardal et al., 2003; Wicha et al., 2006; Lawson et al., 2009).  
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Cancer stem cells were first identified in acute myelogenous leukemia in 1994 (Lapidot et al., 
1994; Zhou et al., 2007). In 1997, it was discovered that the ability to transfer human leukemia 
into non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice was due to a 
small subpopulation of cells displaying the cell surface markers CD34+CD38-, which comprised 
less than 1 in 10 000 cells; while the bulk of the cells were non-tumourigenic (Dick et al., 1997). 
The first solid tumour stem cells were identified in breast cancer a decade later, where it was 
demonstrated that a CD44+CD24- marker-bearing subpopulation could regenerate a tumour 
from as little as 100 cells, whereas tens of thousands of cells from the bulk population failed to 
do so (Al-Hajj et al., 2003). The identification of specific surface markers has resulted in the 
characterization of CSCs in brain tumours as well as cancers of the prostate, pancreas, neck, 
colon, lung, skin, liver and ovary (Singh et al., 2004; Patrawala et al., 2006; Li et al., 2007; 
O’Brien et al., 2007; Prince et al., 2007; Ricci-Vittiani et al., 2007; Eramo et al., 2008; Zhang et 
al., 2008; Marotta and Polyak, 2009).  
 
1.5.1 Implications of the CSC theory on treatment of cancer 
The CSC theory has numerous implications for cancer treatment (Massard et al., 2006). The 
original monoclonal model of carcinogenesis can be described as a stochastic and random 
system, where every cell in an organ has an equal ability to be transformed and become 
tumourigenic. Furthermore, the model suggests that each cell within a tumour is equally 
malignant (Martinez-Climent et al., 2006). Thus, traditional treatments, such as chemotherapy 
and radiation, were aimed at killing the rapidly-dividing bulk population of cells within the 
tumour (Kakarala and Wicha, 2008). However, while these therapies are able to shrink the 
tumour, the effects are usually transient and recurrence remains a reality for a substantial 
proportion of sufferers (Massard et al., 2006; Kakarala and Wicha, 2008). The reason for this is 
that the highly tumourigenic CSC subpopulation, like normal stem cells, is more resistant to 
traditional therapies and remains behind after chemotherapy or radiation treatment (Massard 
et al., 2006). In particular, these cells may possess multidrug resistance transporters which are 
able to efflux chemotherapeutic drugs and specialized enzymes such as aldehyde 
dehydrogenase, which are able to degrade the drugs (Karkarala and Wicha, 2008). 
Furthermore, CSCs often display increased expression of anti-apoptotic molecules such as the 
Bcl-2 family and survivin, which prevent the drugs from initiating programmed cell death 
(Litingtung et al., 1999; Smalley and Clarke, 2005; Marotta and Polyak, 2009). Since these cells 
are capable of both self-renewal and differentiation, they can then repopulate the original 
tumour (Pardal et al., 2003).  
 
Cancer stem cells have also been implicated in metastasis or spreading of the disease to other 
sites in the body, a process which accounts for over 90 % of lethality in cancer patients (Weigelt 
et al., 2005). Cancer cell metastasis consists of six steps: 1) the cells must detach and 
27 
 
extravasate from the primary tumor; 2) invade the extracellular matrix (ECM) and the 
endothelium to reach the blood stream; 3) survive in the bloodstream; 4) attach at another site 
in the body by adhesion to a particular endothelium; 5) extravasate across the endothelium and 
ECM once more and 6) initiate and maintain growth at this new site (Siclari et al, 2006).  
 
The concept of “seeds and soil” was proposed by Paget over a century ago and states that 
metastasis is dependent on the characteristics of both the tumour (seeds) and the environment 
at the distal site (soil) (Wicha, 2006). It has been suggested that the “seeds” in this model are 
CSCs. The ability of CSC to undergo asymmetrical cell division together with their capability of 
anchorage-independent growth and higher adaptability due to increased genetic instability 
lends weight to the argument that secondary tumours are most likely derived from the CSC 
subpopulation (Li et al., 2007). Furthermore, functional genomic studies have suggested that a 
minor population of cancer cells within a heterogeneous breast tumor are already programmed 
to preferentially metastasize and these cells are termed metastatic CSCs (mCSCs) (Ramaswamy 
et al., 2003, Li et al., 2007). To date, however, the exact mechanisms by which cancer stem cells 
metastasize and populate secondary sites are not completely understood (Takebe et al., 2011). 
Either the original CSC, or a new stem cell derived from the original, undergoes a variety of 
genetic and epigenetic changes which result in these cells becoming more invasive in a process 
termed an epithelial-mesenchymal transition (EMT). This has been observed at the invading 
edge of a number of tumours (Mani et al., 2008). Once metastasized, the CSCs may remain 
dormant until they receive the appropriate environmental signals, resulting in recurrence even 
after many years (Wicha et al., 2006).   
 
There is therefore a need for new therapies which are able to specifically target the cancer 
stem cells in order to eliminate the cause of the tumour and prevent recurrence and 
metastasis. There have been some reports of the success associated with using apparently CSC-
specific agents in cancer therapy (Marotta and Polyak, 2008). One such approach is to induce 
differentiation of the malignant stem cells (Korkaya and Wicha, 2007). In one study, the 
administration of all-trans-retinoic acid (tretinoin) in conjunction with chemotherapy increased 
the long-term survival rate of AML patients (Bruserud and Gjertsen, 2000). Similarly, the 
delivery of bone morphogenic protein 4 (BMP4) in vivo has been reported to significantly 
reduce the proportion of stem-like precursors in human glioblastoma (Piccirillo et al., 2006). In 
another report, the combination of parthenolide and rapamycin appeared to target cancer 
stem cells in AML, while the normal haematopoietic cells were unaffected by this treatment 
(Yilmaz and Morrison, 2008). Another important strategy in developing CSC-specific treatments 
is to target the self-renewal pathways operating in these cells. Furthermore, an understanding 
of these pathways may provide a clearer picture of how dysregulation of these pathways leads 
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to malignancies in addition to providing targets for cancer prevention and therapy (Kakarala 
and Wicha, 2008). 
 
1.5.2 Self-renewal signalling pathways in normal and cancer stem cells  
Self-renewal is an essential feature of stem cells allowing them to last the lifetime of the 
organism (Massard et al., 2006). Stem cells may either divide symmetrically to produce two 
daughter stem cells (self renewal), or they may undergo asymmetrical division to produce a 
stem cell and a progenitor cell which is destined to differentiate, an ability termed 
multipotency (Weissman, 2000; Dontu et al., 2004). In healthy tissues, homeostasis is 
maintained by the tight regulation of the balance between these processes. This also ensures 
that mature, differentiated cells may be derived from stem cells without depleting the stem cell 
subpopulation (Korkaya and Wicha, 2007). Thus, all tissues should consist of a hierarchy 
comprising a) stem cells able to generate all progeny, b) committed progenitors and terminally 
differentiated cells (Dontu et al., 2004).  
 
Alterations in the self-renewal pathways found in stem cells may result in their transformation 
to a malignant state, a concept which is at the centre of the cancer stem cell hypothesis (Pardal 
et al., 2003). The bulk differentiated cells within a tumour are unable to undergo self-renewal, 
thus inhibition of these pathways is a means of specifically targeting the stem cell component. 
Clearance of the bulk tumour cells require treatment with agents which either induce 
apoptosis, such as paclitaxel, or target survival pathways, such as rapamycin, in conjunction 
with CSC-specific drugs (Kakarala and Wicha, 2008). The main self-renewal pathways whose 
dysregulation has been implicated in carcinogenesis are the Wnt, Notch and Hedgehog 
systems, the description of which is beyond the scope of this review (Wicha et al., 2006). 
Inhibitors specific to the self-renewal pathways Wnt, Notch and Hedgehog have displayed 
efficacy against breast cancer, in particular the use of gamma secretase inhibitors (GSI’s) in 
combination with chemotherapy has been evaluated in clinical trials (Kakarala and Wicha, 
2008). 
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1.6 Drug discovery in cancer  
There are two major approaches when attempting to develop novel anti-cancer compounds. 
One is to focus on deregulated pathways within the cell and then develop specific inhibitors to 
target key signal transduction molecules within a particular pathway. This approach is called 
the “target to hit” strategy, examples of which are described in Section 1.2. Conversely, the 
second method involves screening a range of novel compounds for cytotoxicity towards a 
malignant cell and then attempting to characterize the anti-proliferative action by identifying 
the pathways that are deregulated by the “hit compound.” This strategy is known as the “hit to 
target” approach (Korkaya and Wicha, 2007; LoPiccolo et al, 2008). The current study will make 
use of the latter approach as a means of identifying novel hit compounds of marine algal origin. 
 
 
1.6.1 The marine environment as a source of biomedical compounds  
In the last century, the bioactive secondary metabolites produced by living organisms have 
provided many compounds of pharmacological importance (Ioannou, 2004). The vast majority 
of novel natural products were originally derived from terrestrial plants due to the ease of 
sample collection (Carté, 1996). However, since the ocean is thought to host at least 80 % of the 
Earth’s plant and animal species, this meant that, potentially, the largest source of 
therapeutically beneficial compounds remained untapped (Jha and Zi-rong, 2004). In particular, 
deep-sea environments exceeding depths of 400 m represent 91 % of the total bottom surface 
area of the ocean. It wasn’t until the 1960s that the development of SCUBA allowed 
researchers to begin probing the rich biodiversity of the ocean floor for organisms which 
produce novel bioactive compounds (Carté, 1996). Since then, thousands of structurally unique 
compounds have been isolated from seaweeds, sponges, corals, sea slugs and marine microbes, 
many of which have displayed biological activity of pharmacological interest (Jha and Zi-rong, 
2004). Marine natural products have been used in the development of antibiotics, anti-viral, 
anti-inflammatory, and anti-cancer drugs (Carté, 1996). 
 
South Africa is ranked as the country with the fifth richest species endemism and biodiversity in 
the world (Le Roux et al., 2002). In terms of marine biodiversity, South African waters host 
more than 10 000 species, making up 15 % of the total number of species on Earth (Le Roux et 
al., 2002). This high species biodiversity has been shown to be associated with high secondary 
metabolite diversity (Davies-Coleman, 2004). 
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1.6.2 Halogenated monoterpenes from marine algae 
Marine algae, in particular those belonging to the Chlorophyta (green algae), Rhodophyta (red 
algae) and Phaeophyta (brown algae), have provided many structurally unique compounds of 
pharmacological importance (Carté, 1996). Two brown algal compounds which have received 
attention in recent years are the carotenoid, fucoxanthin, and the tetraprenylated quinone, 
sargaquinoic acid. The former is the best-characterized among the algal compounds to date and 
has been isolated from a range of species including Laminaria japonica, Undaria pinnatifida and 
Sargassum heterophyllum (Peng et al., 2011). Fucoxanthin has displayed an unprecedented 
range of therapeutic properties including anti-malarial, antioxidant, anti-diabetic, anti-obesity, 
anti-angiogenic and anti-cancer activities, all of which have been demonstrated in in vivo 
systems (reviewed in Peng et al., 2011). The anti-cancer activity of fucoxanthin has been 
demonstrated in a wide range of human cell lines including those for leukemia, prostate, 
bladder and colon cancer, and has been associated with the induction of apoptosis in cancer 
cells in vitro (Hosokawa et al., 1996; Hosokawa et al., 2004; Das et al., 2005; Kotake-Nara et al., 
2005a; Zhang et al., 2008). Sargaquinoic acid, on the other hand, has been isolated from various 
species of the Sargassum genus and has displayed neurite outgrowth promoting and anti-
cholinesterase activity, suggesting a potential role for the compound in the treatment of 
Alzheimer’s disease (Kamei and Tsang, 2003; Choi et al., 2007). In addition, the compound has 
been shown to induce apoptosis in human skin cancer cells (Hur et al., 2008).  
 
Red algae or Rhodophyta are interesting from a biopharmacological point of view due to their 
tendency to incorporate halogen moieties into their secondary metabolites (Carté, 1996). 
Several studies have reported the isolation of novel halogenated monoterpenes from various 
species of marine red algae (Rhodophyta) such as those belonging to the Plocamium and 
Portiera genera (König et al., 2000; Blunt et al., 2003; Knott et al., 2005). These secondary 
metabolites are thought to be produced by the alga as a protective mechanism against, for 
example, reef herbivores (König et al., 1990). In addition, the compounds have been found to 
display anti-tubercular and anti-cancer activities (Fuller et al., 1992; König et al., 2000). 
Monoterpenes are naturally occurring hydrocarbons produced by the condensation of two 
isoprenes (Gould, 1997). It has been reported that these compounds are able to successfully 
treat cancers of the liver, lungs, brain, breast and pancreas in both the early and advanced 
stages (Haag et al., 1992; Crowell et al, 1994; Stark et al., 1995). It is hypothesized that they act 
in the initiation and progression stages of cancer by stimulating the overexpression of various 
cell surface receptors (Kornfeld, 1992). This alters the pattern of signal transduction and 
facilitates cell cycle arrest, apoptosis and redifferentiation (Crowell et al., 1994; Gould, 1997). 
 
A number of novel polyhalogenated monoterpenes have been isolated from the red algae 
Portieria hornemannii (Fuller et al., 1992; Fuller et al., 1994; Gunatilaka et al., 1999). A subset of 
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these were tested for cytotoxicity towards various cancer cell lines obtained from the U.S. 
National Cancer Institute, with the greatest inhibitory effects occurring in the brain, renal and 
colon tumour cell lines (Fuller et al., 1992). One compound, the pentahalogenated 
monoterpene halomon, displayed the highest and most specific cytotoxicity in the NCI’s panel 
of cancer cell lines and was selected for preclinical drug development (Fuller et al., 1992; Fuller 
et al., 1994). However, work on this compound has not proceeded past mouse models (Egorin 
et al., 1996; Adrianoloso et al., 2006). Another red algae species, Plocamium cartilagineum, has 
yielded a large number of new halogenated monoterpene compounds (König et al., 1990; 
Darias et al., 2001; de Inés et al., 2004). In one study, the cytotoxic effects of the compounds 
were tested in a number of cell lines including that from a mouse colon adenocarcinoma (CT26) 
as well as from human colon (SW480) and cervical carcinomas (HeLa) and a malignant 
melanoma (SkMel28) (de Inés et al., 2004). Although a handful of marine natural products have 
reached clinical trials, research on halogenated monoterpenes remains at the pre-clinical phase 
(Sashidhara et al., 2009).  
 
Research into the presence of halogenated monoterpenes in South African marine red algal 
samples has recently been carried out (Knott et al., 2005; Mann et al., 2007). One such study 
reports the isolation of a number of polyhalogenated monoterpenes from the Plocamium 
corallorhiza and Plocamium cornutum species, which were collected along the west coast of 
South Africa (Knott et al., 2005).  The novel compounds were tested for cytotoxicity towards 
the human oesophageal cell carcinoma line WHC01 and displayed IC50 values between 9.3 and 
33.8 μM, respectively, which was comparable to that of the chemotherapeutic drug cisplatin 
(13.0 μM) in the same study (Knott et al., 2005). The cytotoxicity of the compounds was 
determined by crystal violet staining of apoptotic cells (Knott et al., 2005). A later report by the 
same group describes the isolation of novel halogenated monoterpene aldehydes from 
Plocamium corallorhiza, this time harvested from the south-east coast of South Africa (Mann et 
al., 2007). Cytotoxicity tests against the oesophageal cancer line WHC01 were carried out for all 
the compounds using an MTT assay and produced IC50 values of between 7.5 and 64.8 μM 
(Mann et al., 2007). The group later reported the isolation of the quinone sargaquinoic acid 
from the brown alga Sargassum heterophyllum (Afolayan et al., 2008). 
 
 
 
 
 
 
 
 
 
32 
 
2. KNOWLEDGE GAP 
 
A number of novel compounds of marine algal origin have been found to display cytotoxic 
effects towards cancer cell lines. A recent report describes the isolation of a series of 
polyhalogenated monoterpenes and halogenated monoterpene aldehydes from the marine red 
algae Plocamium corollorhiza and Plocamium cornutum (Knott et al., 2005; Mann et al., 2007). 
A number of these compounds displayed cytotoxicity in the low micromolar range against the 
oesophageal cancer cell line, WHC01 (Knott et al., 2005; Mann et al., 2007). However, the 
precise mechanism by which this cytotoxicity occurs was not determined. In addition, the effect 
of these and other compounds isolated by the same group on metastatic breast cancer cell 
lines is unknown. Of particular interest is whether the inhibitory compounds induce apoptosis 
of the cells and, if so, which signalling pathways and molecules mediate this response.  
 
Although breast cancer stem cells were the first solid tumour stem cells to be discovered, this 
research is still in its infancy. A major stumbling block is the limited ability to identify and isolate 
these cells. Furthermore, there are very few reports of drugs which specifically target breast 
cancer stem cells and their clinical significance is, as yet, unestablished (Marotta and Polyak, 
2009).  
 
 
3. RESEARCH QUESTION 
 
What is the potential of South African marine red and brown alga to yield novel lead 
compounds with anti-breast cancer activity using a “hit to target” approach, and can the 
specific mode of action of these compounds be elucidated using standard biochemical assays?  
 
 
4. AIMS 
 
To screen a library of novel marine algal compounds for anti-breast cancer and anti-breast 
cancer stem cell activity and to analyze the mechanisms involved in mediating the cytotoxic 
effects of such compounds on breast cancer cells and their cancer stem cell subpopulation in 
vitro. 
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4. OBJECTIVES 
 
1. Screening of novel marine algal compounds against metastatic ER- PR- HER2neu- breast 
cancer cells in vitro (described in CHAPTER 2) 
 
2. Assessment of the effect of selected novel algal compounds on the survival of non-cancerous 
breast epithelial cells in vitro in order to identify “hit” compounds with differential toxicity 
against breast cancer but not normal breast epithelial cells (CHAPTER 2) 
 
3. Preliminary pharmacological profiling of potential hit compounds (CHAPTER 2) 
 
4. Elucidation of the mode of action of selected marine algal compounds against metastatic 
breast cancer cells in vitro in terms of the type of cell death induced and the effect on cell cycle 
of these compounds (CHAPTER 3) 
 
5. Characterization of the molecular mechanisms mediating toxicity of the novel algal 
compounds sargaquinoic acid and fucoxanthin against breast cancer cells in vitro in terms of 
the involvement of key signal transducer molecules (CHAPTER 4) 
 
6. Screening of novel marine algal compounds for putative anti-cancer stem cell activity in vitro 
using a mammosphere assay system (CHAPTER 5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
 
 
 
 
 
CHAPTER 2 
 
SCREENING OF NOVEL MARINE ALGAL 
COMPOUNDS AGAINST METASTATIC BREAST 
CANCER CELLS IN VITRO 
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2.1 INTRODUCTION 
The marine environment has proven to be a valuable source of structurally unique bioactive 
compounds, with many lead compounds being derived from seaweeds, sponges, corals and 
marine microorganisms (Carté, 1996, Jha and Zi-rong, 2004). In particular, metabolites from the 
highly abundant marine algae represent a wealth of novel compounds with biomedical 
potential (Carté, 1996). The majority of these pharmacologically important compounds are 
derived from species belonging to the Chlorophyta (green algae), Rhodophyta (red algae) or 
Phaeophyta (brown algae) (Carté, 1996). An example of a brown algal metabolite which is 
currently commercially available is the carotenoid, fucoxanthin. This novel compound has been 
isolated from a range of algal species including Laminaria japonica, Undaria pinnatifida and 
Sargassum heterophyllum. Fucoxanthin has been demonstrated to possess a vast array of 
therapeutically beneficial properties, including anti-oxidant, anti-obesity, anti-diabetic, anti-
angiogenic, anti-inflammatory, anti-malarial, and anti-cancer activities in studies which have 
proceeded past cell culture (reviewed in Peng et al., 2011). Of particular interest to this study, 
the compound was found to display cytotoxicity against human leukemia as well as colon and 
prostate cancer cells in vitro (Hosokawa et al., 1996; Das et al., 2005; Kotake-Nara et al., 
2005b). 
In the case of the Rhodophyta group, it was discovered that these red algae produced a 
number of metabolites containing one or more halogen moieties (Carté, 1996). In particular, 
several studies reported the isolation of novel halogenated monoterpenes from various species 
belonging to the Plocamium and Portiera genera (König et al., 2000; Blunt et al., 2003; Knott et 
al., 2005). Two decades ago, a pentahalogenated monoterpene was isolated from Portiera 
hornemanni, which was found to be highly toxic against a range of cancer cell lines, including 
those of the brain, kidneys and colon (Fuller et al., 1992). As a result, halomon was selected for 
pre-clinical drug development. The effect of the compound on non-cancerous cells was not 
determined. In addition, very little is known about the mechanism of action of the compound, 
although it has been suggested that the anti-cancer activity may be due to DNA 
methyltransferase inhibition (Andrianasolo et al., 2006). 
The South African coastline is reported to have one of the richest displays of marine 
biodiversity in the world, representing 15 % of the total number of marine species on Earth (le 
Roux, 2002). This biodiversity has, in turn, been associated with high secondary metabolism 
diversity (Davies-Coleman, 2004). In a recent report, a number of polyhalogenated 
monoterpenes were isolated from South African marine algae of the Plocamium corallorhiza 
and Plocamium cornutum species (Knott et al., 2005; Mann et al., 2007). The same group later 
reported the isolation of a previously described quinone derivative, sargaquinoic acid, from the 
brown alga Sargassum heterophyllum (Afolayan et al., 2008). The Plocamium compounds 
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displayed cytotoxicity in the low micromolar range against the oesophageal cancer cell line, 
WHC01 (Knott et al., 2005; Mann et al., 2007). Nothing is known about the effect of any of the 
indigenous algal compounds described above on metastatic breast cancer cell lines or their 
non-cancerous counterparts. 
 
The aims of this chapter were to identify potential “hit” compounds from a library of novel 
South African algal metabolites by screening for differential cytotoxicity against metastatic 
breast cancer cells but not non-cancerous breast epithelial cells in vitro and, furthermore, to 
assess the “druggability” of these hit compounds by preliminary pharmacological profiling.   
 
2.2 MATERIALS AND METHODS 
2.2.1 Reagents 
Dulbecco’s Modified Eagle Medium (DMEM) with GlutamaxTM, Ham’s F10 medium with 
GlutamaxTM, fetal calf serum (FCS) and Penicillin-streptomycin-amphotericin (PSA) were 
obtained from Gibco (Invitrogen, UK). Epidermal growth factor (EGF) and hydrocortisone (HC) 
were obtained from Sigma-Aldrich. Recombinant human insulin was obtained from NovoRapid 
(Novo Nordisk Pharmaceuticals, Denmark). Cell Proliferation Kit I for MTT assays was from 
Roche (Switzerland). Marine algal compounds were obtained as part of a collaboration with Dr 
Denzil Beukes (Pharmacy Faculty, Rhodes University). The structures of the novel compounds 
were verified by nuclear magnetic resonance (NMR) and stocks dissolved in dimethyl 
sulphoxide DMSO (Sigma-Aldrich, Germany). Paclitaxel and fucoxanthin were from Sigma-
Aldrich (Germany). 
2.2.2 Cell lines and culture conditions 
The breast cancer cell line, MDA-MB-231 (ATCC: HTB-26) was obtained as a gift from Dr Sharon 
Prince (Department of Human Biology, Faculty of Health Sciences, University of Cape Town), 
while the Hs578T line (ATCC: HTB-126) was purchased from The American Tissue Culture 
Collection (ATCC). The MCF12A breast epithelial cell line (ATCC: CRL-10782) was a kind gift from 
Dr Anna-Mart Engelbrecht (Department of Physiology, Stellenbosch University). All cell lines 
were shown to be negative for mycoplasma infection using PCR. 
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Table 2.1: Description of the human cell lines used in this study 
Cell line Origin Receptor status Molecular phenotype 
MDA-MB-231 Pleural effusion, metastatic 
carcinoma 
ER-PR-Her2- Basal 
MCF-7 Pleural effusion, metastatic 
carcinoma 
ER-PR-Her2- Luminal  
Hs578T Primary carcinoma of the 
breast 
ER+PR+Her2- Basal 
MCF-12A Spontaneously 
immortalized breast 
epithelium 
ER-PR-Her2- Basal 
(taken from Subik et al., 2010). 
 
Breast cancer cells were maintained in culture in DMEM containing GlutamaxTM and 
supplemented with either 5 % (v/v) (MDA-MB-231) or 10 % (v/v) (Hs578T) heat-inactivated FCS, 
100 U/ml penicillin, 100 µg/ml streptomycin and 12.5 µg/ml amphotericin (PSA) at 37 ºC in a 
humidified 9 % CO2 incubator. The immortalized non-cancerous MCF12A cells were maintained 
in a 1:1 ratio of Ham’s F10 medium and DMEM, both containing GlutamaxTM, supplemented 
with 10 % (v/v) heat-inactivated FCS, 100 U/ml penicillin, 100 µg/ml streptomycin and 12.5 
µg/ml amphotericin (PSA), 20 ng/ml EGF, 500 ng/ml hydrocortisone and 10 μg/ml insulin.  
2.2.3 Cell proliferation assay 
The effect of paclitaxel as well as the algal compounds of interest on cellular survival and 
proliferation in the MDA-MB-231, Hs578T and MCF12A cell lines was determined by means of 
the MTT assay according to manufacturer’s instructions. Cells were seeded at 6000 cells/well in 
a 96-well plate and allowed to settle overnight before treating with the DMSO vehicle control 
(final concentration of 1.03 % in culture) or a range of concentrations (as indicated in figure 
legends, DMSO content between 0.017 and 1.03 %) of the compounds and incubating for 96 
hours. After treatment, 10 µL of a 5 mg/mL MTT solution was added to each well and the plate 
incubated for a further 4 hours before solubilizing the resultant precipitate in sodium dodecyl 
sulphate (SDS) buffer overnight. The assay measures the conversion of the yellow tetrazolium 
compound to blue formazan crystals by metabolically active cells which can be quantified by 
the characteristic absorbance of the crystals at 550 nm and used as an indicator of cells which 
are metabolically active. The absorbance at 550 nm was determined using a Powerwave 
spectrophotometer (BioTek) and the percentage survival calculated relative to the vehicle-
treated control. The half-maximal inhibitory concentrations (IC50) were calculated over a linear 
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concentration range using the linear regression software in Microsoft Excel 2007. The 
experiment was carried out in triplicate on each of three plates. 
2.2.4 Trypan blue staining 
The viability of MDA-MB-231 and Hs578T breast cancer cells after treatment with paclitaxel and 
selected algal compounds was assessed by their ability to exclude the dye trypan blue. In each 
case, cells were seeded at 6000 cells/well in a 96-well plate, allowed to settle overnight and 
treated with either 0.3 % v/v DMSO or a single concentration of compound (equivalent to the 
IC50 value obtained by MTT assay) over 96 hours. Following treatment, both floating and 
adherent cells were collected for staining. Adherent cells were lifted with a 1 % (v/v) trypsin, 
0.3 % (w/v)  ethalene diamine tetra-acetic acid (EDTA) solution, pooled with the media fraction 
containing the floating cells, and a portion representing 1 % of the total cells stained with an 
equivalent volume of trypan blue (Sigma-Aldrich, Germany). The number of stained and 
unstained cells was counted using a haemocytometer slide and the percentage viability 
calculated as the ratio of unstained (trypan blue negative) cells relative to the total in each 
case. Each treatment was carried out in triplicate and each sample counted a minimum of three 
times.   
2.2.5 Preliminary pharmacological profiling 
The drug-likeness of the algal compounds was assessed using an amended version of the “Rule 
of 5” as described by Lipinski (Lipinski et al., 2001). Lipophilicity, in terms of cLogP values, was 
calculated using ALOGPS 2.1 software from VCC labs (available at http://www.vcclab.org.). 
Analyses were carried out on canonical SMILE formats of the compounds obtained from the 
Pubchem database. 
 
2.3 RESULTS  
2.3.1 Optimization of the MTT cell proliferation kit for cytotoxicity assays 
In order to assess the effect of the algal compounds on cellular survival and proliferation, the 
MTT assay was used. The assay was validated by treatment with the commercially available 
compound paclitaxel (Ptx), which was selected due to the fact that the IC50 value against breast 
cancer cell lines using this assay has previously been reported (Dwight et al., 1997). Ptx is also 
currently used as a chemotherapeutic drug, which would serve as a means of comparison in 
terms of cytotoxicity between potential “hit” compounds and a known drug.  
Ptx is a large and complex aromatic compound, the structure of which is depicted in           
Figure 2.1A. Cells were treated with an increasing concentration of Ptx and a drop in cell 
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survival was detected as a dose-dependent decrease in absorbance at 550 nm. The 
concentration at which cell viability was calculated to be half of that of DMSO-treated cells 
(IC50) was calculated from the linear regression of the survival curve. Using this method it was 
found that Ptx displayed IC50 values of 104.36 ± 3.90 nM cells and 29.17 ± 1.58 nM against 
MDA-MB-231 and Hs578T breast cancer cells, respectively (Figure 2.1B). Although only one 
survival curve is shown for each of the two cell lines, the experiment was carried out in 
triplicate, with the IC50 values being calculated from independent experiments and the 
standard deviation reported.  
 
The kinetics of the observed anti-cancer activity of Ptx were assessed by determining the effect 
of 25, 50, 100 and 200 nM concentrations of the drug on the survival of MDA-MB-231 and 
Hs578T cells after 24, 48, 72 and 96 hours of treatment (Figure 2.1C and Figure 2.1D, 
respectively). In the case of the MDA-MB-231 line, although a noticeable decrease in cell 
survival was seen after 24 hours of treatment with all of the doses of Ptx, it was only after 48 
hours that the effect of the drug was clearly evident, with a further drop in survival at 72 and 
96 hours (Figure 2.1C). The effect of Ptx on MDA-MB-231 cell survival after 72 hours of 
treatment was very similar to that observed after 96 hours, with the exception of that for 
treatment with the lowest dose (25 nM) of the drug, for which the decrease in cell survival was 
greater after 96 hours of treatment. On the other hand, the pattern of susceptibility of Hs578T 
cells to Ptx over time displayed a marked difference when compared to that of the MDA-MB-
231 cell line (Figure 2.1D vs. Figure 2.1C). In the former, the effect of Ptx on cell survival was 
almost negligible after 24 hours of treatment, with a steady increase in susceptibility to the 
drug when treated for increased periods of time over the aforementioned dose range (Figure 
2.1D). Although the differences in the survival curves of the Hs578T cell line between treatment 
for 72 and 96 hours was less than that observed between both 24 and 48 hours as well as 
between 48 and 72 hours, this difference was nonetheless greater than that seen in the MDA-
MB-231 line between the last two treatment intervals. (Figure 2.1C vs. Figure 2.1D). Based on 
this kinetic study for paclitaxel, it was decided that screening of the MDA-MB-231 and Hs578T 
cells with the novel algal compounds would be carried out over 96 hours.   
 
 Figure 2.1: Optimization of the MTT cell proliferation assay using t
A) Chemical structure of paclitaxel drawn using ChemSketch. B) Survival curve for MDA
Hs578T breast cancer cells treated with 
hours. The half maximal inhibitory concentration (IC
above the curves. For each curve, the standard deviations are given where n = 3. C) and D) depict the 
kinetic study for treatment of MDA
and 96 hours. 
he chemotherapeutic paclitaxel.         
either 0.013 % v/v DMSO vehicle control 
50) of the compound in each cell line is
-MB-231 and Hs578T cells, respectively with paclitaxel over 24, 48, 72 
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or paclitaxel for 96 
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2.3.2 Screening of algal compounds in metastatic ER
-
 PR
-
 HER2neu
- 
breast cancer cells in 
vitro 
The library of compounds isolated from Plocamium and Sargassum algae consisted of sixteen 
novel linear polyhalogenated monoterpenes (RU002, RU004, RU007, RU008, RU015, RU016, 
RU017, RU018, RU019, RU048, RU054, RU075, RU076, RU077, RU078 and RU079) three novel 
cyclic polyhalogenated monoterpenes (RU050, RU065 and RU066), as well as the 
tetraprenylquinones, sargaquinoic acid (SQA) and sargahydroquinoic acid (SHQA) (Figure 2.2). 
The carotenoid, fucoxanthin (FXN), was obtained commercially, yet has reportedly been 
isolated from Sargassum heterophyllum and Sargassum elegans (Afolayan et al., 2008). The 
monoterpene compounds all contained between two and five halogen moieties, specifically 
chlorine and/or bromine, and could be grouped into structural series whose terpene backbone 
was identical but in which the halogen substitutions varied from compound to compound. 
These included the RU007, RU008, RU048 and RU054 monoterpene aldehyde group and the 
RU015, RU016, RU017, RU018 and RU019 series (Figure 2.2). 
Throughout the course of this study, the selection of compounds for testing in the various 
assays was made largely on the basis of novelty. However, these decisions were influenced by a 
limited supply of verified compound and, where it was not possible to carry out particular 
assays on all compounds, an attempt was made to either compare between the previously 
described algal compounds (SQA and FXN) and the novel Rhodes University compounds 
(RU002-RU081), or to make comparisons between the two more readily available, known 
compounds (SQA and FXN). 
All twenty-two of the algal compounds (Figure 2.2) were tested against the metastatic ER- PR- 
HER2neu- MDA-MB-231 breast cancer cell line, with a number displaying cytotoxicity in the 
micromolar range against these cells (Figure 2.3). The half-maximal inhibitory concentrations 
(IC50 values) were calculated in the same way as for Ptx (Section 2.3.1) Of the novel 
polyhalogenated monoterpenes, compounds RU002, RU004, RU007, RU008, RU015, RU065, 
RU066, RU077 and RU078, were toxic to MDA-MB-231 cells with IC50 values ranging from 6.2 ± 
0.13 µM (RU015) to 82.7 ± 5.18 µM (RU008) (Figure 2.3A). Compounds for which the IC50 value 
was greater than 200 µM were considered non-toxic (NT). The compounds RU017 and RU018 
are stereoisomers (Figure 2.2) and were tested in MDA-MB-231 cells both as a racemic mixture 
and separately and were non-toxic to the cells in all cases (Figure 2.3A). The previously 
described compounds, sargaquinoic acid and fucoxanthin, also decreased the survival of MDA-
MB-231 cells. The tetraprenylquinone, sargaquinoic acid, displayed an IC50 of 67.4 ± 5.92 µM 
against MDA-MB-231 cells, while the reduced form, sargahydroquinoic acid, gave an IC50 of 
139.5 ± 4.41 µM (Figure 2.3A) The commercially sourced carotenoid, fucoxanthin, displayed an 
IC50 of 11.07 ± 0.56 µM in this cell line (Figure 2.3A).  
 Figure 2.2: Chemical structures of compounds isolated from marine algae of the 
Sargassum genera. Compound structures were generated in ChemSketch. The previously described 
compounds, sargaquinoic acid, sargahydroquinoic acid and fucoxanthin are represented by SQA, SHQA 
and FXN, respectively.     
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 Figure 2.3: Screening of marine algal compounds for anti
cancer cells in vitro. Anti-cancer activity was determined in both the MDA
cell lines. Cells were treated with a range of concentrations of compound over 96 h and the effect on cell 
proliferation determined by MTT assay. The previously described compounds, sargaquinoic acid, 
sargahydroquinoic acid and fucoxant
quoted are the half maximal-inhibitory concentrations (IC
to a 1.03% v/v DMSO vehicle control
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A number of the algal compounds were screened in a different metastatic ER- PR- HER2neu- 
breast cancer cell line, namely the Hs578T cell line. These included the compounds RU002, 
RU004, RU007, RU015, RU017, RU018, RU065, RU066, RU078, sargaquinoic acid and 
fucoxanthin (Figure 2.3B).  With the exception of RU002, the compounds displayed the same 
pattern of cytotoxicity against Hs578T cells as for MDA-MB-231 cells, namely that compounds 
RU004, RU007, RU015, RU065, RU066, RU078, sargaquinoic acid and fucoxanthin were toxic to 
the Hs578T cells in the micromolar range, while RU017 and RU018 were not (Figure 2.3A and 
3B). It was observed, however, that the absolute IC50 values of the compounds as well as the 
ranking of the cytotoxic compounds from least to most toxic differed between the two breast 
cancer cell lines (Figure 2.3A vs. Figure 2.3B).  
 
2.3.3 Trypan blue assessment of cell viability for selected compounds 
As an alternative method of assessing the cytotoxicity of selected algal compounds and in order 
to validate the results obtained using the MTT assay, trypan blue staining was carried out to 
assess cellular viability of MDA-MB-231 and Hs578T cells after treatment with a subset of the 
algal compounds. Unlike the MTT assay, this method allows for both the live and the dead cells 
to be counted. In the MDA-MB-231 cell line, the DMSO vehicle-treated control sample 
displayed a percentage viability of close to 100 % (98 %; Figure 2.4A), while the percentage 
viabilities of the SQA- and FXN-treated cells at their respective IC50 values were 55 % and 48 %, 
respectively (Figure 2.4A). The percentage viability of the Ptx-treated sample was 62 %, while 
cells treated with RU004 and RU007 displayed percentage viability values of 81 % and 78 %, 
respectively (Figure 2.4A). In the Hs578T cell line, the percentage viability calculated for the 
DMSO-treated control sample was 85 %, while cells treated with the chemotherapeutic drug 
Ptx displayed a cellular viability of 38 % (Figure 2.4B). Treatment of Hs578T cells with the algal 
compounds SQA and FXN resulted in percentage viability values of 59 % and 25 %, respectively 
(Figure 2.4B).    
 Figure 2.4: Assessment of cell viability by trypan blue staining of breast cancer cells treated with 
paclitaxel and selected marine algal compounds. For both MDA
breast cancer cell lines, treatment 
control) or relevant algal compound at 
assay. The effect on cellular viability was determined by staining a proportion of the cells equivalent to 1 
% of the total with a 1:1 (v/v) ratio of trypan blue. Values quoted represent the percentage of the total 
number of cells which were not stained by trypan blue and therefore considered to be viable. Error bars 
indicate the standard error of the mean where n=3.
-MB-231 (A) and Hs578T (B) metastatic 
was carried out over 96 h with with either 0.3 % v/v DMSO (vehicle 
a concentration equivalent to the IC50 value as obtained via MTT 
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2.3.4 The effect of selected algal compounds on non-cancerous breast epithelial cells 
Selected compounds were tested for their ability to specifically inhibit growth of breast cancer 
cells, while leaving the immortalized non-cancerous breast epithelial cell line, MCF12A, 
relatively unaffected. In each case, MCF12A breast cells were treated with a concentration 
equivalent to the IC50 value of the compound against MDA-MB-231 breast cancer cells. At a 
concentration of 100 nM, the chemotherapeutic drug, Ptx, reduced survival and proliferation of 
the MCF12A cells to 69 % (69.40 ± 3.82 %, Table 2.2). Of the novel algal compounds, RU004, 
RU007 and SQA were found to be non-toxic to MCF12A cells (percentage survival values of 
111.55 ± 2.30 %, 106.53 ± 1.74 % and 154.14 ± 1.93 %, respectively; Table 2.2), while FXN was 
relatively cytotoxic to the MCF12A cell line (percentage survival of 71.32 ± 9.20 %, Table 2.2). 
The halogenated monoterpene stereoisomers RU017 and RU018 had very little effect on the 
survival of MCF12A cells, even at the very high dose of 300 µM (percentage survival values of 
98.11 ± 4.56 % and 95.15 ± 3.38 %, respectively; Table 2.2).  
 
Table 2.2: Differential cytotoxicity screening of paclitaxel and novel algal compounds in 
MCF12A breast epithelial cells 
Compound Concentration* Percentage survival determined by MTT 
assay 
  
Paclitaxel 100 nM 69.40 ± 2.8 % 
RU004 75 µM 111.55 ± 2.3 % 
RU007 75 µM 106.53 ± 1.7 % 
Sargaquinoic acid 75 µM 154.14 ± 1.9 % 
Fucoxanthin 10 µM 71.32 ± 9.2 % 
RU017 300 µM 98.11 ± 4.6 % 
RU018 300 µM 95.15 ± 3.4 % 
*The IC50 value of each compound in MDA-MB-231 cells 
 
2.3.5 Preliminary pharmacological profiling of “hit compounds” 
Potential “hit” compounds, selected on the basis that they displayed cytotoxicity against 
metastatic breast cancer cells (Figure 2.3 and 2.4), while resulting in greater than 95 % survival 
in non-cancerous breast epithelial cells (Table 2.2), were scored for their “drug-likeness” in 
terms of their lipophillicity according to Lipinski’s Rule of 5 (Ro5) and compared to the 
commonly used therapeutic, Ptx (Table 2.2). These included compounds RU004, RU007 and 
SQA. Of these, only RU007 displayed a favourable cLogP value of below 5 (4.07, Table 2.3), 
while RU004 and SQA had cLogP values of 5.41 and 5.74, respectively (Table 2.3). In the case of 
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Ptx, the compound displayed a cLogP value below 5 (4.2; Table 2.3); however the size of the 
molecule as well as the number of oxygen and hydrogen atoms did not meet the favourable 
druggability criteria defined in the Rule of 5. 
 
Table 2.3: Comparison of drugability of novel monoterpene compounds with that of paclitaxel 
using the Rule of 5 (Ro5) 
 
Compound Assessment of favourable druggable characteristics 
1cLogP < 5 ? 2MW < 500? 3# of H-bond donors 4O + N atoms < 10? 
RU004 No 
(5.41) 
Yes 
(278.05) 
0 Yes 
(0) 
RU007 Yes 
(4.07) 
Yes 
(310.03) 
0 Yes 
(1) 
SQA No 
(5.74) 
Yes  
(424.57) 
1 Yes 
(4) 
PTX Yes 
(4.2) 
No 
(853.906) 
22 No 
(15) 
1cLogP values are indicative of lipophillicity, which, together with compound size (2MW), affect 
the bioavalaibility and absorption of the compound in terms of its ability to cross the intestinal 
wall and blood-brain barrier.
3
An excessive number of hydrogen bond donor groups impairs 
permeability across a membrane bi-lipid layer as does an excessive hydrogen bond accepting 
ability measured by 4the number of oxygen and nitrogen atoms (Lipinski et al., 2001).   
 
2.4 DISCUSSION  
In order to screen a set of novel indigenous marine algal metabolites for anti-cancer activity, 
MTT assays were carried out on breast cancer cells treated with these compounds. The 
commonly used chemotherapeutic agent, Ptx, was used to validate the MTT assay. Ptx is a large 
and complex molecule which was first isolated from the Pacific yew tree Taxus brevifolia 
(Newman et al., 2003) and exerts its effect as an anti-mitotic agent by interacting with tubulin 
in order to inhibit microtubule dynamics (Bharadwaj et al., 2004; Brito et al., 2008). In clinical 
trials, breast cancer patients received 175 mg/m2 of body surface area after adjuvant therapy 
and showed increased overall survival rates compared to untreated control patients (Sparano 
et al., 2008). In vitro, the compound has been tested against MCF-7 breast cancer cell (Dwight 
et al., 1997). The IC50 of paclitaxel obtained in the MDA-MB-231 line in this study (104 nM) was 
very similar to the 100 nM value previously reported for the drug in the MCF-7 breast cancer 
line (Dwight et al., 1997). With an IC50 value that is three times lower, Hs578T cells appeared to 
be more susceptible to paclitaxel than both MDA-MB-231 and MCF-7 breast cancer cells. Since, 
like MDA-MB-231 cells, the Hs578T cell line was derived from an aggressive ER- PR- HER2neu- 
metastatic breast carcinoma (Hackett et al., 1977), the lower IC50 for Ptx in Hs578T cells was 
unexpected. 
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Before analyzing the data provided by the assay, it is essential to reiterate what the MTT 
system is designed to quantify, namely that the absorbance values obtained are a 
representative of metabolically active cells which are able to convert the tetrazolium substrate 
to a coloured formazan product (Berridge and Tan, 1993). Therefore, although commonly used 
as a measure of the “cytotoxicity” of particular compounds (for example in de Inés et al., 2004; 
Das et al., 2005 and Kotake-Nara et al., 2005b), it is important to bear in mind that the kit does 
not discriminate between dead and senescent cells or those which are alive but not 
metabolically active and thus it is more accurate to state that the assay measures the “anti-
proliferative” or “growth-inhibitory” activity of compounds of interest. This is a potential 
shortcoming of the MTT assay as well as other systems which detect metabolic activity as a 
measure of proliferation of cells yet are used to determine the toxicity of a particular 
compound. For the purposes of this study, as is the case in the vast majority of reports in the 
literature, the term “cytotoxic” will be used to describe the anti-proliferative activity of a 
compound irrespective of whether the cells in question are dead or senescent.  
Screening of a library of twenty-two novel algal compounds against the metastatic ER- PR- 
HER2neu- MDA-MB-231 breast cancer cell line identified twelve compounds which were 
cytotoxic to the breast cancer cells with IC50 values in the micromolar range from 6 to 140 µM. 
Although IC50 values in the nanomolar range are preferred in terms of drug development, it is 
important to bear in mind that once a hit halogenated monoterpene compound has been 
identified, rational chemical modification could be carried out to enhance the cytotoxicity of 
the compound of interest (Li and Vederas, 2009). The cytotoxic compounds identified were the 
halogenated monoterpenes RU002, RU004, RU007, RU008, RU015, RU065, RU066, RU077 and 
RU078, as well as the previously described compounds sargaquinoic acid (SQA), 
sargahydroquinoic acid (SHQA) and fucoxanthin (FXN). The most toxic compound was the linear 
polyhalogenated monoterpene RU015, while the least toxic was the prenylated quinone, SHQA. 
Interestingly, it was found that the IC50 of this reduced form of SQA, SHQA, was almost double 
that of SQA, indicating that reduction had a substantial effect on the cytotoxicity of the 
compound. The bioactive form and potential metabolites of a compound are important factors 
to bear in mind when carrying out further characterization of promising anti-cancer agents 
(Peng et al., 2011).  
An earlier study within the Biomedical Biotechnology Research Unit (BioBRU) assessed the 
cytotoxicity of a selection of the marine algal compounds in Figure 2.2 on the non-metastatic 
ER+ PR- HER2neu- MCF-7 breast cancer cell line by MTT assay (Lawson, 2009; MSc thesis). In this 
assay, compounds RU002, RU004, RU007, RU008, RU015, sargaquinoic acid and a racemic 
mixture of RU017 and RU018 displayed identical trends in cytotoxicity against MCF-7 cells as 
reported for MDA-MB-231 cells in the current study; namely that all but RU017/RU018 were 
49 
 
toxic to the breast cancer cells in the micromolar range, with RU015 being the most toxic 
(Figure A1, Appendix). This indicates that the algal compounds were equally effective against 
ER+ (MCF-7) and ER- (MDA-MB-231) breast cancer cells in vitro. 
A subset of eleven of the algal compounds screened in MDA-MB-231 cells in this study were 
also assessed by MTT assay against a different metastatic ER- PR- HER2neu-  breast cancer cell 
line, namely the Hs578T line. In general, the cytotoxicity results obtained in the Hs578T cell line 
agreed with those observed in the MDA-MB-231 line. This served to validate the findings 
obtained for MDA-MB-231 cells due to the shared characteristics of the MDA-MB-231 and 
Hs578T cell lines. However, the actual IC50 values as well as the ranking of compounds from 
least to most toxic varied between the MDA-MB-231 and Hs578T cell lines. In addition, the IC50 
values of the compounds were, in general, higher in the Hs578T cell line when compared to 
those in the MDA-MB-231 cell line. Considering the greater susceptibility of the Hs578T cells to 
Ptx, this was unexpected.  It is important to remember, however, that since testing in the two 
cell lines was not always carried out at the same time, it cannot be ruled out that the changes 
in cytotoxicity may be due to decreased stability of the compounds over time. This was most 
likely the case for compound RU002 (IC50 of 309 µM i.e. non-toxic in Hs578T vs IC50 of 64 µM in 
MDA-MB-231), which was tested in MDA-MB-231 cells a year before the testing was carried out 
in Hs578T cells. Very little is known about the long-term stability of these novel 
polyhalogenated monoterpene compounds. It was encouraging, however, that for all but one 
of the compounds, the anti-cancer activity of the monoterpenes after storage at -80 ºC for 
periods between six and twelve months is retained to the same order of magnitude against the 
metastatic breast cancer cell lines. A further factor to bear in mind is that once a hit 
halogenated monoterpene compound has been identified, chemical modifications could be 
carried out to improve the stability of the compound.  
As a further indication of the cytotoxicity of selected algal compounds against metastatic breast 
cancer cells, trypan blue staining was carried out on treated MDA-MB-231 and Hs578T cells. As 
opposed to the MTT assay, which is able to detect both senescent cells as well as those 
undergoing the initial stages of apoptosis, trypan blue will only stain cells which are either late 
apoptotic or necrotic and whose cell membranes have become compromised (Perry et al., 
1997). Thus a comparison of the results obtained by the MTT and trypan blue assays could 
provide information regarding the mechanism of toxicity of a particular compound. However, it 
is important to remember that the trypan blue assay relies on manual counting of cells and thus 
has a much larger margin for human error than the spectroscopic MTT assay.  
In the MDA-MB-231 cell line, the percentage viabilities determined by trypan blue staining after 
treatment with SQA or FXN at their respective IC50 values were within the expected range of 
around 50 % (48 % and 55 %, respectively). Percentage viability of Ptx as assessed by trypan 
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blue staining was slightly higher than anticipated (62 % viability at the IC50 of Ptx) but, 
considering the larger margin for error with this technique, not out of range. The much higher 
viabilities observed in the RU004 and RU007-treated samples (81 % and 78 %, respectively) 
could indicate that the majority of the cells, while susceptible to the monoterpene compounds, 
are in the earlier stages of apoptosis and thus still able to exclude the dye, or may simply be 
attributed to the inaccuracy of the technique. Since treatment was carried out over 96 hours, 
the former is less likely. A further possibility is that the number of live cells detected by trypan 
blue staining was overestimated due to the complete disintegration of the dead cells after 96 
hours of treatment, such that these cells were not visible when counting.  
For the Hs578T cell line, a much lower viability was calculated for the DMSO vehicle-treated 
control (85 %) as compared to that in the MDA-MB-231 cell line (98 %), a factor which must be 
taken into account when interpreting the percentage viability data in the Hs578T samples 
treated with the compounds of interest. Considering this, the lower percentage viabilities 
calculated for Hs578Tcells treated with Ptx and FXN (38 % and 25 %, respectively), when 
compared to those in MDA-MB-231 cells (62 % and 48 %, respectively), were not unexpected. 
The standard deviations calculated for the IC50 values of the compounds in the Hs578T cell line 
were much greater than those obtained in the MDA-MB-231 line. A simple explanation for this 
is that Hs578T cells, unlike MD-MB-231 cells, tend to clump together, which makes accurate 
counting difficult and can affect the reproducibility of the cell counts since the cells are not 
evenly distributed in solution. On the whole, however, the trypan blue assay results validated 
those obtained by MTT assay, in that the compounds which were found to be cytotoxic to 
breast cancer cells in the MTT assay also reduced cellular viability as assessed by trypan blue 
staining 
Measurement of cellular viability by trypan blue staining has previously been carried out in HL-
60 leukemia cells treated with fucoxanthin (Hosokawa et al., 1996). In this report, the number 
of viable HL-60 cells was counted after treatment with a range of concentrations of fucoxanthin 
over 24 hours and used to derive an IC50 value of 22.6 µM. The cellular viability was also 
determined after treatment with a concentration equivalent to the IC50 of the compound for 
24, 48, 72 and 96 hrs (Hosokawa et al., 1996). In the current study, previous attempts to 
determine the effect of algal compounds on cell viability by trypan blue staining after 24 hours 
were unsuccessful, since almost 100 % of the cells were found to be viable (unstained) for each 
of the treatments at this time point (data not shown). However, treatment was carried out with 
only a single concentration, namely the IC50 obtained by MTT. Should the fucoxanthin dose 
have been increased from 11 and 13 µM (IC50 in MDA-MB-231 and Hs578T, respectively, Figure 
2.3) to 22.6 µM as in Hosokawa et al, it is possible that an effect on cellular viability would have 
been observed after 24 hours of treatment. Indeed, in the Hosokawa study, a much greater 
difference in HL-60 viability between the vehicle- and fucoxanthin-treated samples after 96 
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hours as compared to 24 hours was observed (Hosokawa et al., 1996). In our study, increasing 
the treatment period to 96 hours had the added benefit of allowed for comparison of the 
results obtained using the MTT assay with those derived from the trypan blue staining method. 
The library of novel halogenated monoterpenes screened in this study by MTT assay (and, in 
some cases, trypan blue staining), contained two structural series, in which the monoterpene 
backbone was identical but for which the halogen substitutions varied between compounds, 
namely the RU007, RU008, RU048 and RU054 monoterpene aldehyde group and the RU015, 
RU016, RU017, RU018 and RU019 series (Figure 2.2). When screened against the MDA-MB-231 
breast cancer cell line, these structural series gave preliminary information as to structure-
function relationships and the potential role of the various halogen moieties on the molecule in 
mediating cytotoxicity. In the RU007/008/048/054 series, it appeared that the aldehyde group 
which was common to all four compounds was unlikely to be responsible for toxicity, since, 
while RU007 and RU008 were toxic to MDA-MB-231 cells, RU048 and RU054 were not. 
Interestingly, the substitution of just one bromine atom in RU007 for a chlorine atom in RU054 
rendered the compound non-toxic to the cells (Figure 2.2 and Figure 2.3A).    
In the RU015/016/017/018/019 group, despite their similarities, one of the compounds in this 
series displayed the highest toxicity towards MDA-MB-231 breast cancer cells of all the algal 
compounds screened in this study, while the other four molecules were non-toxic to these cells 
(Figure 2.3A). It would appear that a higher number of halogen atoms in this series resulted in a 
more toxic compound, as there were five halogen moieties in the highly toxic RU015 
compound, while the non-toxic compounds RU016, RU017, RU018 and RU019 had either three 
or four halogen atoms (Figure 2.2). It did not appear that the position of the chlorine moieties 
in RU015 contributed to its toxicity. Interestingly, when the structure of RU015 was compared 
to those of the other toxic novel compounds which contained five halogens, it was found to be 
the only one which contained chlorine alone, with no bromine atoms (Figure 2.2). All further 
attempts at deriving a correlation between halogen number, as well as chlorine and bromine 
content of the compounds, with cytotoxicity, were unsuccessful in elucidating a clear trend 
(data not shown). However, based on the high toxicity of RU015, it could tentatively be 
predicted that substitution of a monoterpene with as many chlorine atoms as possible would 
increase the toxicity towards metastatic MDA-MB-231 breast cancer cells. Expansion of the 
compound library by systematic chemical substitutions could shed more light on how the 
various atoms in the novel monoterpene compounds contribute to their cytotoxicity. 
Since the algal compounds SQA and FXN have previously been described in the literature, this 
provided the opportunity to compare the cytotoxicity of these compounds in various cancer cell 
lines (Choi et al., 2007; Hur et al., 2008; Hosokawa et al., 1996; Das et al., 2005; Kotake-Nara et 
al., 2005a). The quinone derivative, SQA, has reportedly been isolated from samples of 
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Sargassum sagamianum collected off the coast of Korea (Choi et al., 2007).  The compound was 
tested against the human keratinocyte HaCaT cell line by MTT assay and it was found to reduce 
cellular proliferation to roughly 20 % at a concentration of 23 µM (Hur et al., 2008). In our 
studies, the compound supplied was isolated from a different species, namely Sargassum 
heterophyllum, (Afoloyan et al., 2008) and displayed IC50 values of 67.40 and 81.50 µM against 
the breast cancer cell lines MDA-MB-231 and Hs578T, respectively, suggesting that the 
compound had a greater effect on proliferation of human skin cancer HaCaT cells than 
metastatic breast cancer cells in vitro.  
Previous studies have reported the isolation of FXN from the brown alga Laminaria japonica, 
which showed a 50 % reduction in cell proliferation at approximately 100 µM in human colon 
carcinoma cells (Hosokawa et al., 1996). In addition, FXN extracted from Undaria pinnatifida 
completely abolished growth of HL-60 leukemia cancer cells at a concentration of 22.6 µM (Das 
et al., 2005). Furthermore, the compound has been demonstrated to decrease growth of PC-3 
human prostate cancer cells by approximately 50 % when treatment with 20 µM of the 
compound was carried out over 72 hours (Kotake-Nara et al., 2005a). In this study, the supplied 
compound was isolated from Undaria pinnatifida and displayed IC50 values of 11.06 and 13.06 
µM against the breast cancer cell lines MDA-MB-231 and Hs578T, respectively. It would appear, 
therefore, that metastatic breast cancer cells were more susceptible to FXN than human colon 
cells and similarly sensitive to the compound when compared to both human leukemia and 
prostate cancer cells in vitro (Hosokawa et al., 1996; Das et al., 2005; Kotake-Nara et al., 
2005a).  
Selected algal compounds were further assessed for differential toxicity against breast cancer 
but not non-cancerous breast epithelial cells. The commonly used chemotherapeutic drug, Ptx, 
was found to be highly toxic to both breast cancer and non-cancerous breast cells. It is precisely 
this non-selective toxicity which is responsible for the adverse side-effects of anti-cancer drugs 
such as Ptx (Garcia et al., 2007). While compounds RU004, RU007, SQA and, to a lesser extent, 
FXN, displayed greater cytotoxicity against the MDA-MB-231 and Hs578T cancer cell lines than 
the MCF12A cell line, the stereoisomers RU017 and RU018 had no effect on the survival of any 
of the cell lines, even at the very high dose of 300 µM. To the best of our knowledge, this is the 
first report of the testing of halogenated monoterpene compounds or sargaquinoic acid in a 
non-cancerous cell line, apart from other studies carried out within our research group 
(Lawson, 2009) and the first study of fucoxanthin’s effect on a non-cancerous cell line. As part 
of a MSc research project, Lawson screened compounds RU002, RU004, RU007, RU008, 
sargaquinoic acid, RU015 and a racemic mixture of RU017 and RU018 for cytotoxicity against 
the non-cancerous breast epithelial line, MCF12A (Figure A1, Appendix). An important 
difference between the cytotoxicity testing described in the Lawson study and the current 
report is that in the former, MCF12A cells were cultured in the presence of cholera toxin. A 
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further difference between the Lawson study and the current work is that, in the former, 
cytotoxicity was carried out over a range of concentrations for each compound in MCF12A cells, 
in order to obtain an IC50 value; whereas, in the current study, a single-point cytotoxicity test 
was carried out for each compound in the MCF12A line at a concentration equivalent to the IC50 
of the particular compound in MDA-MB-231 cells. Despite these differences, the data 
generated in the current study validated those in the Lawson report, in that the compounds 
RU004, RU007 and sargaquinoic acid were selected as potential “hits” in both cases due to the 
finding that their IC50 values in MCF12A cells were more than three times higher than in MCF-7 
cells (Lawson, 2009; Figure A1).  
The differential toxicity of a hit compound is a very important consideration in the screening of 
novel compounds for anti-cancer activity, since failure to discriminate between cancer cells and 
healthy tissue could result in adverse side-effects of the compound in vivo. It is not uncommon 
in the literature for researchers to carry out detailed studies of the mechanisms of action of 
novel compound without first determining the toxicity of the compound in question towards 
non-cancerous cells. An example of this is the characterization of the anti-cancer activity of the 
pentahalogenated monoterpene halomon, isolated from Portieria hornemannii (Fuller et al., 
1992). The compound displayed strong cytotoxicity against brain, renal and colon cancer cell 
lines in the National Cancer Institute’s in vitro screening panel and was selected for preclinical 
drug development (Fuller et al., 1992). Although the mechanism of cytotoxicity of halomon is 
thought to be due to DNA methyltransferase inhibition, the effect on non-malignant cells was 
not determined (Andrianasolo et al., 2006). Such differential toxicity is an important 
consideration, as has been demonstrated by the Lawson study discussed above, where the 
most toxic compound in our library, RU015, (Figure 2.2, Figure 2.3A) was also found to be highly 
toxic to normal breast epithelial cells (Lawson, 2009; Figure A1). 
The pharmacological potential of the hit compounds identified in this study, namely RU004, 
RU007 and SQA, was assessed using Lipinski’s Rule of 5 (Ro5). Although only four characteristics 
of a compound are assessed in the Ro5, the name is derived from the cutoffs for each of the 
four parameters, which are all close to 5 or a multiple of 5 (Lipinski et al., 2001).The 
chemotherapeutic drug, Ptx, was included in the analysis as a means of comparison with the hit 
algal compounds in terms of their ‘druggability.” What is immediately apparent when 
comparing their chemical structures is that the three algal compounds, in particular the two 
halogenated monoterpenes RU004 and RU007, display much smaller and simpler structures 
than the 850 g/mol aromatic molecule, paclitaxel. In terms of the ”drug-likeness” of the hit 
compounds, RU007 displayed favourable pharmacological properties for all the criteria 
assessed by Lipinski’s Rule of 5. While RU004 and sargaquinoic acid had cLogP values which 
were considered to be out of the “druggable” range, they did meet the other requirements 
outlined in the Ro5. On the other hand, although Ptx displayed a favourable cLogP value, it did 
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not meet the other druggability criteria defined in the Rule of 5, despite being in clinical use. 
Indeed, this compound has been reported to display “poor biopharmaceutical properties” 
including low aqueous solubility and low bioavailability, such that the drug must currently be 
delivered intravenously in an ethanolic solution (Khandavilli and Pnachagnula, 2007). 
Therefore, the therapeutic potential of a compound does not appear to be dependent solely on 
a favourable cLogP value, highlighting the importance of the remaining elements in Lipinski’s 
Ro5. Since compound RU007 met all the druggability requirements outlined in the Ro5, this 
predicted that the compound would display favourable in vivo solubility and bioavailability 
properties. Finally, one must bear in mind that the cLogP values of RU004 and sargaquinoic acid 
could again be improved by chemical modification, as for their stability and toxicity, should the 
compounds warrant further investigation. 
 
2.5 CONCLUSIONS  
In summary, this study reports the screening of twenty-two algal compounds against ER- PR- 
HER2neu- metastatic breast cancer cells in vitro. These included nineteen novel 
polyhalogenated monoterpenes as well as the previously described compounds, sargaquinoic 
acid, sargahydroquinoic acid and fucoxanthin. All twenty two compounds were screened in the 
MDA-MB-231 cell line, of which twelve were toxic in the micromolar range. A subset of the 
compounds were tested in a different ER- PR- HER2neu- metastatic breast cancer line, Hs578T, 
and for the most part mirrored the cytotoxicity profile obtained for the MDA-MB-231 cells. 
From these, priority compounds were selected based on their differential toxicity when tested 
against healthy, non-cancerous MCF12A cells, namely RU004, RU007 and sargaquinoic acid. In 
contrast to paclitaxel, the chemotherapeutic agent often used to treat breast cancer in vivo and 
which was found to be almost equally toxic to breast cancer cells as to normal breast cells in 
this study, the algal compounds RU004, RU007 and sargaquinoic acid had no adverse effect on 
normal breast epithelial cells at concentrations which were toxic to breast cancer cells in vitro.  
The differential toxicity of the hit compounds, together with their novel and relatively simple 
chemical structures, justify further studies on these algal secondary metabolites. The three 
compounds, RU004, RU007 and sargaquinoic acid, together with the commercially sourced 
carotenoid, fucoxanthin, were selected for further characterization in terms of their mechanism 
of action in metastatic ER- PR- HER2neu- breast cancer cells in vitro. 
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CHAPTER 3 
 
ELUCIDATION OF THE MODE OF ACTION OF 
SELECTED MARINE ALGAL COMPOUNDS AGAINST 
METASTATIC BREAST CANCER CELLS IN VITRO 
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3.1 INTRODUCTION 
One of the defining features of cancer cells is their ability to evade apoptosis (Iannolo et al., 
2008). This process of “programmed cell death” is the body’s way of removing irreversibly 
damaged and unwanted cells in a manner which does not result in an immune response (Jin 
and El-Deiry, 2005;). On the other hand, necrosis is described as an unregulated and irreversible 
process, which occurs in response to a “major insult” (Fink and Cookson, 2005; Klener Jr. et al., 
2006). During necrosis, the cell ruptures and releases its contents into the surrounding tissues, 
causing a massive inflammatory response (Leist and Jaattela, 2001). Apoptosis occurs via two 
major pathways, the extrinsic or receptor-mediated pathway and the intrinsic or mitochondrial 
pathway (Nagata, 1997; Kroemer and Reed, 2000). These pathways are interconnected at a 
number of points and the main role-players in both pathways are caspases (Iannolo et al., 
2008). The extrinsic and intrinsic pathways converge on the effector caspase, caspase-3, which 
initiates the cleavage of key molecules in order to execute the final stages of apoptosis (Jina nd 
El-Deiry, 2005; Debatin and Krammer, 2004). One such target of caspase-3 action is poly(ADP-
ribose) polymerase (PARP), an enzyme which is involved in DNA repair. The cleavage of PARP 
allows for cellular disassembly and is traditionally used as a marker of apoptotic cells (Boulares 
et al., 1999). However, PARP has recently been shown to be cleaved during necrosis of cells 
(Chaitanya and Babu, 2009). It has since been reported that it is the specific PARP cleavage 
products generated, and not PARP cleavage in general, which can be used to distinguish 
between the processes of apoptosis and necrosis. While an 85 kDa PARP fragment is produced 
as a result of caspase-3-mediated cleavage and is indicative of apoptosis, a 50 kDA product is 
generated upon cathepsin B action and is typical of necrosis (Chaitanya and Babu, 2009). 
Although a high toxicity towards cancer cells is desirable in a potential chemotherapeutic, it is 
crucial that the mechanism of toxicity be elucidated. Whereas apoptosis is the preferred means 
of eliminating cancer cells, other forms of cell death that are not programmed, such as necrosis, 
cause massive inflammatory and immune responses and compounds which induce such a 
response may not be therapeutically useful (Klener Jr. et al., 2006). Literature reports a limited 
number of studies attempting to elucidate the mechanism of anti-cancer activity of novel 
marine algal compounds in terms of cell death. These include the findings that apoptosis is the 
mode of cell death induced both by sargaquinoic acid in human skin cancer cells and by 
fucoxanthin in leukemia as well as prostate and colon cancer cells in vitro (Hur et al., 2008; 
Kotake-Nara et al., 2001a; Hosokawa et al., 1999; Hosokawa et al., 2004).  
In addition to the induction of cell death, many cytotoxic compounds cause cell cycle arrest 
(Das et al., 2005; Palozza et al., 2002). During normal division, a cell passes through four 
defined phases of the cell cycle. The G1 phase, during which cells increase in size in preparation 
for division; the DNA synthesis or S phase, in which DNA replication occurs; the G2 phase in 
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which the cells continue to increase in size; and the M or mitotic phase, in which the cell divides 
into two daughter cells. Two checkpoints exist within the cycle: the G1/S checkpoint and the 
G2/M checkpoint, which regulate the progression of cells through the cell cycle and prevent 
entry to the next phase until the cell has met the requirements for that phase. The checkpoints 
also ensure that DNA damage may be repaired. When cells exit the cell cycle and no longer 
divide, they are said to be in the G0 phase or resting state (reviewed in Smith and Martin, 1973). 
The anti-cancer activities of novel chemotherapeutic agents are often mediated through cell 
cycle arrest by interacting with various cell cycle-associated proteins. These include cyclin-
dependent kinases (cdks) as well as their activators and inhibitors, namely cyclins, p21WAF1/Cip1 
and p27Kip1 (Das et al., 2005; Palozza et al., 2002). Carotenoids, in particular, have been shown 
to affect the activity of the aforementioned proteins. Other examples of natural products which 
interfere with cell cycle proteins include the modification of cyclin D3 and cdk4 in breast cancer 
MCF-7 cells by retinoic acid, as well as the reduction of cyclin D levels and activation of the 
inhibitor p27Kip1 in breast and endometrial cancer cells by lycopene (Zhu et al., 1997; Nahum et 
al., 2001). The marine algal carotenoid, fucoxanthin, has been demonstrated to cause G0-G1 
phase arrest in WiDr and HCT116 human colon cancer cell lines as well as neuroblastoma GOTO 
cells (Das et al., 2005; Okuzumi et al., 1990). Furthermore, this effect of fucoxanthin on the 
colon cancer cell lines was shown to be mediated by upregulation of the cdk inhibitor 
p21WAF1/Cip1 (Das et al., 2005). 
 
The aim of this body of work was to determine the mode of action of the priority algal 
compounds RU004, RU007, RU015, sargaquinoic acid and fucoxanthin in breast cancer cells in 
vitro. In particular, the type of cell death induced by the compounds as well as their ability to 
cause cell cycle arrest was investigated. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Reagents 
The mouse anti-human poly(ADP-ribose) polymerase (PARP) primary antibody was from Cell 
Signalling Technologies (Massachusetts, USA), while the rabbit anti-β-actin primary antibody as 
well as the goat anti-mouse and donkey anti-rabbit horseradish peroxidase (HRP)-conjugated 
secondary antibodies were obtained from Sigma-Aldrich (Germany), Kirkegaard and Perry 
Laboratories (Maryland, USA) and Amersham Biosciences (UK), respectively. Hoechst 33342 
and propidium iodide for flow cytometric analyses were from Invitrogen (UK) and Sigma-Aldrich 
(Germany), respectively. RNAse-A and Triton X-100 for cell cycle analyses were from Sigma-
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Aldrich (Germany). All other chemicals were of reagent grade. Tissue culture vessels were from 
Corning (Pennsylvania, USA). 
3.2.2 Cell lines and culture conditions 
The breast cancer cell lines, MDA-MB-231 (ATCC: HTB-26) and Hs578T (ATCC: HTB-126), were 
cultured as described in Chapter 2 (Section 2.2.2). 
3.2.3 Western blot analysis 
MDA-MB-231 cells (1 × 106) were seeded into 60 mm plastic tissue culture dishes and allowed 
to settle overnight. The cells were treated with either 0.5 % v/v DMSO vehicle control, 17-
allylamino-17-demethoxygeldanamycin (17-AAG) (5 nM), sargaquinoic acid (0.6, 6 or 60 µM) or 
RUMB-015 (0.3, 3 or 30 µM) over the course of 8, 24, 48 or 96 hrs at 37 ºC and 9 % CO2. 
Thereafter, whole cell lysates were prepared by scraping the adherent cells into the media, 
spinning at 2000 rpm for 3 minutes and resuspending in 100 µM sodium dodecyl sulphate (SDS) 
sample buffer [125 mM Tris-HCl pH 6.8, 2 % (w/v) SDS, 20 % (v/v) glycerol, 0.2 % (w/v) 
bromophenol blue], before boiling for 5 minutes. Lysates from the equivalent of 1 × 105 cells 
were separated by electrophoresis using 12 % SDS polyacrylamide gels, transferred onto 
nitrocellulose membranes and probed with a 1 in 1000 dilution of mouse anti-human PARP 
primary antibody at 4 ºC overnight. The HRP-conjugated goat anti-mouse and donkey anti-
rabbit secondary antibodies (diluted 1 in 5000) were detected using the ECL Advanced Western 
Blotting Kit (GE Healthcare, UK) and visualized using the Molecular Imager ChemiDoc XRS 
System (BioRad, California, USA). Lysates were probed with a 1 in 2000 dilution of rabbit anti-β-
Actin antibody as a loading control. All antibody dilutions were made up using a 5 % (w/v) non-
fat milk powder solution in Tris-buffered saline (TBS) (50 mM Tris, 150 mM NaCl, pH 7.5). 
3.2.4 Cytotoxicity detection by flow cytometry 
Flow cytometric analysis of cells stained with Hoechst 33342 and propidium iodide was used to 
distinguish between the processes of apoptosis and necrosis within treated breast cancer cells, 
according to the protocol described by Dive and colleagues (Dive et al., 1992). MDA-MB-231 or 
Hs578T cells (3 x 105) were seeded into 25 cm2 flasks and allowed to settle and grow over 24 
hrs before dosing with the relevant compounds overnight. Cells were lifted carefully using I x 
trypsin [1% (w/v) trypsin solution made up in 0.3 % (w/v) ethelene diamine tetra-acetic acid 
(EDTA)], washed and resuspended in a pre-warmed 2 % (w/v) solution of bovine serum albumin 
(BSA) in phosphate buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4 pH 7.4). Hoechst 33342 was added to a final concentration of 1 µg/ml, the suspension 
vortexed and incubated at 37 ºC for 7 minutes. Propidium iodide (PI) was added to a final 
concentration of 1 µg/ml, the cells incubated on ice for 10 minutes and analyzed on a FACS Aria 
II flow cytometer. Hoechst 33342 was excited by the ultraviolet laser at 355 nm and emission 
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detected in the 450/50 channel, while PI was excited by the blue laser at 488 nm and detected 
in the 610/20 channel. Data was analysed using FlowJo software Version 7.6.1. (Tree Star Inc., 
2010).    
3.2.5 Cell cycle analysis by propidium iodide staining 
The effect of selected algal compounds on the distribution of MDA-MB-231 cells in the various 
phases of the cell cycle was determined by flow cytometry with propidium iodide staining 
(according to Nunez et al., 2001). Cells were seeded at 2.5 x 105 and, after 24 hours, were 
treated with either 0.024 % v/v DMSO (vehicle control), paclitaxel (50 nM), sargaquinoic acid 
(25, 75, 120 µM) or fucoxanthin (10, 25, 50 µM) for a period of 16 hours. Cells were harvested 
by treatment with 1 x trypsin and resuspended in PBS before fixation with 70 % ethanol. Cells 
were collected by centrifugation and stained in a PI solution (50 µg/ml, containing 0.1 mg/ml 
RNAse A and 0.05 % (v/v) Triton X-100), followed by incubation at 37 ºC for 40 minutes. 
Thereafter cells were collected by centrifugation, resuspended in PBS and analysed by flow 
cytometry as described above. Doublet discrimination was carried out to eliminate false 
positives due to cell aggregates. 
 
3.3 RESULTS  
3.3.1 Discrimination between the induction of apoptosis and necrosis of breast cancer cells 
by marine algal compounds via flow cytometry 
The marine algal compounds sargaquinoic acid (SQA), RU004 and RU007 were selected as 
potential “hit” compounds based on their differential toxicity towards breast cancer cells, but 
not non-cancerous breast cells (Figure 2.3 and Table 2.2, Chapter 2). These compounds, 
together with the indiscriminately toxic monoterpene RU015, the commercially available 
brown algal metabolite fucoxanthin (FXN) and the chemotherapeutic agent paclitaxel (Ptx), 
were selected as priority compounds for further study. In order to ascertain whether the 
cytotoxicity of the algal compounds could be attributed to apoptosis or necrosis, flow 
cytometry using dual Hoechst 33342 (H33342) and propidium iodide (PI) staining was carried 
out on both MDA-MB-231 and Hs578T cells treated with a range of concentrations of the 
compounds. Both cell lines were selected for flow cytometric analyses in order to compare the 
mode of action of selected algal compounds against two different breast cancer cell lines. The 
H33342/PI assay involves the fluorescent detection of compacted chromatin in apoptotic cells 
(Sun et al., 1992). The vital bisbenzimidazole dye, H33342, stains the compacted chromatin of 
apoptotic cells more intensely than the chromatin of live cells; while the DNA-intercalating 
agent, PI, is impermeable to cells with an intact membrane, namely live cells and those in the 
early stages of apoptosis. As a result, cells that are H33342-positive but PI-negative may be 
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alive or undergoing apoptosis, but those that are both H33342-positive and PI-positive are 
either in the late stages of apoptosis or are necrotic (Sun et al., 1992).  
3.3.1.1 Assessment of whether selected novel algal compounds induce apoptosis or necrosis 
in MDA-MB-231 cells 
For the MDA-MB-231 breast cancer cell line, Figure 3.1A depicts the H33342/PI staining for 
selected samples, represented by dot-plots generated using FlowJo software (Tree Star Inc., 
2010). These include the fluorescence data detected for the DMSO vehicle-treated samples as 
negative controls (i-iv), the Triton X-100 necrosis positive control sample (viii), as well as a dose-
response study for SQA as a representative of the novel marine algal compounds (v-vii). In each 
case, the dot-plot is divided into four quadrants or “gates” which defined whether a particular 
“dot” or fluorescence “event”, representing the emission from a single cell, was “positive” or 
“negative” for either H33342 or PI. The four quadrants are characterized as follows: The upper 
left hand (UL) quadrant defines cells which were PI-positive, but H33342-negative; the lower 
left hand (LL) quadrant represents cells which were H33342-negative and PI-negative; the lower 
right hand (LR) quadrant defines cells which were H33342-positive, but PI-negative; and the 
upper right hand (UR) quadrant represents cells which were both H33342-positive and PI-
positive. The latter gates were set according to the dot-plots obtained for the vehicle-treated 
control samples which were stained for H33342 and/or PI, and the gates copied to all other 
samples.  
Figure 3.1B was derived by plotting the percentage of cells for each sample in Figure 3.1A which 
were both H33342-positive and PI-positive and thus located in the UR quadrant of the dot-
plots. The latter proportion of cells is depicted as being “late apoptotic or necrotic” in the y-axis 
of Figure 3.1B. In addition, Figure 3.1B represents a summary of all the flow cytometry 
experiments performed in MDA-MB-231 cells, including those not represented in Figure 3.1A, 
but for whom the “percentage late apoptotic/necrotic” value was derived from dot-plots of the 
fluorescence data obtained (histograms not shown). These included cells treated with a range 
of concentrations of either Ptx, RU004, RU007, RU015 or FXN.  
For the DMSO-treated samples, it was observed that the entire population in the unstained 
control (i.e. 100 % of cells) was located in the H33342-negative, PI-negative LL quadrant (Figure 
3.1Ai). In the case of the DMSO control where cells were stained with H33342 only, the vast 
majority of cells were detected in the H33342-positive, PI-negative LR quadrant (99.9 %, Figure 
3.1Aii); while DMSO-treated cells stained with PI alone were located largely in the H33342-
negative, PI-negative LL quadrant (97.3 %, Figure 3.1Aiii); and cells stained with both H33342 
and PI were detected mainly in the H33342-positive PI-negative LR quadrant (98.6 %, Figure 
3.1Aiv).
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The gating strategy derived from the DMSO-treated control allowed for the quantification of 
the proportion of cells treated with the compounds of interest which were potentially 
apoptotic or necrotic. The staining profiles for the negative controls indicated that the 
experimental system was free of background staining or auto-fluorescence which would 
confound the results obtained for the test compounds.   
Treatment with SQA caused a dose-dependent shift in staining towards the H33342-positive, PI-
positive UR quadrant representing late apoptotic or necrotic cells (1.0 %, 11.9 % and 87.1 % for 
treatment with 25, 75 and 150 µM, respectively; Figure 3.1Av - vii). This shift to the UR 
quadrant via the LR quadrant upon treatment with a compound is typical of apoptosis (Dive et 
al., 1992). In contrast to SQA, treatment of MDA-MB-231 cells with Triton X-100 caused a shift 
in staining directly to the H33342-positive, PI-positive UR quadrant, appearing as a “comet-
shaped” population on the fluorescence dot plot (96 % the UR H33342-positive, PI-positive 
quadrant; Figure 3.1Aviii). Triton X-100 is a detergent which permeabilizes cells by disruption of 
their phospholipid membrane, allowing PI to enter the cells, such that this treatment 
represented a positive control for H33342-positive PI-positive necrotic cells (Dive et al., 1992). 
Indeed, these cells displayed a characteristic H33342-positive, PI-positive necrotic staining 
pattern with the majority of cells being detected in the UR quadrant of the dot-plot (Figure 
3.1A).  
As mentioned previously, the fluorescence data plotted for the treatment of MDA-MB-231 cells 
with Ptx, RU004, RU007, RU015 and FXN (Figure 3.1B) were obtained from the percentage of 
cells located in the H33342-positive/PI-positive UR quadrant of their respective dot blots (data 
not shown) in the same manner as for SQA-treated cells. While treatment of cells with the 
novel polyhalogenated monoterpene, RU007, resulted in a similar flow cytometric profile to 
that seen for treatment with SQA, namely a dose-dependent increase in late-apoptotic or 
necrotic cells; treatment with the compounds Ptx, RU004, RU015 and FXN did not produce 
many cells which were detected as late apoptotic or necrotic at any of the concentrations 
tested (Figure 3.1B).  
3.3.1.2 Determination of whether selected novel algal compounds induce apoptosis or 
necrosis in Hs78T breast cancer cells 
In the case of the Hs578T cell line, flow cytometric detection of H33342 and PI staining was 
carried out for cells treated with Ptx, RU004, RU007 and FXN (Figure 3.2) in the same manner as 
for the MDA-MB-231 cell line (Figure 3.1). For the DMSO vehicle-treated negative controls, the 
unstained population was detected as being both H33342-negative and PI-negative (99.7 % of 
cells in the LL quadrant, Figure 3.2Ai), the H33342-stained cells exhibited H33342-positive and 
PI-negative staining (99.7 % of cells in the LR quadrant, Figure 3.2Aii), the PI-stained cells were 
negative for both H33342 and PI (89.3 % of cells in the LL quadrant, Figure 3.2Aiii) and the 
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double-stained H33342 and PI cells were detected as H33342-positive and PI-negative (95.6 % 
of cells in the LR quadrant, Fig3.2Aiv).  
As for MDA-MB-231 cells, the controls represented the expected staining patterns, indicating 
the absence of autofluorescence or background levels of H33342 and PI staining (Figure 3.2A). 
The positive control sample treated with Triton X-100 also displayed the expected characteristic 
necrotic staining pattern in the UR quadrant of the H33342/PI dot plot (94.3 % H33342-positive 
PI-positive cells, Figure 3.2Aviii).  
For the Hs578T cell line, Figure 3.2A depicts the fluorescence dot-plots generated for the 
vehicle-treated negative controls as well those for cells treated with a range of concentrations 
of the halogenated monoterpene, RU007, as a representative of the novel marine algal 
compounds; while Figure 3.2B is derived by plotting the percentage of cells in the UR quadrant 
of the dot blots for each sample (including those not shown in Figure 3.2A) as a “percentage of 
late apoptotic/necrotic cells”. The monoterpene RU007 was selected as a model compound 
due to its differential toxicity and favourable pharmacological profile (Figure 2.3B, Table 2.2; 
Chapter 2). Treatment with RU007 resulted in a dose-dependent shift in staining of the Hs578T 
cells towards the H33342-positive PI-positive UR quadrant (4.4 %, 5.8 % and 23.9 % for 
treatment with 50, 100 and 200 µM, respectively; Figure 3.2Av-vii). A similar staining pattern 
was observed for cells treated with Ptx (4.3 %, 10.8 % and 14 % late apoptotic/necrotic cell for 
treatment with 5, 25 and 125 nM, respectively), as well as for cells treated with the novel 
monoterpene RU004 (9.4 %, 11.1 % and 24.9 % late apoptotic/necrotic cells for treatment with 
50, 100 and 200 µM, respectively) (Figure 3.2B). For both of these compounds, the dose-
dependent H33342/PI staining patterns were different between the MDA-MB-231 and Hs578T 
breast cancer cell lines.  
In the case of the carotenoid, FXN, Hs578T cells treated with the compound displayed very low 
levels of late apoptotic/necrotic cells, even at 25 µM (0.8 %; Figure 3.2B), a concentration 
almost double the IC50 of the compound (13 µM, Figure 2.3B; Chapter 2), which agreed with the 
results obtained in the MDA-MB-231 cell line (Figure 3.1B)   
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3.3.2 Elucidation of the mode of action of SQA and RU015 in MDA-MB-231 cells by the 
PARP cleavage assay 
Whereas the Hoechst/propidium iodide staining and flow cytometric analyses represented a 
broader screening-type approach, the PARP cleavage assay was selected as a more focused 
apoptosis detection assay. Since insufficient amounts of compound were available to perform 
the latter assay for all compounds, one of the previously characterized algal compounds (ie. 
SQA and FXN) and one of the novel Rhodes University algal compounds (RU002-081) were 
selected. The PARP cleavage assay is a more specific protein-based method for the detection of 
apoptosis and can be used to distinguish between apoptosis and necrosis according to the size 
of the cleavage products produced; an 85 kDa PARP fragment is typical of apoptosis, while a 50 
kDa fragment is indicative of necrosis (Chaitanya and Babu, 2009). The experiment was 
optimized using the Hsp90 inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), 
which is known to induce apoptosis in the MCF-7 breast cancer cell line (Chiosis, 2006). It was 
determined that treatment with 17-AAG induced PARP cleavage to produce an 85 kDa product, 
which was evident after 8 hours of treatment (Figure 3.3A). Thereafter, all PARP assays were 
carried out after 8 hours of treatment with the compound of interest. Cleavage products of 85 
kDa for PARP were observed after treatment of MDA-MB-231 cells with increasing 
concentrations of SQA (Figure 3.3B), while treatment with the novel halogenated monoterpene 
RU015 generated 50 kDa PARP cleavage products (Figure 3.3C). 
The membranes in Figure 3.3B and 3.3C were probed for β-actin as a loading control and 
indicated that the levels of protein loaded per well in the SQA-treated samples were roughly 
equivalent (Figure 3.3B), while for the RU015-treated samples, the β-actin signals varied 
somewhat between samples (Figure 3.3C). The latter changes in the levels of β-actin were 
reflected in the levels of PARP and its cleavage products (Figure 3.3C). Despite the differences 
in quantities of protein loaded, PARP cleavage was observed for treatment with all three 
concentrations of RU015, albeit that this effect was not necessarily dose-dependent. 
 
  
Figure 3.3: Elucidation of the mechanism of cell death induced by
MDA-MB-231 breast cancer cells by PARP assay. 
lysates, with cleavage of poly(ADP
necrosis. A) Optimization of assay by treatment with the apoptosis
17-allylamino-17-demethoxygeldanamycin (17
carried out over 8 h. B) PARP cleavage products upon treatment with 
control), sargaquinoic acid (SQA) or
equal loading of protein between samples. The We
lysates a minimum of two times in order to confirm the results obtained.
 
 
3.3.3 Determination of the effects
231 cells by flow cytometry 
To determine if either SQA or FXN arrest MDA
the cell cycle, cells were treated with a range of concentrations of the compound
DNA content assessed by flow cytometry with propidium iodide (PI) staining. In addition, this 
protocol measures the extent of apoptosis according to the DNA content of the cells, such that 
those cells whose DNA content is less than the G
 
 sargaquinoic acid and RU015 in 
Western analyses were carried out on whole cell 
-ribose) polymerase (PARP) used as an indicator of either apoptosis or 
-inducing Hsp90 inhibitor, 
-AAG) over 8, 24, 48 and 96 h. Thereafter assays were 
either 0.5 % v/v DMSO (vehicle 
 (C) RU015. In each case, detection of β-actin was used to ensure 
stern analyses were carried out
 
 of SQA and FXN on cell cycle distribution in MDA
-MB-231 breast cancer cells in a certain phase of 
0-G1 proportion in the untreated population 
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are considered to be apoptotic. Figure 3.4A depicts the doublet gating strategy, while Figure 
3.4B shows the fluorescence histograms depicting the cell cycle profiles for MDA-MB-231 cells 
treated with either DMSO vehicle control (i), Ptx (ii), or a range of concentrations of SQA (iii-v), 
and Figure 3.4C represents a summary of the data in Figure 3.4B obtained by plotting the 
percentage distribution of the cells in each phase of the cell cycle for each treatment. 
In Figure 3.4A, gating of the population was carried out to allow for doublet discrimination. In 
the analysis of cell cycle distribution by DNA content, it is essential to carefully gate the 
population of cells on a PI:Area vs. PI:Width dot plot. The reason for this is that the PI Pulse 
Area (PI:A) signal is unable to distinguish between two cells with a G1 phase DNA content which 
are clumped together (2 x n), and a single cell which has twice the DNA content ie G2-M phase 
(1 x 2n). Since the PI Pulse Width (PI:W) signal is a representative of the size of the cells, the 
PI:A vs. PI:W plot allows for the discrimination between cell clumps and cells which are in the 
G2-M phase (Nunez et al., 2001). 
In Figure 3.4Bi and 3.4Bii, the histograms depicting the cell cycle profiles for the DMSO vehicle-
treated negative control and Ptx–treated positive control samples were used to define the 
gates for each cell cycle phase. Ptx treatment was used as a control since this is known to cause 
G2-M phase arrest in breast cancer cells (Tzu-Hao et al., 2000). Gating was carried out by 
assigning the dominant peak as G0-G1 phase (PI:A values between 80K and 120K) and defining 
the G2-M phase as a peak at a PI:A value along the X-axis that was roughly double that for G0-G1 
and that corresponded to the dominant peak in the Ptx-treated control (PI:A values between 
140K and 240K). The remainder of the histogram was divided up into the sub-G0 apoptotic and 
S-phase gates and copied to all samples. For the positive control, treatment with Ptx resulted in 
a shift from 39.8 % of the population in the G2/M phase in untreated MDA-MB-231 cells to 45.2 
% in cells treated with 50 nM Ptx (Figure 3.4Bi and Figure 3.4Bii, respectively).  
 
In the case of SQA, treatment with various concentrations of the quinone compound resulted in 
an altered cell cycle profile when compared to the vehicle treated control (Figure 3.4Biii-v and 
3.4Bi, respectively, Figure 3.4C). In addition to a dose-dependent increase in the sub-G0 
apoptotic population (1.7 %, 7.4 % and 14.9 % for treatment with 25, 75 and 120 µM, 
respectively), an increase in the G0-G1 phase (63.8 %, 55.6 % and 56.7 %, respectively) as well as 
a dose-dependent decrease in the G2-M phase (27.8 %, 25.9 % and 17.7 %, respectively) was 
observed upon treatment with SQA (Figure 3.4Biii-v and C).  
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Figure 3.4: Analysis of the effect of sargaquinoic acid on cell cycle in MDA-MB-231 breast cancer cells. 
Cells were treated with vehicle control (0.24 % v/v DMSO), 25, 75 or 120 µM sargaquinoic acid (SQA) or 
50 nM paclitaxel (Ptx) for 16 h, stained with propidium iodide (PI) and analysed by flow cytometry. (A) 
Gating of cell population to allow for doublet discrimination, in which false positives due to cell aggregates 
are eliminated. The singlet gate was copied to all samples such that subsequent analyses were carried 
out only for cells within the gate. (B) Histograms showing the cell cycle profile of MDA-MB-231 cells upon 
treatment with either the DMSO vehicle control (i), Ptx (ii) or a range of concentrations of SQA (iii-v). The 
phases of the cell cycle were gated according to the DMSO-treated control such that the dominant peak 
represented G
0
-G
1
 phase and the G
2
-M gate was defined for a peak at a PI-A value along the X-axis that 
was roughly double of that for G
0
-G
1
. The remainder of the histogram was divided up into the sub-G
0
 
apoptotic and S-phase gates. (C) Summary of the alterations in cell cycle distribution and apoptosis 
induction by SQA and Ptx as depicted in B. The assay was repeated twice, with the same trends in terms 
of changes in cell cycle distribution upon treatment being observed. 
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For treatment of MDA-MB-231 cells with FXN, Figure 3.5 is laid out in a similar manner as for 
SQA treatment (Figure 3.4), where Figure 3.5A represents the doublet gating strategy, Figure 
3.5B depicts the individual fluorescence histograms for each treatment and Figure 3.5C 
represents a summary of the data in Figure 3.5B in graph form. The gating of the various cell 
cycle phases according to the DMSO and paclitaxel controls in Figure 3.5Bi was carried out 
using the same criteria to that in Figure 3.4Bi, although the position of the gates is not identical 
due to variations in the controls between the two data sets. This demonstrated the importance 
of carrying out the gating separately for each flow cytometry experiment. In Figure 3.5B, the 
G0-G1 gate was set at PI:A values between 80K and 100K, while the G2-M gate was set between 
140K and 240K, allowing for the assignment of the sub-G0 and S phases. These gates were 
copied to all the samples and variations in cell cycle distribution noted. Treatment with 50 nM 
Ptx revealed a shift in PI staining for the G2-M phase from 13.2 % in untreated cells to 45.2 % in 
treated cells (Figure 3.5Bi and Figure 3.5Bii, respectively). For the carotenoid, FXN, a similar 
alteration in cell cycle distribution was observed in treated cells to that observed for SQA 
(Figure 3.5B vs. Figure 3.4B), namely a dose-dependent increase in both the Sub-G0 apoptotic 
population (5 %, 8 % and 12 %  for treatment with 10, 25 and 50 µM, respectively) and the G0-
G1 phase (23 %, 33 % and 40 %, respectively), as well as a dose-dependent decrease in both the 
S (43 %, 36 % and 30 %, respectively) and G2-M phases (30 %, 23 % and 18%, respectively) of 
the cell cycle (Figure 3.5Biii-v vs. Figure 3.4Biii-v).  
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Figure 3.5: Determination of the effect of fucoxanthin treatment on cell cycle in MDA-MB-231 cells. Cells 
were treated with vehicle control (0.24 % v/v DMSO), 10, 25 or 50 µM fucoxanthin (FXN) or 50 nM 
paclitaxel (Ptx) for 16 h, stained with propidium iodide (PI) and analysed by flow cytometry. (A) Gating of 
cell population to allow for doublet discrimination. The singlet gate eliminates false positives due to cell 
aggregates and was copied to all samples. Further analyses were carried out on populations contained 
within the gate.(B) Histograms representing the cell cycle profile of MDA-MB-231 cells upon treatment 
with either DMSO (i), Ptx (ii) or a range of concentrations of FXN (iii-v). The phases of the cell cycle were 
gated with respect to the DMSO-treated control such that the dominant peak was defined as the G
0
-G
1
 
phase and the G
2
-M gate was set for a peak whose PI-A value along the X-axis was roughly double of 
that for G
0
-G
1
. The remainder of the histogram was divided into the sub-G
0
 apoptotic and S-phase gates. 
(C) Summary of changes in cell cycle distribution and apoptosis induction by FXN and Ptx derived from 
the histograms in B. The assay was repeated and similar alterations in cell cycle distribution observed. 
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3.4 DISCUSSION  
The present study aimed to elucidate the mode of action of selected novel marine algal 
compounds shown to display cytotoxicity against breast cancer cells in vitro. In the first 
instance, the mode of cell death was established for selected compounds by means of flow 
cytometry with Hoechst and propidium iodide staining in order to distinguish between the 
induction of programmed cell death (apoptosis) and necrosis. The former is preferred in terms 
of drug development since necrosis would result in an undesirable inflammatory response in 
vivo (Klener Jr. et al., 2006).  
In the case of the tetraprenylated quinone SQA, shown to display differential toxicity against 
breast cancer but not non-cancerous breast cells (Chapter 2), the dose-dependent increase in 
treated cells which were stained positive for both H33342 and PI suggested that the compound 
induced apoptosis in MDA-MB-231 breast cancer cells (Dive et al., 1992). This finding was 
consistent with that in a previous study in which SQA was reported to induce apoptosis in the 
human keratinocyte cell line HaCaT using flow cytometry with PI staining alone (Hur et al., 
2008). The current study was encouraging since, at 75 µM, a concentration near the IC50 of SQA 
(67 µM, Chapter 2; Figure 2.3A), only 11 % of treated cells were detected as being late 
apoptotic or necrotic.  
As was described for SQA, the staining profile of cells treated with RU007 suggested the 
induction of apoptosis by this compound. It was expected that the chemotherapeutic, 
paclitaxel (Ptx), known to induce apoptosis in breast cancer cells in vitro, (Tzu-Hao et al., 2000) 
would display a similar dose-dependent increase in the percentage of late apoptotic/necrotic 
cells (derived from the upper right hand (UR) quadrant of a PI vs. H33342 dot plot). This was, 
however, not observed in our study (2.0 % and 2.4 % late apoptotic/necrotic cells after 
treatment with 100 nM and 200 nM, respectively). It must be noted at this point that failure of 
a compound to produce an increase in the proportion of late-apoptotic/necrotic cells does not 
necessarily indicate that the compound was not inducing apoptosis of the cells, since both live 
and early apoptotic cells are stained H33342-positive PI-negative. Since treatment of cells for 
flow cytometry was carried out overnight, as opposed to the 96 hour treatment interval used 
for cytotoxicity screening of the marine algal compounds (Chapter 2), it is possible that the cells 
were in the early stages of apoptosis and thus indistinguishable from live cells. This represented 
a potential shortcoming of the flow cytometric assay in that, although a dose-dependent 
increase in H33342-positive/PI-positive staining (or the proportion of late apoptotic/necrotic 
cells) has been associated with apoptosis induction in the literature (Dive et al., 1992), the 
assay was originally designed largely for the detection of necrotic cells, which are stained PI-
positive. More accurate methods exist for the detection of apoptosis, such as the PARP 
cleavage and TUNEL assays.  
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For all the compounds tested in MDA-MB-231 cells, none displayed the characteristic necrotic 
staining pattern exhibited by Triton X-100. In the case of the potential “hit” compound RU004, 
the fact that the compound did not appear to induce necrosis was encouraging and described a 
further favourable characteristic of the compound, in terms of its development as a lead 
compound. For RU015, the most toxic compound in the library of novel marine algal 
compounds towards breast cancer cells (Chapter 2, Figure 2.3) and which had previously been 
shown to be equally toxic to cancerous MCF-7 and non-cancerous MCF12A cells (Lawson, MSc 
thesis, 2009; Figure A1), one might expect that the compound would induce necrosis of the 
cells and thus display a H33342/PI staining pattern similar to that of Triton X-100-treated cells. 
This was, however, not observed in the flow cytometry profiles for RU015-treated MDA-MB-
231 cells (2.1 %, 3.3 % and 2.7 % late apoptotic/necrotic cell for treatment with 5, 15 and 30 
µM, respectively).  
In the case of the Hs578T cell line, H33342/PI staining was carried out on cells treated with 
either RU004, RU007, FXN or Ptx in order to compare the modes of action of priority 
compounds between this and the MDA-MB-231 cell line. For Hs578T cells, treatment with 
RU007 resulted in a dose-dependent shift in staining the towards the H33342-positive PI-
positive UR quadrant, suggesting that the compound induces apoptosis of the cells, a result 
which was similar to that obtained for the compound in MDA-MB-231 cells. A dose-dependent 
shift in staining the towards the H33342-positive PI-positive UR quadrant was also observed for 
cells treated with either Ptx or RU004, once more suggesting that the compounds induced 
apoptosis of the cells. For both of these compounds, the dose-dependent H33342/PI staining 
patterns were different between the MDA-MB-231 and Hs578T breast cancer cell lines. These 
variations could be point to different modes of action of the compounds in the different breast 
cancer cell lines, a phenomenon which has previously been observed for resveratrol in MCF-7 
versus MDA-MB-231 cells (Pozo-Guisadoa et al., 2002). On the other hand, the differences in 
staining patterns could be attributed to the inability of the flow cytometric technique to 
distinguish between live and early apoptotic cells, such that an apoptotic effect of the 
compounds in MDA-MB-231 cells was not detected.   
In the case of the carotenoid FXN, Hs578T cells treated with the compound displayed a very low 
proportion of late apoptotic/necrotic (H33342-positive/PI-positive) cells, even at 25 µM, a 
concentration almost double the IC50 of the compound (13 µM, Chapter 2, Figure 2.3B), which 
agreed with the results obtained in the MDA-MB-231 cell line. 
As mentioned previously, the PARP cleavage assay is a more accurate and definitive measure of 
cells undergoing apoptosis. Two of the priority compounds used in the H33342/PI flow 
cytometry studies were further analyzed in terms of their ability to induce apoptosis or necrosis 
of MDA-MB-231 cells by means of the PARP cleavage assay.  In this assay, 85 kDa PARP 
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cleavage products were observed for cells treated with a range of concentrations of SQA, 
indicating that the compound induced apoptosis in MDA-MB-231 cells. Apoptotic PARP 
fragments have been reported in human HaCaT skin cancer cells treated with 23.6 µM of SQA, a 
concentration at which cell viability was reduced to 20 % as assessed by MTT assay (Hur et al., 
2008). Interestingly, in the latter, no PARP fragments were detected at lower concentrations of 
the compound, while in the current study, apoptotic PARP fragments were detected at a 
concentration one hundred times lower than the IC50 of the compound in MDA-MB-231 cells 
(67 µM, Figure 2.3A). 
It was thought that the novel halogenated monoterpene RU015 may be having an effect on the 
cells which was not detectable by flow cytometry and further mechanistic studies were carried 
out on the compound. Indeed, treatment with RU015 generated a 50 kDa PARP cleavage 
product in MDA-MB-231 cells. Such cleavage products are typical of degradation by cathepsin B 
(Chaitanya and Babu, 2009) and suggested that necrosis was responsible for the high 
cytotoxicity of the compound in these cells and potentially in both Hs578T breast cancer and 
MCF12A non-cancerous breast cells. PARP fragments of 50 kDa and 62 kDa have been observed 
during necrosis in Jurkat cells, while 89, 50, 40 and 35 kDa fragments have been reported in 
necrotic HL60 cells (Soldani and Scovassi, 2002). 
Since it has been reported that many compounds exert their cytotoxic effects by causing cell 
cycle arrest, in addition to the induction of apoptosis (Palozza et al., 2002) the effects of both 
SQA and FXN treatment on cell cycle distribution was assessed in the MDA-MB-231 cell line. 
The assay was validated by treatment with Ptx, which is known to cause G2-M phase arrest in 
breast cancer cells (Tzu-Hao et al., 2000), and resulted in an increase in the proportion of MDA-
MB-231 cells in G2-M phase compared to the DMSO vehicle treated control. In the case of SQA, 
the dose-dependent increase in the Sub-G0 apoptotic population for treated cells confirmed the 
findings obtained by H33342/PI staining and PARP cleavage assays, namely that SQA appeared 
to induce apoptosis in MDA-MB-231 cells. At the sub-lethal SQA dose of 25 µM (IC50 of 67 µM; 
Figure 2.3A, Chapter 2), an increase in G0-G1 phase from 49 % to 64 % was observed, indicating 
cell cycle arrest at that phase. This effect decreased with increased SQA concentration, when 
apoptosis became the main mode of action of the compound (as opposed to cell cycle arrest). 
In addition, SQA caused a dose-dependent decrease in the G2-M phase, a trend which was 
opposite to that observed for paclitaxel-treated cells and points to a different mechanism of 
action of the quinone. It has been found that the twenty carbon aromatic compound retinoic 
acid, which is structurally similar to SQA (Figure A2), causes G1 arrest in MCF-7 breast cancer 
cells (Zhu et al., 1997), which is consistent with our findings in metastatic MDA-MB-231 cells.  
Treatment of MDA-MB-231 cells with the carotenoid FXN also resulted in an altered cell cycle 
profile compared to the DMSO-treated control. The dose-dependent increase in the Sub-G0 
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apoptotic population provided the first evidence that FXN may be inducing apoptosis in the 
MDA-MB-231 breast cancer cells, since this was not distinguishable by the H33342/PI flow 
cytometry analyses. FXN has previously been demonstrated to induce apoptosis in leukemia as 
well as prostate and colon cancer cells in vitro (Kotake-Nara et al., 2001a and b; Hosokawa et 
al., 1999; Hosokawa et al., 2004).  In addition, the G0-G1 phase arrest observed for FXN in breast 
cancer cells is consistent with that reported for the compound in both WiDr and HCT116 
human colon cancer cell lines, as well as GOTO neuroblastoma cells in previous studies (Das et 
al., 2005; Okuzumi et al., 1990). In the former study, the effect of FXN on cell cycle was further 
characterized and found to be mediated through the up-regulation of p21WAF1/Cip1 (Das et al., 
2005). This allows for the tentative prediction that the compound may display a similar 
mechanism of action in human colon and breast cancer cells in vitro.  
The similarity in cell cycle alterations induced by SQA and FXN could point to similar 
mechanisms of action of the two compounds. This would not be unexpected considering that 
their structures are much alike, consisting of either one (SQA) or two (FXN) aromatic rings 
linked to a sixteen carbon long aliphatic chain (Figure 2.2, Chapter 2). The cell cycle data 
obtained for treatment of MDA-MB-231 cells with either SQA or FXN could be validated by 
treatment with a compound known to cause G0-G1 phase arrest in breast cancer cells. The 
similarities between the cell cycle distribution after FXN treatment in this study and those 
reported in the literature for other cancer cell lines (Das et al., 2005; Okuzumi et al., 1990) are, 
however, encouraging.  
What is immediately apparent is that the untreated controls vary greatly in terms of their cell 
cycle distribution between the two different cell cycle studies (Figure 3.4 vs. Figure 3.5). The 
cell cycle distribution is dependent on the growth rate of the cells in culture overnight, which 
may fluctuate from experiment to experiment and highlights the importance of comparing the 
cell cycle distribution of treated cells in each experiment to an untreated control from the same 
experiment, as opposed to assuming that the cell cycle distribution of the untreated population 
is constant. 
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3.5 CONCLUSIONS 
In summary, the data herein describes the further characterization of selected novel algal 
compounds in terms of their mode of action. While there have been several reports describing 
the anti-cancer activity of marine algal metabolites, this is one of a limited number attempting 
to determine the manner in which novel algal compounds exert their cytotoxic effects (Jha and 
Zi-Rong, 2004; Fuller et al., 1994). Of the compounds selected for further analysis in this study, 
RU007 and SQA appeared to induce apoptosis in MDA-MB-231 cells, while the flow cytometric 
profile of both RU004 and RU007 were suggestive of apoptosis in the Hs578T cell line. The 
ability of RU004 to induce apoptosis in MDA-MB-231 cells could not be ruled out using the 
H33342/PI staining protocol. The more informative PARP assay was utilized to determine the 
mode of cell death induced by SQA and RU015 in MDA-MB-231 cells and it was determined 
that the differentially toxic “hit” compound, SQA , induced apoptosis in MDA-MB-231 cells; 
while the indiscriminately toxic halogenated monoterpene, RU015, induced necrosis in these 
cells, resulting in its exclusion from further characterization in this study. The former result for 
SQA treatment represented the first report as to the mode of cell death induced by the 
compound in breast cancer cells. 
In addition to investigation into the type of cell death induced by novel marine algal 
compounds, the present study examined the effect on cell cycle distribution in MDA-MB-231 
breast cancer cells of both SQA and FXN. Interestingly, the latter compounds exhibited similar 
effects on cell cycle in MDA-MB-231 cells, namely an arrest in G0-G1 phase with an increase in 
the Sub-G0 apoptotic population, a trend which is both consistent with the previous findings for 
FXN in human colon cancer and neuroblasoma cells, and mimics that of the structurally similar 
compound, retinoic acid (Das et al., 2005; Zhu et al., 1997). To the best of our knowledge, this is 
the first report of the effect of SQA acid on cell cycle distribution in cancer cells and the first 
study of the effect of either SQA or FXN on cell cycle in breast cancer cells. 
The aforementioned studies into their mode of action validated the selection of the “hit” 
compounds RU004, RU007 and SQA in Chapter 2. Furthermore, the data generated in this body 
of work justified further study of these novel marine algal compounds in terms of the specific 
signaling pathways and molecules involved in mediating their cytotoxicity in metastatic breast 
cancer cells. 
 
 
 
 
 
 80 
 
80 
 
 
 
 
 
CHAPTER 4 
 
CHARACTERIZATION OF THE MOLECULAR 
MECHANISMS MEDIATING TOXICITY OF THE 
NOVEL ALGAL COMPOUNDS SQA AND FXN 
AGAINST BREAST CANCER CELLS IN VITRO 
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4.1 INTRODUCTION 
Cancer cells are characterized by multiple alterations in key signal transduction pathways in 
order to achieve uncontrolled proliferation and evasion of apoptosis (Martin, 2003; Dhillon et 
al., 2007). The deregulation of apoptosis by either the decreased expression of pro-apoptotic 
molecules or increased expression of anti-apoptotic molecules has been reported for many 
cancers, including breast cancer (Jin and El-Deiry, 2005). As a result, the apoptotic machinery 
has become an important target for drug development (Debatin and Krammer, 2004). Cysteine 
aspartic acid-specific proteases or caspases play a key role in both in the initiation and 
execution of apoptosis (Green and Kroemer, 1998; Jin and El-Deiry, 2005). Caspases are 
expressed as inactive precursors which are activated by proteolytic cleavage giving rise to 
cascades where each caspase cleaves and activates the next in the chain. These proteases are 
traditionally classified into two main groups; those that mediate apoptosis (caspase-2, -3, -6, -7, 
-8, -9, 10) and those that participate in inflammation (caspase-1, -4, -5, -11, -12, -13 and -14) 
(Thornberry et al., 1997; Martinon et al., 2002; Jin and El-Deiry, 2005; Klener Jr. et al., 2006). 
The apoptotic caspases are further divided into initiator and effector caspases. The initiator 
caspases (2, 8, 9 and 10) activate the effector caspases (3, 6 and 7), which in turn cleave various 
cellular substrates in order to induce cell death (Jin and El-Deiry, 2005).  
 
Apoptosis occurs via two main signaling cascades, namely the extrinsic and the intrinsic 
pathways. In the extrinsic or receptor-mediated pathway, a death ligand such as tumour 
necrosis factor alpha (TNFα) binds to its cognate death receptor, in this case TNF receptor 
(TNFR), resulting in the recruitment and subsequent activation of caspase-8, the initiator 
caspase of this pathway (Nagata, 1997). On the other hand, the intrinsic mitochondrial pathway 
is induced in response to cellular stresses including exposure to cytotoxic agents, DNA damage 
and growth factor deprivation, which induce mitochondrial outer membrane permeabilisation 
(MOMP) and subsequent release of cytochrome C. The end result of this process is the cleavage 
and activation of the initiator caspase, caspase-9 (Jin and El-Deiry, 2005; Klener Jr. et al., 2006; 
Iannolo et al., 2008). MOMP is tightly regulated by Bcl-2 family proteins, which are classified as 
either pro-apoptotic (Bax, Bak, Bim, Bad, Bid) or anti-apoptotic (Bcl-2, Bcl-XL, Mcl-1) (Jin and El-
Deiry, 2005). The extrinsic and intrinsic pathways are interconnected via the pro-apoptotic Bid 
protein and converge on an executioner caspase, such as caspase-3 (Debatin and Krammer, 
2004).   
 
In order to progress through the phases of drug development, the precise cellular pathways 
and target molecules mediating the activity of a “hit” anti-cancer compound must be 
elucidated (Li and Vanderas, 2009). Of particular interest are the effects that such an agent may 
have on the apoptotic and survival pathways described above. In the case of algal anti-cancer 
lead compounds, few reports exist in which the cellular targets of the novel compounds have 
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been identified. One rare example includes the finding that sargaquinoic acid (SQA) induces 
apoptosis via caspase-3, -8 and -9 in human skin cancer cells in vitro (Hur et al., 2008). Perhaps 
the best characterized algal metabolite is the carotenoid, fucoxanthin (FXN), isolated from a 
range of brown algal species including Laminaria japonica, Sargassum heterophyllum and 
Undaria pinnatifida (Peng et al., 2011). Several preliminary investigations into the molecular 
mechanisms mediating the cytotoxicity of the compound have been carried out and have 
identified caspase-3, -7, -8 and -9, as well as the Bcl-2 proteins Bax, Bcl-2 and Bcl-XL as potential 
targets of FXN. However, these data are fragmented since studies were carried out in a range of 
different cancer cell lines using different techniques, with few corroborating results (Kotake-
Nara et al., 2005a and b; Hosokawa, 1999; Das et al., 2005; Ishikawa et al., 2008; Peng et al., 
2011). Thus, to date, the precise molecular mechanism of action of both SQA and FXN are 
incompletely understood 
 
The broad aim of the following section entailed the identification of specific pathways and 
signal transducer molecules involved in mediating the cytotoxicity of the previously described 
algal compounds sargaquinoic acid and fucoxanthin in breast cancer cells. In particular, the 
potential role of a number of caspases, together with the anti-apoptotic molecule, in mediating 
the action of FXN and/or SQA was assessed. 
 
4.2 METHODS AND MATERIALS 
 
4.2.1 Reagents 
The rabbit anti-human caspase-9 primary antibody was obtained from Cell Signaling 
Technologies (Massachusetts, USA), while the rabbit anti-β-actin and mouse anti-human Bcl-2 
primary antibodies were from Sigma-Aldrich (Germany) and Abcam (UK), respectively. The 
donkey anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody was obtained 
from Amersham Biosciences (UK), while the donkey anti-mouse fluorescein isothiocyanate 
(FITC)-conjugated secondary antibody was from Invitrogen (UK). The caspase inhibitor sampler 
kit and MTT cell proliferation kit were obtained from R and D Systems (Minneapolis, USA) and 
Roche (Switzerland) respectively. Tumour necrosis factor alpha (TNFα), paclitaxel and 
fucoxanthin were from Sigma-Aldrich (Germany). Tissue culture vessels were from Corning 
(Pennsylvania, USA). All other chemicals were of reagent grade.  
  
4.2.2 Cell lines and culture conditions 
The breast cancer cell lines, MDA-MB-231 (ATCC: HTB-26) and Hs578T (ATCC: HTB-126), were 
cultured as described in Chapter 2 (Section 2.2.2). The MCF-7 breast cancer cell line (ATCC: 
HTB-22) was a gift from Dr Sharon Prince (Department of Human Biology, Faculty of Health 
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Sciences, University of Cape Town) and was cultured in the same manner as the MDA-MB-231 
cell line.  
 
4.2.3 Caspase inhibitor studies 
MCF-7, MDA-MB-231 or Hs578T cells were seeded at a density of 6000 cells per well in a 96-
well plate and allowed to settle overnight, followed by pre-treatment with 500 nM, 5 µM or 50 
µM of the caspase inhibitor (dissolved in DMSO, max concentration 0.5 % v/v) of interest for 4 
hours. Thereafter, cells were treated with either DMSO vehicle control (0.5 % v/v) or 200 ng/ml 
TNF or 75 µM sargaquinoic acid or 15 or 25 µM fucoxanthin for 96 hours. Treated cells were 
assessed for viability by MTT assay as described in Chapter 2 (Section 2.2.3). 
 
4.2.4 Western analyses 
MDA-MB-231 cells (1 × 106) were seeded into 60 mm plastic tissue culture dishes and allowed 
to settle overnight. The cells were treated with either DMSO vehicle control (0.5 % v/v) or 
sargaquinoic acid (0.6, 6 or 60 µM) for 8 hours at 37 ºC and 9 % CO2. Thereafter, whole cell 
lysates were prepared by scraping the adherent cells into the media, spinning at 2000 rpm in an 
Eppendorf 5415 R centrifuge using a F45-24-11 rotor (Eppendorf, Germany) for 3 minutes and 
resuspending in 100 µM sodium dodecyl sulphate (SDS) sample buffer [125 mM Tris-HCl pH 6.8, 
2 % (w/v) SDS, 20 % (v/v) glycerol, 0.2 % (w/v) bromophenol blue) before boiling for 5 minutes. 
Lysates from the equivalent of 1 × 105 cells were separated by electrophoresis using a 12 % SDS 
polyacrylamide gel, transferred onto a nitrocellulose membrane and probed for caspase-9. 
Incubation with rabbit anti-human caspase-9 antibody (1 in 1000 dilution) was carried out at 4 
ºC overnight. Following incubation with the HRP-conjugated donkey anti-rabbit secondary 
antibody (1 in 5000) for I hour at room temperature, detection was carried out using the ECL 
Advanced Western Blotting Kit (GE Healthcare, UK) and visualized using the Molecular Imager 
ChemiDoc XRS System (BioRad, California). Lysates were probed with rabbit anti-β-Actin 
antibody as a loading control. All antibody dilutions were carried out using a 5 % (w/v) non-fat 
milk powder solution in Tris-buffered saline (TBS) (50 mM Tris, 150 mM NaCl, pH 7.5).  
 
4.2.5 Quantification of Bcl-2 protein levels using flow cytometry 
MDA-MB-231 or Hs578T cells were seeded at a density of 3 x 105 cells/ml into 25 cm2 culture 
flasks and allowed to settle and grow over 24 hours before dosing with the DMSO vehicle 
control (0.02 % v/v) or relevant compounds (as indicated in figure legends) overnight. Cells 
were lifted with 1 % (v/v) trypsin solution made up in 0.3 % (w/v) ethelene diamine tetra-acetic 
acid (EDTA), washed twice in ice-cold phosphate buffered saline (PBS) (137 mM NaCl, 2.7 mM 
KCl, 2 mM KH2PO4, 10 mM Na2HPO4, pH 7.4) and collected by centrifugation at 4000 rpm in a 
Eppendorf 5804 R centrifuge with a A-4-44 rotor (Eppendorf, Germany). The resulting pellet 
was resuspended to a density of 5 X 106 cells/ml in 0.01 % (v/v) formaldehyde and fixed on ice 
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for 10 minutes. Cells were collected by centrifugation and resuspended to a density of 5 X 106 
cells/ml in permeabilisation buffer (PB) [0.1 % (v/v) Triton X-100 in PBS containing 0.5 % (w/v) 
BSA] prior to incubation in the dark for 15 minutes on ice. Thereafter cells were collected by 
centrifugation and resuspended in PB to the same density as before. Immunostaining of cells 
was carried out using 1 µg of mouse anti-human Bcl-2 primary antibody in 100 µL of cell 
solution and incubated at 4 ºC for 1 hour. Cells were washed twice with permeabilisation wash 
buffer (PWB) [0.1 % (v/v) Triton X-100 in PBS, pH 7.4], followed by incubation with 2 µL of 
donkey anti-mouse FITC-conjugated secondary antibody for 45 minutes at 4 ºC in the dark. Cells 
were washed in PWB, resuspended in 100 µL PBS and analysed by flow cytometry. Excitation of 
FITC was achieved at 488 nm and emission detected at 530 nm. Data was analysed using FlowJo 
software Version 7.6.1. (Tree Star Inc., 2010).    
 
4.3 RESULTS 
 
4.3.1 Identification of caspases involved in mediating the cytotoxicity of paclitaxel and 
selected algal compounds in breast cancer cells in vitro         
In an attempt to characterize the molecular mechanism of action of the commonly used 
chemotherapeutic drug paclitaxel (Ptx), as well as the marine algal compounds sargaquinoic 
acid (SQA) and fucoxanthin (FXN) in breast cancer cells, the ability of various caspase inhibitors 
to reverse the cytotoxicity of these compounds against breast cancer cells was investigated. 
Although a single graph is represented in each case, the assays were repeated and consistent 
results obtained. 
 
4.3.1.1 Optimization of caspase inhibitor-coupled MTT assay using tumour necrosis factor 
alpha (TNF-α)-treated MCF-7 breast cancer cells 
Since a wide range of effective concentrations had been reported for the caspase inhibitor kit 
utilized in this study, optimization experiments were carried out for two of the inhibitors, 
namely the general caspase inhibitor (Z-VAD-FMK) and the caspase-8 inhibitor (Z-IETD-FMK). 
MCF-7 breast cancer cells were pre-treated with 500 nM, 5 µM or 50 µM of the caspase 
inhibitors, followed by treatment with 200 ng/ml of TNF-α and assessed in terms of percentage 
survival by MTT assay. All of the samples depicted in Figure 4.1A, with the exception of the 
DMSO control, were treated with TNFα, which was selected as a positive control due to the fact 
that it is known to bind to its cognate receptor TNFR1 at the cell surface and initiate the 
extrinsic apoptotic pathway via caspase-8 (Nagata, 1997).  
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Thus, treatment with both a general caspase inhibitor as well as a caspase-8-specific inhibitor 
should reduce the toxicity of TNF-α towards breast cancer cells. The percentage survival of 
MCF-7 cells treated with TNF-α alone was 26 % (26.43 ± 0.65 %, Figure 4.1A) relative to that of 
the DMSO vehicle treated-control (regarded as 100 % survival). For the general caspase 
inhibitor, pre-incubation of cells with 500 nM, 5 µM or 50 µM of the inhibitor prior to 
treatment with TNF-α increased cell survival to 33, 57 and 53 %, respectively (33.06 ± 1.87 %, 
57.24 ± 2.12 % and 52.87 ± 0.67 %, respectively; Figure 4.1A), indicating that Z-VAD-FMK was 
most effective at reducing TNF-α-mediated cytotoxicity when cells were pre-treated with 5 µM 
of this inhibitor. On the other hand, pre-treatment with 500 nM of the caspase-8 inhibitor was 
unable to alter the viability of TNF-α-treated cells (26.27 ± 0.38 %, Figure 4.1A), while pre-
treatment with 5 and 50 µM of the inhibitor increased cell survival from 26 % to 32 % and 44 %, 
respectively  (32.26 ± 1.34 % and 44.38 ± 0.59 %, respectively; Figure 4.1A). The latter indicated 
that the caspase-8 inhibitor was most effective when pre-treatment was carried out using 50 
µM of the inhibitor.  
Taken together, these data led to a decision that the maximum concentration of caspase 
inhibitors (i.e. 50 µM) be used in subsequent assays for all ten of the caspase inhibitors in both 
MDA-MB-231 and Hs578T cells as a means of ensuring activity of the inhibitors.   
 
4.3.1.2 Identification of specific caspases involved in mediating the cytotoxicity of SQA 
against MDA-MB-231 breast cancer cells 
In order to indentify caspases which may have played a role in mediating the observed 
cytotoxicity of SQA in MDA-MB-231 cells (Chapter 2), pre-treatment of cells with a range of ten 
caspase inhibitors was carried out as optimized in 4.3.1.1 above, followed by treatment with a 
concentration equivalent to the IC50 of SQA in MDA-MB-231 cells (67 µM, Fig 2.3; Chapter 2). 
The MTT assay revealed that treatment with the marine algal quinone SQA alone reduced cell 
survival to 44 % (44.30 ± 2.67 %, Figure 4.1B), an effect which was completely reversed by pre-
treatment with the general caspase inhibitor Z-VAD-FMK (percentage survival of 104.93 ± 3.97 
%, Figure 4.1B). The inhibitors against caspase-3, -6, -8, -9, -10 and -13 all increased cell survival 
to above 80 % when cells were treated with these compounds prior to treatment with SQA 
(percentage cell survival values of 118.38 %, 85.14 %, 85.59 %, 95.24 %, 80.66 % and 96.31 % 
for pre-treatment with caspase-3, -6, -8, -9, -10 and -13 inhibitors, respectively; Figure 4.1B). 
The caspase inhibitors which had the least effect on cell survival after treatment with SQA were 
those inhibiting caspase-2 (percentage survival of 54.79 ± 11.67 %), caspase-1 (percentage 
survival of 70.56 ± 9.33 %) and caspase-4 (percentage survival of 75.72 ± 10.90 %), (Figure 
4.1B).  
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4.3.1.3 Investigation of the role of various caspases in mediating the toxicity of FXN in 
MDA-MB-231 cells 
In order to gain insight into the molecular mechanism of action of FXN, the ability of various 
caspase inhibitors to reverse the cytotoxicity of the brown algal carotenoid against MDA-MB-
231 breast cancer cells was assessed. Treatment of MDA-MB-231 cells with 25 µM of FXN 
resulted in a decrease in cell survival to 29 % (29.26 ± 7.35 %, Figure 4.1C), relative to the 
DMSO treated control (taken as 100 % survival). On the other hand, pre-treatment with the 
general caspase inhibitor increased the survival of cells treated with FXN to 89 % (89.07 ±     
7.35 %, Figure 4.1C). In the case of pre-treatment with inhibitors against caspase-1, -2, -3 -9 and 
-10, cell survival was increased to above 80 % in all cases, compared to treatment with FXN 
alone (percentage cell survival values of 85.95 %, 81.67 %, 85.63 %, 88.64 % and 80.49 % for 
pre-treatment with caspase-1 -2, -3, -9, -10 and -13 inhibitors, respectively; Figure 4.1C). The 
caspase inhibitors for which pre-treatment resulted in the smallest increases in cell survival 
upon FXN treatment were those for caspase-4 (48.45 ± 5.68 %), caspase-13 (50.27 ± 9.05 %), 
caspase-8 (54.77 ± 7.40 %) and caspase-6 (64.95 ± 3.61 %) (Figure 4.1C).  
 
4.3.1.4 Identification of the caspases involved in mediating the cytotoxicity of FXN against 
Hs578T breast cancer cells 
In order to compare the mechanism of action of FXN in two different breast cancer cell lines, 
the role of various caspases in mediating the cytotoxicity of the carotenoid compound was 
investigated in Hs578T cells. Treatment of Hs578T cells with FXN alone at a concentration 
equivalent to the IC50 of FXN in these cells (13 µM, Chapter 2; Fig 2.3) decreased cell survival to 
41 % (41.24 ± 4.12 %, Figure 4.1D), relative to the DMSO treated control. None of the caspase 
inhibitors tested were able to increase the percentage survival of FXN-treated cells; in fact, cell 
survival was decreased upon pre-treatment with the general caspase inhibitor as well as for 
pre-treatment with the inhibitors of caspase-1, -2, -3, -4, -6, -8, -9, -10 and -13 (Figure 4.1D). 
 
4.3.2 Determination of the effect of SQA on caspase-9 cleavage in MDA-MB-231 cells by 
Western analysis 
As an alternative method of assessing the potential involvement of a caspase, in this case 
caspase-9, in mediating the cytotoxicity of SQA, MDA-MB-231 cells were treated with a range 
of concentrations of SQA and Western analysis carried out on treated whole cell lysates. As 
depicted in Figure 4.2A, treatment with 0.6, 6 and 60 µM of SQA appeared to cause a dose-
dependent increase in the detection of the 37 and 17 kDa cleavage products of caspase-9 
compared to that observed for the DMSO-treated control, a result which was validated by 
performing densitometry on the signals detected by Western analysis (Fig 4.2B).  
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The ratio of the signals detected for both of the caspase-9 cleavage products to that for the β-
actin loading control, calculated using ImageJ (National Institute of Health Freeware), was used 
as a measure of caspase-9 activation (Fig 4.2B). 
 
4.3.3. Analysis of the effect of Ptx, SQA and FXN on Bcl-2 protein levels in breast cancer 
cells in vitro by flow cytometry 
In order to investigate whether the induction of apoptosis by the algal compounds SQA and 
FXN in breast cancer cells was linked to the ability to alter the expression levels of anti-
apoptotic proteins, the levels of the anti-apoptotic mitochondrial protein Bcl-2 in treated cells 
were compared to that in the DMSO vehicle-treated control sample for two breast cancer cell 
lines. In all cases, flow cytometry experiments were repeated at least twice and similar trends 
in Bcl-2 levels observed in each case. 
 
4.3.3.1 Identification of alterations in Bcl-2 protein levels between untreated MDA-MB-231 
cells and those treated with Ptx, SQA and FXN 
MDA-MB-231 cells were treated with either DMSO vehicle control or 100 nM Ptx, 75 µM SQA 
or 25 µM FXN (concentrations equivalent to the IC50 value) and the Bcl-2 protein levels in 
treated cells quantified by flow cytometry. Figure 4.3A depicts histogram representations 
generated using FlowJo software (Tree Star Inc., 2010) of the fluorescence data detected for 
each sample, while Figure 4.3B is a summary of the data generated by plotting the percentage 
Bcl-2 positive events from each histogram in Figure 4.3A (events within the gate). The 
secondary antibody control sample was immunostained with the fluorescently labeled 
secondary antibody alone (i.e. not the anti-Bcl-2 primary antibody) and was used both to 
determine the level of background immunostaining and, in conjunction with the vehicle-treated 
control, in the gating of cell populations to define the Bcl-2 positive population. The proportion 
of Bcl-2 positive events was used as a comparative measure of the levels of Bcl-2 protein in cells 
treated with either DMSO or the selected cytotoxic compounds. The level of immunostaining 
detected in the secondary antibody control was set at a proportion of 5.60 % Bcl-2 positive 
events (Fig 4.3Ai and Fig 4.3B) and was considered to be an acceptable level of background 
staining in this and subsequent experiments. The vehicle-treated control sample displayed a 
proportion of 29.80 % Bcl-2 positive events, which was reduced to 22.30 % following treatment 
of the cells with 100 nM Ptx (Fig 4.3Aii and 4.3Aiii, respectively; Fig 4.3B). Treatment with 75 
µM SQA and 25 µM FXN decreased the Bcl-2 protein levels to 17.40 % and 5.66 % Bcl-2 positive 
events, respectively, relative to the DMSO-treated control (Fig 4.3Aiv and 4.3Av, respectively; 
Fig 4.3B).  
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4.3.3.2 Comparison of Bcl-2 protein levels in untreated Hs578T cells with those treated 
with Ptx and FXN 
As a means of comparison of the molecular mechanisms mediating the cytotoxicity of Ptx and 
FXN between two breast cancer cell lines, Hs578T cells were treated with 30 nM and 15 µM, 
respectively (according to the IC50 values of the compounds) and the effects on Bcl-2 protein 
levels analyzed by flow cytometry as for MDA-MB-231 cells. Figure 4.4A represents the 
fluorescence data obtained by flow cytometry depicted as histograms for each sample, while 
Figure 4.4B is an overview of this data obtained by plotting the percentage Bcl-2 positive events 
in Figure 4.4A. In this experiment the secondary antibody control was used to set the gate for 
Bcl-2-positive events, giving rise to a background immunostaining level of 5.24 %, which was 
comparable with that set for the secondary antibody control in the MDA-MB-231 cell line (Fig 
4.4Ai vs. Fig 4.3Ai). Treatment of the Hs578T cells with Ptx and FXN reduced the proportion of 
Bcl-2 positive events from 41.5 % in the DMSO control to 23.9 % and 25.4 %, respectively (Fig 
4.4Aiii and 4.4Aiv, respectively; Fig 4.4B).  
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DISCUSSION 
As a means of further elucidation of the mechanism of action of marine algal compounds 
against breast cancer cells, the involvement of specific signal transducer molecules in mediating 
their activity was assessed. Unfortunately, there were unsufficient quantities of the novel algal 
“hit” compounds (RU004, RU007) on which to carry out these analyses. However, the 
previously described algal compounds SQA and FXN were more readily available and allowed 
for the comparison, both between the two known compounds in terms of their molecular 
mechanism of action, as well as comparisons between the data generated in this study and that 
published in previous reports. 
  
The prenylated quinone SQA was found to be cytotoxic against a range of breast cancer cell 
lines, while having no adverse effects on the growth of non-cancerous breast epithelial cells 
when added at a dose equivalent to the IC50 in breast cancer cells, resulting in its designation as 
a “hit” compound in this study (Fig 2.3 and Table 2.2, Chapter 2; Fig A1, Appendix). 
Furthermore, the compound appeared to induce apoptosis in MDA-MB-231 breast cancer cells 
as evidenced by flow cytometric and PARP cleavage studies and caused a G0-G1 arrest in these 
cells (Fig 3.1, 3.3 and 3.4, Chapter 3). These data justified further studies as to the molecular 
mechanisms of action of SQA. On the other hand, although the commercially available 
carotenoid FXN was more toxic than SQA to breast cancer cells, the compound also displayed 
cytotoxicity against non-cancerous breast cells (Fig 2.3 and Table 2.2, Chapter 2). While there 
was no conclusive data as to the mode of cell death induced by the carotenoid, the compound 
was shown to cause G0-G1 arrest in MDA-MB-231 cells in the same manner as SQA. Thus, 
although not designated as a “hit” compound, FXN was included in subsequent mechanistic 
studies as a means of comparison with SQA due to their structural similarities (Fig 2.2, Chapter 
2) and potential parallels in molecular mechanisms of action. 
 
In the first instance, the role of specific caspases in mediating the cytotoxicity of SQA and FXN 
in breast cancer cells in vitro was analyzed using a caspase-inhibitor-coupled MTT assay. 
Optimization of the assay using TNFα as a positive control in terms of caspase-mediated 
cytotoxicity was carried out in MCF-7 cells due to previous reports that MDA-MB-231 and, to a 
lesser extent Hs578T cells, were resistant to TNFα (Pirianov and Colston, 2001). The latter 
finding was confirmed in this study (data not shown). The effect of caspase-inhibitor alone on 
MCF-7 cell survival was also assessed and revealed that, at the concentration range used in the 
assay, the inhibitors were non-toxic to the breast cancer cells (data not shown). Thus, the 
caspase-inhibitor negative control was eliminated from future assays in MDA-MB-231 and 
Hs578T cells. 
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Following optimization of the caspase-inhibitor assay, screening for the involvement of various 
caspases in mediating the anti-cancer activities of SQA and FXN was carried out. Treatment of 
MDA-MB-231 cells with 75 µM SQA alone produced a percentage survival of 44 %, a result 
which was in alignment with the previously determined IC50 value of 67 µM. This cytotoxicity 
was completely reversed by pre-treatment with the general caspase inhibitor Z-VAD-FMK, 
which was consistent with the previous findings both in this study (Fig 3.1 and 3.3, Chapter 3) 
and that reported in the literature, that the compound is able to induce apoptosis in human 
cancer cells in vitro (Hur et al., 2008). Furthermore, the data herein suggested a role for 
caspase-3, -6, -8, -9, -10 and -13 in mediating the anti-cancer activity of SQA in MDA-MB-231 
cells due to the ability of the inhibitors of these caspases to substantially reduce SQA-induced 
toxicity. The findings that pre-treatment with the inhibitors of caspase-3, caspase-9 and, to a 
lesser extent, caspase-8 were able to reverse the cytotoxic effects of SQA were consistent with 
those obtained by Western analyses in HaCaT human skin cancer cells (Hur et al., 2008). On the 
other hand, a role for caspase-6, -10 and -13 in mediating the cytotoxicity of SQA in cancer cells 
has not previously been reported. The discovery that both caspase-8 and caspase-9 inhibition 
reverse the cytotoxicity of SQA points to the involvement of the extrinsic as well as the intrinsic 
apoptotic pathways in mediating the activity of SQA.  
 
Pre-treatment of MDA-MB-231 cells with the inhibitors of caspase-1 and caspase-4 was unable 
to increase cell survival to above 76 % upon treatment with SQA, although these differences in 
percentage survival relative to the DMSO control were not found to be statistically significant. 
This may indicate either partial involvement of these caspases in mediating the toxicity of SQA 
or inability of the inhibitors to completely block the activity of the caspases under the specific 
experimental conditions. Since optimization of the two inhibitors was not carried out using a 
positive control compound known to require these inhibitors for its toxicity, the latter 
possibility cannot be ruled out. It is tempting, however, to conclude that caspase -1 and -4 do 
not play a role in mediating the action of SQA, since these caspases are involved in the initiation 
of an inflammatory response (Klener Jr et al., 2006). In the case of caspase-2, pre-treatment 
with the inhibitor of this protein appeared to have little effect on the toxicity of SQA against 
MDA-MB-231 cells. However, it was determined that the difference in percentage survival for 
cells pre-treated with caspase-2 relative to the DMSO control were not statistically significant, 
suggesting that it was possible that the caspase did play a role in mediating the anti-cancer 
activity of SQA. 
 
In the case of the brown algal metabolite FXN, treatment of MDA-MB-231 cells with 25 µM of 
the compound decreased cell survival to 29 %. Since the IC50 value obtained for FXN in MDA-
MB-231 cells was 11 µM (Figure 2.3A, Chapter 2) the low percentage survival when treated 
with 25 µM was not unexpected. As was the case for SQA, pre-treatment with the general 
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caspase inhibitor was able to reverse the cytotoxicity of FXN to a large extent. This result 
represented the first compelling evidence in the current study that the carotenoid induced 
apoptosis in breast cancer cells, as has been reported in the literature for leukemia as well as 
prostate and colon cancer cells in vitro (Kotake-Nara et al., 2005a; Hosokawa et al., 1999; 
Hosokawa et al., 2004).  Furthermore, pre-treatment of MDA-MB-231 cells with inhibitors 
against caspase-1, -2, -3, -9 and -10 increased cell survival to above 80 % in all cases, compared 
to treatment with FXN alone. The involvement of caspase-3 and caspase-9 in mediating the 
cytotoxicity of FXN is consistent with that obtained in previous studies in leukemia, prostate 
and bladder cancer cells in vitro (Kotake-Nara et al., 2005a and b; Zhang et al., 2008). The 
finding that inhibition of caspase-9, but not caspase-8, is able to reverse the cytotoxicity of FXN 
suggests that the compound acts via the intrinsic and not the extrinsic apoptotic pathway in 
these cells, a result which differs from that observed in leukemia cells where both pathways 
were implicated in mediating the cytotoxicity of FXN (Ishikawa et al., 2008). Prior to the current 
study, the involvement of caspase-1, -2, or -10 in facilitating the anti-cancer activity of FXN had 
not been reported. In addition, this study revealed that pre-treatment with the inhibitors of 
caspase-4, -6 or -13 appeared unable to reverse the cytotoxicity of FXN in MDA-MB-231 cells, 
evidence of which has not been reported elsewhere. Since caspase-4 and -13 have been 
implicated in the initiation of the inflammatory response (Klener Jr et al., 2006), the latter 
result was encouraging, particularly since the difference in percentage survival relative to the 
DMSO control for cells pre-treated with inhibitors against caspase-4 or caspase-13 were found 
to be statistically significant. 
 
While the proposed role of caspase-3, -9 and -10 in mediating the cytotoxicity of FXN is 
consistent with the findings for SQA, the involvement of caspase-2 in facilitating the toxicity of 
FXN differs from that observed for SQA. Furthermore, while caspase-8 and caspase-13 were 
found to play a role in mediation of the cytotoxicity of SQA, this was not the case for FXN. 
These data suggest that while similarities exist in the molecular mechanism of action of SQA 
and FXN, the two compounds do not activate identical signal transducer molecule targets.  
 
Unexpectedly, in the Hs578T breast cancer cell line, pre-treatment with caspase inhibitors was 
unable to reverse the cytotoxicity of FXN for all ten of the caspases tested. Since the effect of 
the caspase inhibitors alone on cell survival was not carried out for the Hs578T cell line, but 
only the MCF-7 line, it is possible that the caspase-inhibitors themselves were toxic to Hs578T 
cells. On the other hand, the failure of the caspase inhibitors to reverse the cytotoxicity of FXN 
to Hs578T cells could indicate either that the carotenoid compound displays a different mode 
of action in the Hs578T cell line as compared to that in the MDA-MB-231 cell line, or that the 
caspase inhibitors were not functioning optimally under the selected experimented conditions, 
in terms of the concentrations of inhibitor utilized and the period of pre-treatment. Since 
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optimization was not carried out for each caspase-inhibitor in the Hs578T cell line using a 
positive control, the latter interpretation cannot be excluded. However, differences in the 
mechanism mediating the cytotoxicity of a compound in different breast cancer cell lines have 
previously been reported. In particular, it has been demonstrated that the mode of action of 
resveratrol varies between MDA-MB-231 and MCF-7 cell lines (Pozo-Guisadoa et al., 2002).  
 
The role of the intrinsic pathway initiator, caspase-9, in mediating the cytotoxicity of SQA in 
MDA-MB-231 cells was confirmed by Western analysis as evidenced by a dose-dependent 
increase in the levels of cleaved and thus active form of the protein upon treatment with the 
quinone. As stated previously, a similar study had been carried out in human skin cancer cells 
and a comparable result obtained, although only a single caspase-9 cleavage product was 
shown in the latter report (Hur et al., 2008). The correlation between the findings obtained by 
Western analysis and caspase-inhibitor assay in terms of the potential involvement of caspase-
9 in mediating the cytotoxicity of SQA in MDA-MB-231 cells validated the results obtained by 
caspase inhibitor assay. 
 
Since Bcl-2 has been demonstrated to be up-regulated in a range of cancers, the levels of this 
anti-apoptotic mitochondrial protein have been correlated with tumour progression (Jin and El-
Deiry, 2005). The ability of a compound to decrease expression of Bcl-2 would thus be 
therapeutically useful. The capability of the novel algal compounds SQA and FXN as well as a 
clinically approved anti-cancer drug, namely Ptx, to decrease Bcl-2 levels was assessed by flow 
cytometry. In DMSO-treated MDA-MB-231 cells, Bcl-2 levels were quantified to be 29.80 %, in 
terms of positive fluorescence events. The latter percentage is derived from the gating of the 
secondary antibody control, which was set at a value considered to represent an acceptable 
level of background. Thus, it is not the absolute value of Bcl-2 positive events which is 
important in these experiments, but rather the comparison of these levels between identically 
gated samples. Treatment of MDA-MB-231 cells with Ptx reduced the levels of Bcl-2 to 22.30 %, 
a result which agreed with previous reports that the mechanism of action of the compound 
involves inhibition of this anti-apoptotic protein (Srivastava et al., 1999).  In addition, treatment 
with SQA and FXN decreased Bcl-2 levels to 17.40 % and 5.65 %, respectively, suggesting that 
the novel algal compounds were more effective than the chemotherapeutic agent Ptx in down-
regulating Bcl-2 expression. In particular, FXN treatment was able to decrease Bcl-2 levels to 
the equivalent of the secondary antibody baseline control (5.60 %). The greater effect on Bcl-2 
levels by FXN was, however, most likely due to the fact that the compound was used at a 
concentration more than twice the IC50 value (11 µM, Figure 2.3A, Chapter 2), while Ptx and 
SQA were added at concentrations equivalent to their IC50 values.  
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The identification of alterations in Bcl-2 levels induced by SQA and FXN in MDA-MB-231 cells 
suggest that the compounds act by inducing the intrinsic apoptotic pathway, which is 
consistent with the findings above in the caspase inhibitor studies and, in the case of SQA, the 
caspase-9 cleavage assay. While the decrease in Bcl-2 levels in MDA-MB-231 cells treated with 
FXN in this study correlated positively with previous reports for leukemia and prostate cancer 
cells in vitro (Kotake-Nara et al., 2005a and b), the reduced Bcl-2 levels in breast cancer cells 
described here after treatment with SQA differed from that reported for human skin cancer 
cells, where the compound had no effect on Bcl-2 expression (Hur et al., 2008). While one may 
make tentative conclusions as to the similarities and differences in molecular mechanisms of 
action of FXN and SQA in this study with reports in the literature for other cancer cell lines, it is 
important to bear in mind the differences in methods of quantification of Bcl-2 i.e. while the 
current study made use of flow cytometry to quantify Bcl-2 protein levels, the aforementioned 
reports in literature performed Western analyses in order to assess Bcl-2 levels.  
 
The effect of treatment with either Ptx or FXN on Bcl-2 levels was determined in the Hs578T 
cell line as a means of comparison of the mechanism of action of the compounds in two 
different breast cancer cell lines. The decrease in Bcl-2 levels from 41.5 % Bcl-2-positive events 
to 23.9 % and 25.4 % after treatment with Ptx and FXN is consistent with the results obtained in 
the MDA-MB-231 cell line that the compounds were able to down-regulate Bcl-2 expression. 
Furthermore, in the Hs578T cell line, it was observed that treatment with FXN at a 
concentration close to the IC50 value of the compound resulted in a decrease in Bcl-2 levels 
which was comparable to that produced by Ptx. This was in contrast as to the much higher 
concentration of FXN used in the MDA-MB-231 cell line, which caused a much greater decrease 
in Bcl-2 levels as compared with Ptx.  
 
An interesting study which was not carried out in this body of work would be to compare the 
Bcl-2 levels in untreated breast cancer cells, such as the Hs578T and MDA-MB-231 cell lines, to 
those in non-cancerous breast epithelial cells, such as the MCF12A cell line. This would confirm 
whether the protein is indeed up-regulated in breast cancer cells, as has been reported in the 
literature (Jin and El-Deiry, 2005). 
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CONCLUSIONS 
In summary, the aims in this study were achieved by the identification of specific pathways and 
signal transducer molecules which played a role in mediating the cytotoxicity of both 
sargaquinoic acid (SQA) and fucoxanthin (FXN) in breast cancer cells. The “hit” compound SQA 
was shown to require the activity of caspase-3, -8, -9, -6, -10 and -13 for its cytotoxicity against 
MDA-MB-231 cells. Furthermore, the compound was found to be able to decrease the level of 
the anti-apoptotic protein Bcl-2 in treated cells. These findings allude to a mechanism of action 
of the quinone involving both the intrinsic and the extrinsic apoptotic pathways. On the other 
hand, the cytotoxicity of FXN was shown to be dependent on the activity of caspase-1, -2, -3, -9 
and -10, suggesting a more specific mechanism of action of the carotenoid involving the 
intrinsic apoptotic pathway alone. The ability of FXN to decrease the expression of Bcl-2 was 
consistent with this proposed mechanism of action. This body of work represents the first in-
depth study of the molecular mechanisms mediating the cytotoxicity of both SQA and FXN in 
breast cancer cells in vitro.  
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CHAPTER 5 
 
SCREENING OF NOVEL MARINE ALGAL 
COMPOUNDS FOR POTENTIAL ANTI-CANCER STEM 
CELL ACTIVITY IN VITRO 
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5.1 INTRODUCTION 
The cancer stem cell theory states that tumours are initiated and maintained by a 
subpopulation of cells with both cancer and stem cell characteristics, termed “cancer stem 
cells” (CSCs). Most importantly the theory purports that CSCs are able to undergo asymmetrical 
division, meaning that the cells can both self-renew to produce more stem cells and 
differentiate to give rise to the various cell types within a tumour (Pardal et al., 2003; Wicha et 
al., 2006). The first solid tumour stem cells were identified in breast cancer (Al-Hajj et al., 2003). 
Breast cancer stem cells (BCSCs), comprising 1 % to 10 % of the total population have been 
isolated  from  both primary patient samples and cell lines such as MCF-7 and SKBR3, thus 
breast cancer has been described as a “stem-cell disease” (Al-Hajj et al., 2003; Patrawala et al., 
2005; Ponti et al., 2005; Dontu et al., 2005).  
Cancer stem cells can be isolated in a number of ways. BCSCs have been identified and 
extracted from the bulk population using fluorescence-activated cell sorting (FACS) based on 
their specific cell surface markers, such as the CD44+CD24-lin- phenotype (Al-Hajj et al., 2003; 
Kakarala and Wicha, 2008; Zhou et al., 2008). The increased expression of aldehyde 
dehydrogenase enzyme, detected by the Aldefluor assay, can also be used to isolate BCSCs 
(Armstrong et al., 2004; Kakarala and Wicha, 2008). Recently, the term “side population” (SP) 
has been used to describe a subpopulation of cancer cells that is able to exclude the fluorescent 
dye, Hoechst 33342, in flow cytometry. This ability is due to the presence of a number of ATP-
binding cassette (ABC) transmembrane proteins, such as breast cancer resistance protein 1 
(BCRP1 or ABCG2), which actively pump the dye out of these cells (Kondo et al., 2004; 
Patrawala et al., 2005; Zhou et al., 2007). These SP cells are known to be enriched for CSC-like 
cells in a variety of tumour cell lines and those extracted from the MCF-7 cell line have 
displayed higher tumourigenicity than the bulk MCF-7 population both in vitro and in vivo (Zhou 
et al., 2007).    
Cancer stem-like cells have also been isolated based on their functional characteristics, in 
particular their ability to grow anchorage-independently in serum-free non-adherent 
conditions. In these culture conditions non-stem cancer cells undergo anoikis, a programmed 
cell death associated with loss of adhesion, thus selecting for the CSC-enriched subpopulation 
(Reynolds and Rietze, 2005; Dontu et al, 2003). These CSC-like cells form tumourspheres in 
suspension in vitro and have been shown to be capable of in vivo tumour formation at limiting 
cell dilutions (Ponti et al, 2005). 
The identification of CSCs within breast tumours has resulted in a major shift in focus in terms 
of the development of novel therapies to treat this disease (Kakarala and Wicha, 2008). It is 
now thought that complete eradication and prevention of relapse requires the removal of the 
CSC subpopulation within a tumour (Massard et al., 2006). Therefore, the race is on to find 
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agents which are able to specifically target CSCs. To date, most potential anti-cancer stem cell 
agents have been designed to target this population either by the inhibition of the self-renewal 
pathways upregulated in the cells or by inducing differentiation of the CSC (Korkaya and Wicha, 
2007).  Self-renewal target pathways include the Wnt, Notch and Hedgehog signaling cascades, 
which are activated in a range of malignancies as well as in CSCs (Korkaya and Wicha, 2007). 
Examples of specific pathway inhibitors include the γ-secretase inhibitor, GSI-18, used to block 
the Notch pathway; as well as the natural product alkaloid, cyclopamine, which is able to 
suppress the Hedgehog pathway (Fan et al., 2006; Chen et al., 2002). In the second approach to 
anti-CSC drugs, clinical studies have made use of the FDA-approved combination therapy of all 
trans retinoic acid (tretinoin) together with the histone deacetylase inhibitor, sodium 
phenylbutyrate, in the treatment of various forms of leukemia (Tallman et al., 1997; Bruserud 
and Gjertsen, 2000; Zhou et al., 2002). However, to date there have been no reports of a 
compound which is able to target CSCs while leaving both normal healthy cells and bulk tumour 
cells unaffected.   
While attention in the past decades has turned towards marine natural products as a source of 
lead anti-cancer compounds, marine algae have received considerably less attention in terms of 
their potential for bioactive metabolites than other marine organisms such as sponges, 
Cnidarians and cyanobacteria (Jha and Zi-rong, 2004). In addition, very few studies of the 
biological activity of algal metabolites go beyond the standard in vitro cytotoxicity screening 
tests (Carte, 1996; Adrianosolo et al., 2006). Recently, a number of polyhalogenated 
monoterpene compounds were isolated from the red alga, Plocamium corallorhiza, collected 
from the South African coastline, which were cytotoxic to oesophageal cancer cells in vitro 
(Knott et al., 2005; Mann et al., 2007). The effect of these compounds on normal, non-
cancerous cells as well as their activity against other cancer cell lines and their respective CSC 
subpopulation were unknown. 
 
The aims in this chapter included the screening of novel marine algal compounds for potential 
anti-CSC activity using the mammosphere assay, comparison of this activity to that of a 
commonly used chemotherapeutic and, finally, preliminary studies into the mechanism of 
action of identified putative anti-CSC agents. 
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5.2 MATERIALS AND METHODS 
5.2.1 Reagents 
Dulbecco’s Modified Eagle Medium (DMEM) containing GlutamaxTM, fetal calf serum (FCS) and 
penicillin-streptomycin amphotericin (PSA) were obtained from Gibco (Invitrogen, UK). 
Recombinant human epidermal growth factor (EGF), basic fibroblast growth factor (bFGF) and 
heparin were from Sigma-Aldrich (Germany), while the B-27 supplement was from Invitrogen 
(UK). Recombinant human insulin was obtained from NovoRapid (Novo Nordisk 
Pharmaceuticals, Denmark). The WST-1 Cell Proliferation kit was from Roche (Switzerland). The 
algal compounds sargaquinoic acid, RU017 and RU018 were obtained as part of a collaboration 
with Dr Denzil Beukes (Pharmacy Faculty, Rhodes University). Paclitaxel and fucoxanthin were 
from Sigma-Aldrich (Germany). 
5.2.2 Cell lines and culture conditions 
The breast cancer cell line MCF-7 (ATCC: HTB-22) was maintained in culture either in 
anchorage-dependent or anchorage-independent conditions. In the former, cells were cultured 
as for the MDA-MB-231 and Hs578T breast cancer cell lines (described in Chapter 2, Section 
2.2.2) in either T25 tissue culture flasks (Corning, Pennsylvania) or regular 96-well plates (Nunc, 
Thermo Scientific, USA). Anchorage-independent growth conditions were modified from Dontu 
et al., 2003 and are described in the mammosphere assay protocol.  
5.2.3 Mammosphere assay 
The capability for anchorage-independent growth was assessed by the “mammosphere” assay, 
modified from that previously described (Dontu et al., 2003). Cells were lifted with trypsin-
EDTA solution, washed with phosphate-buffered saline (PBS) and passed through a 40 µM cell 
strainer (BD Biosciences, Belgium) to achieve a single cell suspension. Cell were seeded at a 
density of either 1000 or 3000 cells per well in ultralow attachment 96-well plates (Corning, 
Pennsylvania) containing DMEM with GlutamaxTM supplemented with 100 U/ml penicillin, 100 
µg/ml streptomycin and 12.5 µg/ml amphotericin (PSA), 2% (v/v) B-27 supplement, 20 ng/ml 
EGF and bFGF, 4 ng/ml heparin and 10 μg/ml insulin. Treatment with either 0.61 % v/v DMSO 
vehicle control or paclitaxel, fucoxanthin, RU017 or RU018 at concentrations indicated in figure 
legends was carried out either upon seeding (Day 0) or four days after seeding (Day 4) for 
quintuplicate samples. The cultures were supplemented with fresh medium, which was added 
to exisiting media every 48 hrs, and the resultant mammospheres were photographed using a 
Nikon camera (Coolpix 990) attached to a light microscope at 100x magnification. Images were 
analyzed and scale bars calculated using ImageJ (NIH freeware).  
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5.2.4 Cell proliferation assay 
Cell viability upon treatment with the compounds was assessed by means of the WST-1 assay 
according to manufacturer’s instructions. After growth of the mammosphere cultures for 8 
days, 10 µL of a 5 mg/mL WST-1 reagent was added to each well and incubated for a further 4 
hours at 37 ºC before reading the absorbance at 450 nm using a Powerwave 
spectrophotometer (BioTek). Cell survival was determined by the ability of live cells to convert 
the WST-1 reagent to a soluble coloured formazan product and percentage survival calculated 
according to the absorbance of the treated samples at 450 nm compared to that of the DMSO 
vehicle-treated control. All treatments were carried out in quintuplicate. 
 
5.3 RESULTS 
5.3.1 Observation of the formation and development of MCF-7 mammospheres in 
anchorage-independent serum-free culture conditions  
The mammosphere assay was carried out for the MCF-7 breast cancer cell line in order to 
enrich for cancer stem cell-like cells, which are able to grow in anchorage-independent serum-
free conditions (Dontu et al., 2003). The development of non-adherent mammospheres or 
tumourspheres (Dontu et al., 2003) under these conditions after seeding of 1000 MCF-7 cells 
per well in a 96-well plate was observed under a light microscope over the course of one week. 
As depicted in Figure 5.1, the single-cell suspension seeded on Day 0 had formed small, 
irregular cell “clumps” by Day 1 (Figure 5.1A), which had developed into small suspended 
colonies representative of mammospheres (as described by Dontu et al., 2003) by Day 3 (Figure 
5.1B). By Day 5, the mammospheres had increased in size to approximately 0.1 mm (100 µM) in 
diameter and displayed a more regular spherical shape (Figure 5C). After seven days growth in 
anchorage-independent serum-free conditions, the mammospheres, while remaining roughly 
the same size as Day 5, began to exhibit different morphologies (Figure 5.1D). The most striking 
feature of the Day 7 cultures was the formation of hollow mammospheres; empty bubble-like 
structures surrounded by one or more cells or small mammospheres attached to what 
appeared to be an outer membrane of the hollow spherical bodies (Figure 5.1D, inset bottom 
right).  
 
  
Figure 5.1: Time-course study of the formation of tumourspheres in the MCF
anchorage-independent serum-free 
tumourspheres was observed over the course of seven days. Photographs were taken at Day 1 (A), Day 
3 (B), Day5 (C) and Day 7 (D). Images are representative of at least three randomly selected fie
Insets show specific structural features of MCF
Images were captured under a light microscope at 100x magnification using a Nikon Coolpix 990 camera. 
Images were analyzed and scale bars inserted 
representative of 0.1 mm.  
 
 
These observations in terms of the formation and development of MCF
consistent over the course of many experiments for 
5.8) and were used as a means of comparison with treated MCF
independent conditions over the same time period.
The mammosphere assay has been validated within the Biomedical Biotechnology Research 
Unit (BioBRU) by flow cytometry to detect specific CSC markers, revealing that MCF
mammospheres were enriched for CD44
marker Oct4 (unpublished data, Jason Sterrenberg, 2011).
-7 breast cancer cell line in 
culture conditions. Alterations in number, size and shape of 
-7 tumourspheres at various stages of their development. 
in ImageJ. Note: Insets not set to scale.
-7 mammospheres were 
0.16 % v/v DMSO-treated cells (Figu
-7 cells cultured in anchorage
 
high/CD44low CSC-like cells and express the stem cell 
 
105 
105 
 
lds. 
 Scale bars 
re 5.2 – 
-
-7 
 106 
 
106 
Repeated attempts within the research group to culture both MDA-MB-231 and Hs578T breast 
cancer cells under the anchorage-independent, serum-free conditions described above were 
unsuccessful (Personal communication: Dr Mugdha Sukhthankar and Jason Sterrenberg).  
5.3.2 Screening of marine algal compounds for potential anti-cancer stem cell activity using 
the MCF-7 mammosphere assay 
The effect of the previously described marine algal compounds sargaquinoic acid (SQA) 
fucoxanthin (FXN), as well as the novel halogenated monoterpenes RU017 and RU018, on the 
formation and development of MCF-7 mammospheres was assessed by addition of these 
compounds to the culture medium either at seeding (Day 0) or after four days growth in 
anchorage-independent conditions (Day 4). The compounds were added at a concentration 
equivalent to the IC50 values in MDA-MB-231 cells as determined by MTT assay (Chapter 2, 
Figure 2.3). In the case of the novel non-toxic compounds RU017 and RU018, a concentration of 
300 µM was selected due to the preliminary findings within the research group that a racemic 
mixture of the compounds appeared to reduce the ABCG2+ “side population” as assessed by 
flow cytometry at that concentration (Figure A3, Appendix). This high concentration of the 
compounds was not, however, toxic to MCF-7 cancer or non-cancerous MCF12A breast 
epithelial cells under regular adherent conditions (Figure A1 and Table 2.2).  
The effect of other novel algal “hit” compounds described in Chapters 2 through 4 (eg. RU004 
and RU007) on mammosphere formation could not be assessed due to insufficient quantities of 
these compounds.  
5.3.2.1 Analysis of the effect of selected algal compounds on MCF-7 mammosphere 
formation and development when added upon seeding  
When added to the anchorage-independent serum-free culture conditions at Day 0, the 
prenylated quinone SQA, though able to slow down mammosphere formation compared to the 
DMSO control by Day 3, was unable to prevent the formation of MCF-7 mammospheres by Day 
6 (Figure 5.2, second column vs. first column). In fact, the compound appeared to stimulate the 
formation of the more mature hollow mammosphere structures as compared to the DMSO-
treated control sample after 6 days growth (inset in image in third row of Figure 5.2). In the 
case of the carotenoid, FXN, while the compound was able to reduce the number and size of 
the mammospheres both at Day 3 and Day 6 compared to the control, mammosphere 
formation was not completely inhibited by FXN (third column of Figure 5.2). On the other hand, 
for both of the novel halogenated monoterpene stereoisomers RU017 and RU018, the MCF-7 
mammospheres were eliminated by Day 3, leaving only single cells or clusters of two or three 
cells in the treated samples (fourth and fifth columns in Figure 5.2), despite having no effect on 
MCF-7 cells under adherent conditions at the same concentration (Figure A1). 
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5.3.2.2 Elucidation of the effect of algal compounds on MCF-7 mammosphere development 
when added after four days growth in anchorage-independent culture conditions 
For all of the algal compounds tested, the effect of the compounds on mammosphere 
development when added at Day 4 differed from that obtained when the compounds were 
added upon seeding of the MCF-7 cells (Figure 5.2, third vs. fourth row). When added to 
existing MCF-7 mammospheres on Day 4, none of the compounds screened were able to 
remove the existing MCF-7 mammospheres or prevent their further development (fourth row 
of Figure 5.2). In particular, SQA appeared to have little, if any, effect on the development of 
the mammospheres when added at Day 4 as compared to the DMSO control (second image vs. 
first image in fourth row of Figure 5.2). On the other hand, the addition of FXN after four days 
resulted in the formation of much larger, irregularly shaped mammospheres than those 
observed in the DMSO-treated MCF-7 cells (third image in the third row of Figure 5.2). In 
contrast to the effects when added upon seeding, neither of the stereoisomers RU017 or 
RU018 were able to eliminate the MCF-7 mammospheres or affect their further development 
when added at Day 4 (fourth and fifth images, respectively, in the third row of Figure 5.2).  
In order to gain information as to the mode of action of the novel marine algal compounds 
against MCF-7 mammospheres, and as an attempt to quantify the changes in mammosphere 
number and size, the WST-1 cell proliferation assay was carried out after eight days growth in 
anchorage-independent culture conditions. The percentage survival values relative to the 
DMSO-treated negative control for each sample are indicated on the relevant images in Figure 
5.2. In this assay, SQA was found to decrease cell survival to 62 % when added at seeding and 
to 74 % when added at Day 4. While FXN reduced cellular survival to 70 % when added upon 
seeding, the compound was unable to decrease cell survival when added four days after 
seeding. The halogenated monoterpenes RU017 and RU018 decreased cellular survival to 53 % 
and 44 %, respectively, when added at Day 0; with a slight reduction in survival to 84 % and 77 
%, respectively, when added at Day 4. 
The screening of SQA, FXN, RU017 and RU018 described in Section 5.3.2 above was carried out 
in a mammosphere assay where cells were seeded at a density of 1000 cells per well. These 
experiments were repeated for mammospheres obtained by seeding with 3000 MCF-7 cells and 
treating with the compounds upon seeding. The results obtained in terms of the effects of the 
compounds on mammosphere formation and viability were largely consistent with those 
observed when seeding with 1000 cells (Figure A4, Appendix). All subsequent assays were 
carried out using 1000 MCF-7 cells for seeding into mammosphere conditions. 
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5.3.3 Dose-response study of the effect of paclitaxel and selected algal compounds on   
MCF-7 mammosphere formation 
The effects of the algal compounds Fxn, RU017 and RU018 on the formation and development 
of MCF-7 mammospheres were more thoroughly investigated by determining whether the 
observed alterations to the mammospheres (Section 5.3.2) were dose-dependent. In addition, 
the effect of various concentrations of the chemotherapeutic agent, paclitaxel (Ptx), on 
mammosphere formation was assessed. In all cases, the compounds were added upon seeding 
of 1000 MCF-7 cells and the tumoursphere assay carried out as before.  
5.3.3.1 The effect of various doses of RU017, RU018, FXN and Ptx on mammosphere 
formation and development 
For both of the novel monoterpene stereoisomers, RU017 and RU018, treatment with 25 µM of 
the compound did not have a noticeable effect on the number or size of the MCF-7 
mammospheres formed after six days; however, the mammospheres were observed to be 
more irregular in shape when compared to the DMSO-treated control (first and second 
columns of Figure 5.3; first and second row, respectively). In addition, the latter concentration 
did not reduce cellular survival of the treated mammospheres compared to the DMSO control 
as determined by WST-1 assay. At a concentration of 50 µM, treatment with either RU017 or 
RU018 resulted in a decrease in mammosphere size compared to the control, while having no 
effect on cell survival (third column in Figure 5.3, first and second row respectively). Treatment 
with 100 µM inhibited mammosphere formation almost completely but had little effect on 
percentage survival relative to the control (fourth columns in Figure 5.3, first and second row 
respectively). As was observed in Section 5.3.2, treatment of MCF-7 cells upon seeding in 
anchorage-independent conditions with 300 µM of either RU017 or RU018 prevented 
mammosphere formation entirely and substantially reduced cell survival (fifth column of Figure 
5.3; first and second row, respectively). 
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In the case of the carotenoid compound FXN, none of the concentrations tested were able to 
completely eliminate mammosphere formation when added to MCF-7 cells upon seeding into 
anchorage-independent conditions, although a dose-dependent decrease in mammosphere 
size was observed (third row of Figure 5.3). On the other hand, the cytotoxicity of FXN against 
MCF-7 mammospheres was not dose-dependent, with only the 10 µM treatment effectively 
reducing cell survival relative to the DMSO control (third row of Figure 5.3). The dark granular 
structures depicted in the FXN-treated samples were undissolved FXN crystals which appear 
orange under the microscope (data not shown).   
The chemotherapeutic drug Ptx appeared to increase the number of MCF-7 mammospheres 
when 50 nM was added upon seeding, while treatment with 100 nM had little effect on 
mammosphere formation compared to the DMSO-treated control (fourth row of Figure 5.3). 
This was despite the latter concentration being reported as the IC50 value for MCF-7 cells under 
adherent conditions (Dwight et al., 1997). On the other hand, Ptx was only mildly toxic towards 
MCF-7 mammospheres when added at both 50 and 100 nM in anchorage-independent 
mammosphere conditions (Figure 5.3).    
 
5.3.4 Analysis of the effect of pre-treatment with either Ptx or selected novel algal 
compounds on MCF-7 tumoursphere formation 
As a final strategy to characterize the observed effects of RU017, RU018, FXN and Ptx on the 
formation, development and survival of MCF-7 mammosphere, the compounds were used to 
pre-treat MCF-7 cells in regular anchorage-dependent conditions overnight prior to seeding 
into anchorage-independent tumoursphere conditions. The consequences of such treatment on 
mammosphere development and viability were compared to those obtained for treatment at 
Day 0 and Day 4. 
5.3.4.1 Analysis of the effects on MCF-7 mammosphere formation as a result of pre-
treatment with RU017, RU018, FXN or Ptx 
For all four of the compounds RU017, RU018, FXN and Ptx, pre-treatment of MCF-7 cells in 
anchorage-dependent culture conditions prior to seeding into anchorage-independent 
conditions in the tumoursphere assay was unable to either prevent mammosphere formation 
or effectively reduce cell survival relative to the DMSO control (first row in Figure 5.4). In 
particular, pre-treatment with the chemotherapeutic agent Ptx appeared to produce larger, 
more regular shaped mammospheres when compared to the DMSO vehicle-treated control, 
while having little effect on cell survival (first vs. last image in the first row of Figure 5.4).  
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As before, treatment with Ptx on Day 0 was unable to prevent either mammosphere formation 
or decrease cellular viability (last image in the second row of Figure 5.4 and Figure 5.3). When 
added to existing mammospheres on Day 4, Ptx was unable to remove the mammosphere or 
reduce cell survival and resulted in the formation of a greater number of hollow 
mammospheres by Day 6 when compared to the DMSO-treated control (last image in third row 
of Figure 5.4). 
The effect of the algal compounds RU017, RU018 and FXN on mammosphere formation and 
development when added either at Day 0 or Day 4 were consistent with those observed in 
previous assays. That is that RU017 and RU018 completely inhibited mammosphere formation 
when added at Day 0, but had little effect on the viability or further development of existing 
mammospheres when added on Day 4; while FXN was unable to prevent mammosphere 
formation or effectively reduce cell viability when added either at Day 0 or Day 4 (second and 
third row of Figure 5.4). 
 
5.4 Analysis of the effect of RU017, RU018, FXN and Ptx on the ability of MCF-7 
mammospheres to revert to anchorage-dependent growth 
The effect of treatment with RU017, RU018, FXN and Ptx on the ability of MCF-7 
mammospheres to attach and grow when transferred back into regular growth conditions 
without compound was assessed. For each compound, similar results were obtained for all the 
concentrations tested (data not shown) and thus only a single example is shown for each of the 
treatments (experiments carried out in in quadruplicate). For the algal compounds RU017, 
RU018 and FXN (at concentrations of 50 µM for RU017 and RU018 and 10 µM for FXN), none of 
the treatments appeared to inhibit the ability of the MCF-7 mammospheres to attach and grow 
in regular anchorage-dependent growth conditions (Figure 5.5). It was observed, however, that 
those samples containing larger and more numerous mammospheres took a greater amount of 
time to fully attach to the culture vessels, as was the case for FXN-treated mammospheres 
(Figure 5.5). The chemotherapeutic agent, Ptx, had a significant impact on the MCF-7 
mammospheres once they were placed in anchorage-dependent culture conditions, being able 
to prevent adhesion and/or growth, even after four days incubation (Figure 5.5).  
 
 
 
 
  
Figure 5.5: Assessment of the ability of treated MCF
returned to anchorage-dependent culture conditions. Cells were originally treated upon seeding with 
either the DMSO vehicle control (
RU017 or RU018, fucoxanthin or paclitaxel in anchorage
sample, mammospheres were transferred from anchorage
placed into regular anchorage-depe
Day 4 under a light microscope at 100x magnification and set to a common scale in ImageJ. Scale bars 
equivalent to 0.1 mm. Each image was representative of at least 3 randomly selected fields.
 
 
DISCUSSION 
The mammosphere cultivation system developed by Dontu 
propagation of mammary stem and progenitor cells based on their ability to grow in suspension 
in anchorage-independent serum
modified and optimized within the Biomedical Biotechnology Research Unit (BioBRU, Rhodes 
University) to allow for the in vitro
MCF-7 breast cancer cell line (unpubli
-7 tumourspheres to re-attach and grow when 
0.61 % v/v) or either of the halogenated monoterpene stereoisomers 
-independent serum-free conditions. For each 
-independent conditions after 8 days and 
ndent culture conditions without compound. Images were taken on 
et al. allows for the 
-free conditions (Dontu et al., 2003). This technique was 
 cultivation of the cancer stem cell-like subpopulation of the 
shed data; Mugdha Sukthankar and Jason Sterrenberg, 
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2011). In the current study, the mammosphere system was used to develop an assay which 
allowed for the screening of novel marine algal compounds for potential anti-cancer stem cell 
(CSC) activity. 
The formation and development of MCF-7 mammospheres was observed after seeding of one 
thousand cells into anchorage-independent serum-free conditions over the course of one 
week. As reported by Dontu et al. in the case of dissociated breast epithelial cells, “floating 
spherical colonies” or mammospheres were observed to develop under the anchorage-
independent assay conditions (Dontu et al., 2009). While the aforementioned study reported 
the formation of mammospheres after five to seven days, the MCF-7 breast cancer cell line 
generated mammospheres after only three days (Dontu et al., 2003). The more rapid 
development of the mammospheres by a cancer cell line compared to that by dissociated 
breast epithelial cells could be attributed to the more rapid growth of cancer cell lines in 
general, as suggested by Fillmore and Kupperwasser (2009).  
The mammospheres observed in the suspension growth conditions were not uniform in 
appearance, varying in both size and morphology. The larger MCF-7 mammospheres generated 
in anchorage-independent conditions have previously been reported to have a diameter of 
between 100 and 150 µm (0.1 – 0.15 mm) after seven days growth in suspension (Sansone et 
al., 2007), a size which is consistent with those observed in this study. In addition, the 
mammospheres have been demonstrated to consist of a “ball” of cells as opposed to being 
hollow in the centre (Sansone et al., 2007; Fillmore and Kupperwasser, 2009). However, in the 
current study, hollow and apparently empty mammospheres were observed after seven days 
growth in suspension, and were thought to represent a more mature phenotype. There are no 
reports in the literature describing such a phenotype for either mammospheres or 
tumourspheres in general, and the closest resemblance of the hollow mammospheres is to the 
zona pellucida, the spherical glycoprotein shell surrounding a developing oocyte (Connor et al., 
2005). Further characterization of the various morphological sub-types of the MCF-7 
mammospheres would be required in order to understand their significance. 
The mammosphere assay was used to determine whether the marine algal compounds SQA, 
FXN, RU017 and RU018 displayed potential anti-CSC activity in terms of their ability to prevent 
both formation and development/maturation of the MCF-7 mammospheres. While the addition 
of the test compounds at the stage of seeding of MCF-7 cells into anchorage-independent 
culture conditions assessed their effect on mammosphere formation, dosing with the 
compounds to existing mammospheres on Day 4 measured their ability to remove the 
mammospheres or alter their further development. Furthermore, assessment of the cellular 
viability of mammospheres after treatment with the algal compounds was carried out as a 
measure of cytotoxicity of the compounds to MCF-7 cells in anchorage-independent serum-free 
 119 
 
119 
culture conditions and in an attempt to quantify the inhibitory effects of the compounds on 
mammosphere formation and development.  
The prenylated quinone, SQA, was found to be differentially toxic to metastatic MDA-MB-231 
and Hs578T breast cancer cells, while having no adverse effect on healthy breast epithelial 
MCF12A cells and was thus identified as a potential “hit” compound (Chapter 2, Figure 2.3 and 
Table 2.2). The quinone was, however, unable to prevent formation of MCF-7 mammospheres 
either when added upon seeding or after four days growth in anchorage-independent 
conditions. In fact, when added upon seeding, the compound appeared to speed up the 
maturation of the mammospheres as evidenced by an increase in hollow mammospheres.  
Although unable to inhibit MCF-7 mammosphere formation, SQA was nonetheless found to 
reduce the viability of treated mammospheres when added either at seeding or on Day 4. This, 
together with the apparent ability of SQA to speed up mammosphere maturation, could 
indicate a mechanism whereby the lifespan of the mammospheres may be reduced by the 
quinone. The latter possibility could be tested by culturing the mammospheres for longer than 
the standard eight day incubation and comparing the SQA-treated mammospheres with those 
in the vehicle-treated control. 
More in-depth studies in terms of the effect on mammosphere formation and development 
were carried out for the algal compounds RU017, RU018 and FXN as well as the 
chemotherapeutic drug Ptx. These studies assessed the dose-dependency and potential mode 
of action responsible for the effects on MCF-7 mammospheres. As a means of gaining insight 
into the specific cell sub-populations targeted by the compounds of interest, the effect of pre-
treatment of MCF-7 cells with the compounds in anchorage-dependent culture conditions prior 
to seeding into mammosphere conditions was assessed. The rationale behind the latter 
approach was that, should a compound specifically target the CSC sub-population, this effect 
would be evident by a decrease in mammosphere formation when the treated cells were 
transferred into anchorage-independent serum-free culture conditions. In addition, further 
functional studies involved the assessment of the ability of the selected compounds to prevent 
attachment and growth of mammospheres when transferred into regular anchorage-
dependent culture conditions. This in vitro assay mimics the in vivo process of metastasis and 
regeneration of a tumour at a distant site, since in the latter case, the cells would need to 
detach from the extracellular matrix (ECM), survive in suspension in the blood stream, attach at 
another site in the body and then initiate and maintain growth at the new site (Siclari et al, 
2006). The ability to survive and grow in anchorage-independent conditions, as well as the 
capability of asymmetric cell division has led to the hypothesis that CSCs are responsible for 
metastasis of cancers (Li et al., 2007; Lawson et al., 2009).  
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The carotenoid compound, FXN, was shown to be highly toxic to MDA-MB-231 and Hs578T 
breast cancer cells and, to a lesser extent, non-cancerous MCF12A breast epithelial cells 
(Chapter 2, Figure 2.3 and Table 2.2). However, the compound was unable to prevent the 
formation of MCF-7 mammospheres when added upon seeding or at Day 4 or when used to 
pre-treat MCF-7 cells prior to seeding into anchorage-independent mammosphere conditions. 
The carotenoid did, however, reduce the size of the mammospheres when added upon seeding 
and, when added to existing mammospheres in suspension on Day 4, appeared to alter further 
development, resulting in larger and more irregular shaped mammospheres by Day 6.  In terms 
of the viability of the treated mammospheres, FXN displayed moderate toxicity against MCF-7 
mammosphere cells when added to the cultures upon seeding, but not when added to existing 
mammospheres on Day 4. Dose-response studies revealed that, even at a concentration which 
was more than double the IC50 value against breast cancer cells (Chapter 2), FXN remained 
unable to inhibit either mammosphere formation or viability when added upon seeding. In 
addition, the compound had no effect of the ability of the mammospheres to attach and grow 
when transferred into regular anchorage-dependent culture conditions. This was despite the 
toxicity of FXN against breast cancer cells under regular adherent culture conditions (Chapter 2, 
Figure 2.3), but agreed with the low cytotoxicity of the compound under anchorage-
independent conditions. A possible interpretation of these data could be that the specific cell 
sub-type(s) able to survive in anchorage-independent mammosphere conditions, and enriched 
for by this assay, are resistant to FXN.   
In the case of the novel halogenated monoterpene stereoisomers RU017 and RU018, both of 
which were shown to have no effect on the survival and proliferation of either breast cancer 
cells or healthy breast cells in vitro (Chapter 2, Figure 2.3 and Table 2.2), the compounds were 
able to completely inhibit mammosphere formation when added to MCF-7 cells upon seeding 
in the mammosphere assay. This agreed with the preliminary results obtained within the 
research group, in which a racemic mixture of the compounds was shown to decrease the 
ABCG2+ MCF-7 “side population,” thought to be enriched for CSCs (Lawson, 2009; MSc thesis). 
On the other hand, when added to existing mammospheres on Day 4, neither of the 
compounds was able to remove the mammospheres or affect their further development.  
In terms of the effect of the compounds on cell viability, RU017 and RU018 appeared to 
substantially decrease cell survival when added upon seeding and, to a lesser extent, when 
added on Day 4. Interestingly, in both cases, mammosphere cell viability was reduced to a 
greater extent in RU018-treated cells compared to those treated with RU017, indicating that 
the stereoisomers differ in their cytotoxicity against the cell sub-type(s) enriched by the 
mammosphere assay. However, considering that the RU017- and RU018-treated samples did 
not contain any visible mammospheres by Day 8, the percentage survival values of roughly      
50 % relative to the DMSO control were higher than expected. This raised questions as to the 
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suitability of the WST-1 assay for either the assessment of mammosphere cell viability or as a 
means of quantifying the mammospheres present in each sample. One of the problems 
associated with assessing cellular viability in the mammosphere assay is the large variation in 
both the number and size of the mammospheres between samples. For the larger 
mammospheres, it is not known whether the WST-1 reagent is able to penetrate the 
mammospheres or whether the absorbance from the buried cells within the mammospheres 
would be detectable. Thus, it was not possible to conclude whether the values obtained 
indicate toxicity against the total population of the mammospheres or simply those exposed on 
the surface. Dissociation of the mammospheres to a single cell suspension prior to cytotoxicity 
assays could potentially overcome this problem, providing that this was carried out in such a 
way that cell viability would not be affected. Since the tumoursphere assay is a relatively new 
technique (Fillmore and Kupperwasser, 2007), cytotoxicity testing for the screening of 
compounds in this system has not been optimized and thus the results obtained using the WST-
1 assay in this study were interpreted with caution.     
The inhibitory effect of the halogenated monoterpene stereoisomers RU017 and RU018 on 
mammosphere formation when added upon seeding into anchorage-independent conditions 
was further characterized in terms of the dose-dependency of the anti-mammosphere activity. 
The 300 µM concentration of the compounds used in the initial screening, though non-toxic to 
breast cancer and healthy breast cells in regular adherent conditions, was considered to be 
unfavourably high in terms of a hit compound, whose activity should ideally fall between 1 and 
50 µM (Keseru and Makara, 2006). Therefore, the ability of lower doses of the compounds to 
inhibit mammosphere formation was assessed. For both compounds, a three times lower 
concentration than that used in screening (ie. 100 µM) was able to effectively prevent 
mammosphere formation. As a result, the latter concentration of the compounds was used in 
subsequent studies, albeit that this dose displayed only mild cytotoxicity in the WST-1 assay.  
Pre-treatment of MCF-7 cells with either RU017 or RU018 prior to seeding into anchorage-
independent conditions had no effect on the ability of MCF-7 cells to form mammospheres 
under these conditions. One might expect that pre-treatment with the algal monoterpene 
stereoisomers would decrease or prevent mammosphere formation due to the ability of the 
compounds to completely inhibit mammosphere formation when added upon seeding. A 
possible explanation for this discrepancy is that the effect of the compounds on the MCF-7 sub-
population enriched by the mammosphere assay may be specific to growth in anchorage-
dependent conditions. The latter sub-population thought to be targeted by RU017 and RU018 
was predicted to represent CSCs. If this hypothesis was correct and since CSCs are thought to 
undergo both morphological and phenotypic changes enabling them to grow in suspension 
(Fillmore and Kupperwasser, 2007), it is not unlikely that RU017 and RU018 was targeting such 
adaptations of the CSCs. When transferred to anchorage-dependent conditions, 
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mammospheres treated with either RU017 or RU018 were able to attach and grow as adherent 
monolayers, indicating that this property of the mammosphere-enriched cell sub-type was not 
inhibited by the halogenated monoterpenes. 
The commonly used chemotherapeutic agent, Ptx, was analysed for the ability to inhibit 
mammosphere formation and viability. Ptx was unable to prevent mammosphere formation 
when added at a concentration which was toxic to both breast cancer and normal breast cells 
under adherent conditions (Chapter 2). Furthermore, neither of the concentrations tested were 
found to be particularly toxic to MCF-7 mammospheres, being unable to reduce cellular 
viability to below 84 % as assessed by WST-1 assay. The effect of 10 ng/L (12 pM) of Ptx has 
previously been reported to have no effect on MDA-MB-231 mammosphere survival (Fillmore 
and Kupperwasser, 2009). Since CSCs have been reported to be resistant to Ptx and other 
chemotherapeutic agents due to the presence of high levels of ABC drug transporters which are 
able to efflux the drugs, thus protecting the CSCs (Dean et al., 2009), this lent strength to the 
hypothesis that the cells comprising the mammosphere may be CSCs.  In addition, when added 
at a concentration equivalent to half the IC50 value determined in MD-MB-231 cells (Figure 2.1; 
Chapter 2), Ptx appeared to stimulate mammosphere formation. This agreed with published 
reports which have suggested that, since the compound is cytotoxic to the bulk population of 
tumours and not the CSC sub-population, chemotherapy with this and similar drugs may 
effectively enrich for CSCs (Lawson et al., 2009). This CSC enrichment theory could also explain 
the observation that pre-treatment with Ptx appeared to speed up mammosphere growth and 
development as evidenced by the larger more regularly-shaped mammospheres arising from 
pre-treated MCF-7 cells. 
In adherence studies, mammospheres treated with Ptx did not produce an adherent culture 
when transferred to regular anchorage-dependent conditions, even after four days incubation 
in these conditions. Rather, the large mammospheres were replaced by small floating cell 
clumps in adherent conditions. This was thought to have occurred in one of two ways: either 
the mammosphere cells were unable to attach and thus underwent anoikis; or the cells were 
able to attach to the culture vessel, but were subsequently rapidly eliminated by traces of Ptx 
transferred along with the mammospheres into the new culture conditions (Ptx was diluted by 
a factor of ten when transferred into regular media). The latter possibility could be explored by 
washing the mammospheres prior to transferring into adherent conditions to completely 
remove the drug. Since no such adherence study has been reported in the literature for 
treatment of mammospheres with Ptx, there was no data with which to compare the results 
obtained in this body of work.  
For all of the treatment described above, further experiments to determine the cellular sub-
type composition of the treated mammospheres could shed light onto the specific cells 
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targeted by the compounds. For example, the ability of RU017 and RU018 to inhibit 
mammosphere formation when added at Day 0, but not when added at Day 4 could indicate 
that the compounds targeted the self-renewal and differentiation capabilities of CSCs, while 
leaving their progenitors unaffected. 
 
 
CONCLUSIONS 
Finally, the body of work described in this chapter reports the screening of the novel marine 
algal compounds SQA, FXN, RU017 and RU018 in the mammosphere assay and revealed that 
the latter monoterpene stereoisomers displayed putative anti-CSC activity. This was suggested 
by the ability of both RU017 and RU018 to completely inhibit mammosphere formation in 
anchorage-independent conditions even after six days incubation. In stark contrast, the 
commonly used chemotherapeutic drug Ptx appeared to enhance both the formation and 
maturation of MCF-7 mammospheres. The inability of SQA and FXN to inhibit mammosphere 
formation and development revealed that the putative anti-CSC activity was not a feature 
shared by all compounds of marine algal origin. This is the first report of the screening of novel 
marine algal compounds against BCSCs and indeed against CSCs in general. It is also the first 
report of compounds which are able to selectively inhibit CSCs while leaving both the bulk 
cancer cells and non-cancerous breast epithelial cells unaffected. More work is required to 
determine the specific molecular mechanism mediating the CSC-specific activity of the 
halogenated monoterpenes as well as their respective cellular targets.  
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CHAPTER 6 
FINAL DISCUSSION 
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6.1 SUMMARY OF RESULTS 
 
The rich biodiversity of the marine environment of South Africa, in particular that of marine 
algae, has proven to be an abundant source of structurally unique natural products (Le Roux et 
al., 2002; Davies-Coleman, 2004). Indeed, the library of compounds from red and brown algae 
analyzed in this study contained a large number of novel polyhalogenated monoterpenes and 
monoterpene aldehydes, as well as the previously described tetraprenylated quinone 
sargaquinoic acid (SQA) and the carotenoid (FXN) (see Figure 2.2, Chapter 2 for structures) 
(Knott et al., 2005; Mann et al., 2007; Afoloyan et al., 2008). Algal secondary metabolites such 
as these have been demonstrated to possess a range of pharmacologically beneficial properties 
including anti-bacterial, anti-fungal, anti-viral, anti-malarial and anti-cancer activities (Carté, 
1996; Peng et al., 2011). While a subset of the novel compounds in the current study had 
previously been subject to preliminary cytotoxicity screening in WHC01 oesophageal cancer 
cells in vitro (Mann et al., 2007), the majority of the algal metabolites had not been assessed 
for biological activity. In particular, none of the algal compounds had been tested for 
cytotoxicity against metastatic ER-PR-HER2/neu- breast cancer cells or the putative breast 
cancer stem cells (BCSCs) contained in MCF-7 mammospheres in vitro.  
 
The aims of this study included the screening of novel compounds of South African marine algal 
origin against metastatic ER-PR-HER2/neu- breast cancer cells, non-cancerous breast epithelial 
cells and BCSC, as well as the characterization of the molecular mechanisms of action of 
identified hit compounds. The aims were achieved using a range of biochemical and cell 
biological techniques including MTT cytotoxicity assays, Western analyses, flow cytometry 
studies using vital dyes and antibodies, PARP cleavage assays, caspase inhibitor studies and 
MCF-7 mammosphere assays. The results from this body of work are summarized in Table 6.1.  
 
The novel algal compounds were divided into four groups based on their differential toxicity 
when screened against breast cancer, non-cancerous breast and putative BCSCs (Table 6.1). 
Group 1 contained the compound with the highest toxicity against MDA-MB-231 breast cancer 
cells and which was demonstrated in a previous study within the Biomedical Biotechnology 
Research Unit (BioBRU) to be equally toxic to non-cancerous MCF12A breast epithelial cells 
(Lawson, 2009; MSc thesis). The mode of cell death induced by RU015 was investigated and the 
50 kDa PARP cleavage products generated within treated cells were suggestive of the induction 
of necrosis; however this was not confirmed by flow cytometry using the vital dyes Hoechst 
33342 (H33342) and propidium iodide (PI).  
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Group 2 included the compounds RU004, RU007 and SQA, which were found to be toxic to 
breast cancer but not healthy breast epithelial cell lines. Flow cytometric analysis of treated 
breast cancer cells stained with the aforementioned vital dyes were suggestive of the induction 
of apoptosis for all three compounds, a result which was confirmed for SQA by the presence of 
85 kDa PARP cleavage products in treated cells. The latter compound was also demonstrated to 
cause G0-G1 cell cycle arrest and produce a sub-G0 apoptotic population as determined by flow 
cytometry with PI staining. Further studies into the specific molecular mechanisms mediating 
the cytotoxicity of SQA revealed that the compound potentially required the activity of 
caspase-3, -6, -8, -9 and -13 for its activity and was able to decrease the levels of both the anti-
apoptotic protein Bcl-2 and the activated phosphorylated form of the survival kinase ERK1/2. 
Although SQA was mildly toxic against the putative BCSCs contained within MCF-7 
mammospheres, the compound was unable to prevent mammosphere formation or 
development in anchorage-independent culture conditions.  
 
Group 3 contained the previously described carotenoid FXN, which was demonstrated to be 
highly toxic to breast cancer cell lines and, to a lesser extent, the non-cancerous MCF12A breast 
epithelial cell line. In terms of the mode of action of FXN, while flow cytometry studies with 
H33342/PI staining were inconclusive, the sub-G0 population detected in cell cycle analyses was 
suggestive of the induction of apoptosis. This was verified by the finding that the caspases -1, -
3, and -9 were potentially required for the cytotoxicity of FXN, together with the observed 
ability of the compound to decrease the levels of the anti-apoptotic Bcl-2 protein. FXN, like 
SQA, also appeared to cause G0-G1 cell cycle arrest in treated cells in flow cytometry 
experiments. In terms of potential anti-BCSC activity, FXN was non-toxic to MCF-7 
mammospheres and was unable to prevent mammosphere formation in vitro. 
 
Finally, Group 4 contained the novel algal polyhalogenated monoterpenes which were found to 
be non-toxic to breast cancer cells. Of these, the stereoisomers RU017 and RU018 were also 
demonstrated to be non-toxic to healthy MCF12A breast cells. On the other hand, these 
compounds were found to be able to completely inhibit mammosphere formation in vitro, 
indicating potential anti-BCSC activity. 
 
These findings together represent a rigorous interrogation of the biological activity of the 
library of novel compounds extracted from South African marine algae and assessed a number 
of characteristics of the compounds which are not often addressed in the field of natural 
product research. In particular, cytotoxicity against healthy non-cancerous cells for the vast 
majority of novel natural products is not routinely performed. As seen in this and previous 
studies within our research group, toxicity against non-cancerous cells is an important factor to 
consider, since the compound which displayed the most promising activity against breast 
cancer cells was also toxic to healthy breast cells (Lawson, 2009; MSc thesis). It is not 
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uncommon in the literature for researchers to carry out studies into the mechanism of action of 
novel compounds without first assessing whether the observed cytotoxicity is specific to cancer 
and not healthy cells (Andrianosolo et al., 2006). On the other hand, it is also evident from the 
literature that few studies report the investigation of the mode of action of novel compounds 
after the initial screening for biological activity.  
 
 
6.2 PROPOSED MODEL FOR MOLECULAR MECHANISM OF ACTION 
OF SQA AND FXN 
 
Two of the best-characterized novel marine algal compounds to date are the quinone SQA, 
isolated from various species of the Sargassum genus, and the carotenoid FXN, extracted from 
species belonging the Sargassum, Laminaria and Undaria genera (Choi et al., 2007; Hur et al., 
2008; Peng et al., 2011). The data previously reported for these compounds provided the 
opportunity for comparison between the molecular mechanisms uncovered in the current 
study in breast cancer cells with those in other human cancer cell lines. 
 
The precise target(s) to which SQA and FXN bind in breast cancer cells was not determined in 
this study and could represent either an extracellular receptor or an intracellular protein. 
However, a number of proteins were implicated in mediating the anti-cancer activities of the 
compounds. Figure 6.1 represents an overview of the interconnected apoptotic and survival 
pathways within human cells and indicates those signal transducer proteins identified in this 
study as potential role-players in mediating the toxicity of SQA and FXN against MDA-MB-231 
breast cancer cells. The majority of proteins identified as potential mediators for the activity of 
SQA and FXN in this study are caspases. Since it has been predicted that, in most cases, the 
activity of anti-cancer therapies will involve caspases (Fulda and Debatin, 2006), this was not 
unexpected.  
 
 
  
  
 
Figure 6.1: Signal transducer pathways and molecules thought to be involved in mediating the 
cytotoxicity of sargaquinoic acid (SQA) and fucoxanthin (FXN) against 
in this study. Proteins which are pro
white text, while pro-apoptotic molecules are.represented by light grey ovals with black text. Red stars 
indicate signal transducer molecules
FXN. Phosphorylation events are indicated by the letter P. (Adapted from Klener Jr. 
McCubrey et al., 2007).  
 
 
What is immediately apparent from Figure 6.1 is that, while SQA and FXN require a number of 
the same signal transducer molecules to mediate thei
action are not identical for these compounds. Whereas the cytotoxicity of FXN appears to be 
mediated exclusively by the intrinsic apoptotic pathway, the mechanism of action of SQA 
appears to be less specific, invo
The latter phenomenon may be explained by the fact that the two apoptotic pathways are 
interconnected at various points (Klener Jr. 
signal transducer. Furthermore, a similar result has previously been reported for SQA in human 
skin cancer cell lines and, unlike the findings in this study, for FXN in human leukemia cells (Hur 
et al., 2008; Ishikawa et al., 2008). A further possibility is that the cy
MDA-MB-231 
-survival and anti-apoptotic are indicated by dark grey ovals with 
 identified as potential mediators of the cytotoxicity of 
r cytotoxicity, the specific mechanisms of 
lving caspases from both the extrinsic and intrinsic pathway. 
et al., 2006) and may point to a common upstream 
totoxicity of SQA and/or 
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breast cancer cells 
SQA and/or 
et al., 2006 and 
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FXN may be mediated by a global regulator of transcription, translation or protein folding which 
impacts on multiple signal transduction pathways. 
 
The finding that caspase-1 and -13 may be required for the activity of FXN and SQA, 
respectively, was unexpected, since these caspases are traditionally classified as being involved 
in the induction of inflammatory cell death programs and not apoptosis (Thornberry et al., 
1997). This could indicate a mixed mode of cell death induced by the compounds. Although this 
study assessed the ability of the hit compounds to induce apoptosis, recent reports have 
controversially suggested that necrosis and autophagy may be equally useful as a means of 
removing cancer cells (Fulda and Debatin, 2006). It is further possible that the compounds may 
be pro-inflammatory, resulting in the release of specific cytokines which, in turn, bind to cell 
surface receptors in an autocrine signaling cascade to facilitate the observed apoptosis of 
treated cells (Sporn and Roberts, 1992). 
 
 
6.3 DRUG DEVELOPMENT: EVOLUTION OF A HIT COMPOUND TO A 
DRUG 
 
Despite the almost casual use of the term “drug” in research laboratories, the reality is that 
numerous costly steps are involved between the initial identification of a hit compound in in 
vitro studies and the marketing of a clinically tested drug (Dimasi, 2002). What follows is an 
overview of the process of drug development and the procedures which would be involved in 
developing the compounds identified as promising hits in the current study into bona fide 
drugs. It is appreciated, however, that of the 5000 to 10000 compounds that start this process, 
only one will emerge as an approved drug (Dimasi, 2001). Nonetheless, should a molecule itself 
fail to reach drug status, there remains the potential for the compound to act as a scaffold for 
rational drug design (Keseru and Makara, 2006).    
 
Research activities in the pharmaceutical industry involve both drug discovery and drug 
development phases. In the drug discovery phase, a hit compound displaying favourable 
pharmacological properties in initial screening experiments is identified. Following this, the 
lengthy process of drug development begins and includes pre-clinical, clinical and post-clinical 
phases. In the pre-clinical phase of development, the so-called “New Chemical Entity” will be 
subject to further rigorous testing (Bleicher et al., 2003; Meadows, 2006). Before large amounts 
of capital are invested in the development of a hit compound into a drug, potential 
infringements on intellectual property (IP) rights must be ruled out and the patentability 
assessed. Both SQA and FXN, analyzed in the current study, have patents associated with their 
use as part of plant extracts. SQA, as part of an extract of African nutmeg is patented for use as 
an antioxidant (US patent 737413), while both the extraction procedure to obtain FXN from 
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Undaria pinnatifida as well as the dietery supplement obtained thereby are patented (US 
patent 7892580). Since neither of these patents describes the use of the compounds in pure 
form or as anti-cancer agents, this should not represent a violation of IP regulations. Finally, the 
feasibility of synthesis of a hit compound must also be carefully assessed (Dimasi, 2001; 
Meadows, 2006).  
 
Once the above criteria have been satisfied, identification of the precise targets and biophysical 
testing of the strength and specificity of binding to the target will be carried out (Bleicher et al., 
2003; Keseru and Makara, 2006). The biologically active form of the compound and toxicity of 
potential metabolic derivatives must also be determined (Meadows, 2006; Li and Vederas, 
2009). The finding in the current study that the reduced form of SQA was only half as toxic as 
the original compound against breast cancer cell lines highlights the importance of this step.  
 
A promising lead compound is defined as one which, besides displaying significant biological 
activity, is highly selective, both membrane permeable and water soluble and is not rapidly 
metabolized (Dimasi, 2001; Lipinski et al., 2001). Preliminary pharmacological profiling was 
carried out in this report using Lipinski’s Rule of 5 (Ro5) (Lipinski et al., 2001) and it was 
determined that the hit compound RU007 met all of the criteria included in this assessment. 
While the lipophillicity of RU004 and SQA, in terms of cLogP values, were considered to be out 
of the druggable range, the compounds met all the remaining requirements outlined in the 
Ro5. 
 
Once verified, lead compounds are altered in subsequent “lead optimization” experiments 
where sequential chemical modifications are performed and the structure activity relationships 
(SAR) of the derivatives determined to generate analogues which display enhanced potency, 
improved biophysical properties and fewer potential disadvantages (Dimasi, 2001; Meadows, 
2006; Li and Vederas, 2009). Preliminary SAR data was obtained in this study as a result of the 
presence of structural series in the library of compounds, whose monoterpene backbone was 
identical but which differed in the number and position of halogen atoms. Though a direct 
relationship between structure and activity was not identified, it did appear that substitution of 
a monoterpene with numerous chlorine moieties made for a highly toxic compound, as was the 
case for RU015. 
 
Testing of an optimized lead product in vivo in animal models forms the final pre-clinical step in 
drug development (Bleicher et al., 2003; Meadows, 2006). The information generated from 
these studies may be used to apply for “Investigational New Drug (IND)” status from the 
relevant regulatory bodies and, if granted, the compound will move into the clinical phase of 
testing. Three phases exist for human testing from Phase I, in which safety is determined 
usually in healthy subjects, through Phase II, where the safety and efficacy are assessed in a 
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small number of sick patients and finally to Phase III, the large scale clinical trial phase 
(Meadows, 2006). Should the IND perform well in these clinical trials, the final phase in drug 
development would involve the registration of the drug with the appropriate authorities in 
order to obtain a license to market the drug (Dimasi, 2001; Meadows, 2006). In the case of FXN, 
the fact that the compound is already marketed as a dietary supplement (Peng et al., 2011) 
could indicate that at least some of the safety testing and licensing for FXN has already been 
carried out. This could represent significant savings in terms of time and expenditure in the 
marketing of FXN as an anti-cancer drug. 
 
 
6.4 IMPORTANCE OF CANCER STEM CELL-SPECIFIC THERAPIES 
 
The hypothesis that cancers arise from and are maintained by cancer stem cells (CSCs), which 
are capable of asymmetric cell division and are resistant to traditional chemotherapy drugs, has 
caused a major shift in focus in the development of new therapies to treat the disease (Lawson, 
2009; Massard et al., 2006). It is now thought that effective treatment and prevention of 
recurrence and metastasis requires the removal of the CSC component of a tumour (Massard et 
al., 2006; Marotta and Polyak, 2008). It has been proposed that an effective cure for cancer will 
require two steps: first the rapidly proliferating bulk tumour cells must be removed and, 
second, elimination or differentiation therapies must remove the CSC subpopulation (Massard 
et al., 2006). Both of these steps must occur without causing generalized toxicity to healthy 
cells (Widakowich et al., 2007). There is to date no report of a compound able to specifically 
target BCSCs while leaving both breast cancer and non-cancerous breast cells unaffected. 
 
In the current study, the novel algal monoterpene stereoisomers RU017 and RU018 were 
demonstrated to inhibit MCF-7 mammosphere formation in vitro despite being non-toxic to 
both breast cancer and healthy breast epithelial cell lines. Since the MCF-7 mammospheres 
were shown to be enriched for BCSC-like cells (Jason Sterrenberg, unpublished data), the 
results in this study indicate potential specific anti-BCSC activity for RU017/18. The potential of 
an agent capable of targeting BCSCs is that treatment with such a compound, in conjunction 
with a drug displaying specific activity against cancer cells and which is not toxic to healthy 
tissues, could represent the two-step cure proposed by Massard et al. (2006). 
 
 
 
 
 
 
 
 
 133 
 
133 
6.5 OPPORTUNITIES FOR FUTURE STUDY 
 
The novelty and structural simplicity of the algal hit compounds analyzed in this body of work, 
together with their promising biological activity, justify further biochemical characterization of 
these compounds. Despite the fact that this body of work represents one of the few in-depth 
studies into the biological activity of novel natural products, there remain numerous 
opportunities for further analysis of the algal hit compounds. The induction of apoptosis by 
RU004, RU007, SQA and FXN in breast cancer cell lines could be confirmed using Annexin V 
staining, TUNEL tests and DNA fragmentation analyses. In addition, the role of specific caspases 
identified as being involved in mediating the cytotoxicity of SQA and FXN could be verified by 
Western analyses as performed for caspase-9 in this study. While the levels of the anti-
apoptotic molecule Bcl-2 were found to be decreased by both SQA and FXN, it would be 
interesting to assess the levels of other anti-apoptotic regulators such as Bcl-xL, as well as the 
pro-apoptotic proteins Bad, Bid, Bim, Bax and Bak. Furthermore, the effect of SQA, FXN and the 
other hit algal compounds on the Raf/MEK/ERK and Akt/PI3K/PTEN survival pathways are 
unknown. 
 
The putative anti-BCSC activity of RU017 and RU018 as assessed by mammosphere assay 
represent preliminary findings and certainly requires validation and further characterization. In 
particular, the effect of treatment with RU017/18 on the proportion of BCSC in breast cancer 
cell lines could be determined using flow cytometry to detect specific stem cell and CSC 
markers. The levels and activation state of key signal transducer molecules forming part of the 
self-renewal, survival and apoptotic pathways in treated mammosphere-derived cells could also 
be investigated by means of Western analyses. 
 
Further studies into the mechanism of action of the novel compounds have been hampered by 
the availability of these algal metabolites. In particular, in-depth investigation into the 
molecular mechanisms of action of the novel polyhalogenated monoterpenes RU004 and 
RU007 was not possible in this study due to challenges in sourcing the compounds. Apart from 
the fact that collection of the algal samples is expensive and time-consuming, the secondary 
metabolites of interest are not always present, despite the alga being collected from the same 
area (Li and Vederas, 2009). Seasonal variations in algal secondary metabolites have previously 
been reported. For example, attempts to re-isolate a series of halomon-related compounds 
from the red algae Portiera hornemannii, collected from a specific location in the Phillipines, 
proved unsuccessful just one month after the initial collection and purification of the 
compounds (Fuller et al., 1994). As with all natural products, while it may be appropriate for 
initial screening studies to extract the compounds from the seaweed, the conservation of the 
marine ecosystem must also be considered should large amounts of the seaweed be required 
(Li and Vederas, 2009). Of the marine algal metabolites analyzed in this study, FXN was the only 
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commercially available compound. FXN is marketed as a dietery supplement to aid weight loss 
and as a natural anti-oxidant (Peng et al., 2011). Taken together, these factors highlight the 
need to develop synthetic strategies to produce priority compounds to enable further 
characterization or hit to lead refinement (Li and Vederas, 2009).  
 
Synthetic strategies for the mass production of a compound may be either chemical or 
biological in nature. In the former, synthetic chemists make use of established reagents or 
structurally similar precursor molecules in multiple non-enzymatic steps to generate a 
particular compound, while the latter approach involves genetic engineering to allow for the 
heterologous expression of those enzymes involved in producing the compounds of interest in 
the alga (Li and Vederas, 2006). While both chemical and biological synthetic methods have 
been developed for FXN (Yamano and Ito, 1994; Eonseon et al., 2002), no such techniques exist 
for either SQA or the novel monoterpenes analysed in this study.  
 
 
 
 
CONCLUDING REMARKS 
 
The development process from hit to lead to drug outlined in section 6.3 above takes on 
average 10 to 15 years and has been estimated to cost anything from $50 million to over $2 
billion (Dimasi, 2001; Dimasi et al., 2003; Adams and Brantner, 2006). Since the majority of this 
cost is incurred in the later stages of development, increasing emphasis is being placed on pre-
clinical studies and the comprehensive characterization of hit and lead compounds in vitro, to 
avoid the investment of large amounts of capital on a compound which ultimately fails in 
clinical trials (Dimasi, 2002; Dimasi et al., 2003). The current study is an example of such 
increasingly important in vitro investigations and could serve as a useful starting point for 
further pre-clinical analyses.  
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APPENDIX FIGURES 
 
 
 
Figure A1: Differential toxicity screening of selected marine algal compounds in MCF7 cancer and 
MCF12A non-cancerous breast cells (Lawson, 2009; MSc thesis). Both cell lines were treated with a 
range of concentrations of algal compound for 96 h and their viability assessed by MTT assay. 
Sargaquinoic acid is represented by SQA. Values quoted are the half maximal-inhibitory concentrations 
(IC50) of each compound in µM. Concentrations greater than 200 µM are an extrapolation and considered 
non-toxic (NT). Error bars indicate the standard error of the mean where n=3.  
 
 
 
 
 
Figure A2 :Chemical structure of the vitamin A metabolite, retinoic acid 
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Figure A3: Flow cytometric analysis of the effect of a racemic mixture of the novel halogenated 
monoterpenes RU017 and RU018 on the proportion of the MCF-7 side population using ABCG2 staining 
(Lawson, 2009; MSc thesis). Cells were treated with either DMSO vehicle control (A) or 300 µM of 
RU017/RU018 (B) for 96 hours, stained for the drug transporter ABCG2 and analysed by flow cytometry. 
Gating of the bulk cells (a) and “side population” cells (b) was carried out on the DMSO control and 
copied to the treated sample. 
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